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EXECUTIVE SUMMARY 
Background 
Enlarged breasts are a major concern for women all over the world impacting them both 
physically and emotionally. Mammary reduction is a well-known surgical procedure but 
not without complications. Post-operative scarring continues to be a reality and a 
lingering concern for women and also a reason why women sometimes opt not to go for 
surgery. Women are continually seeking for new treatment modalities to improve scar 
appearance post-operatively. Mesotherapy Eporex treatments with active ingredients is 
well established for treating cellulite, wrinkles, muscle spasms and to firm skin, but 
lacks scientific evidence whether it could be effective to treat post-operative scarring. 
Therefore, the aim of the research study was to assess if Mesotherapy Eporex 
treatment with active ingredients could effectively reduce scar appearance after bilateral 
mammary reduction surgery. 
Methods 
A randomized, experimental design was used to assess the Mesotherapy Eporex 
treatment with active ingredients in thirty (30) female participants receiving mammary 
reduction surgery. Demographic- [age (years), ethnicity (W/B/C/A)] anthropometric- 
[weight (kg), height (cm) and Body Mass Index (BMI)] and clinical data [bra size (cup A-
DD), ptosis (cm), concomitant medication, and amount of breast tissue removed (g)] 
were recorded from the patients’ medical record. The Wise pattern with inferior pedicle 
surgical technique (inverted T) was used on all patients. 
The Mesotherapy Eporex treatment with active ingredients (2ml Asian Centella, 5ml 
20% Vitamin C and 5ml Hyaluronic Acid) commenced six (6) weeks after surgery. Thirty 
(30) participants were randomly divided into two (2) groups of 15 (fifteen) participants 
each. Group one (1) Mesotherapy Eporex treatment was performed on the right breast 
(experimental breast) and the left breast served as the control breast (not receiving 
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treatment) and vice versa for group two (2). Each participant received eight (8) 
Mesotherapy Eporex treatments on the experimental breast three (3) days apart. Scar 
appearance was assessed with the Vancouver Scar Scale (VSS) by the researcher, 
independent assessor (prior to treatment 1, 3, 5, 7 and after treatment 8) and plastic 
surgeon [prior to treatment one (1) and after treatment eight (8)]. The plastic surgeon 
and independent assessor was blinded and did not know which breast was treated. 
Results and discussion 
No statistical significant differences were observed for demographic, anthropometric 
and clinical data indicating that the sample population was comparable. No difference in 
healing ability was observed between the right experimental breast and left 
experimental breast (p=0.3288). Both, the independent assessor (-0.567) and plastic 
surgeon (-1.700) reported improvements in scar appearance when comparing the 
baseline VSS results with the endpoint VSS results after applying the Mesotherapy 
Eporex treatment (p=0.0002). Inter-observer reliability remains a problem due to the 
subjective nature of the VSS. The internal consistency of the VSS was lower than 
acceptable (Cronbach’s alpha 0.4355). Emphasis was placed on the results of the 
independent assessor because assessments were done throughout the treatment 
period. The independent assessor reported a maximum of 11% or minimum of 0.6% 
improvement in scar appearance in the experimental group and a statistical significant 
improvement for scar pliability (95% CI: -3.88 ; -0.87) and height (95% CI: -2.58 ; -0.11). 
Improvement in scar appearance can be attributed to the Mesotherapy Eporex 
treatment with active ingredients (reduced inflammation due to deeper product 
penetration, promote collagen synthesis, restore tissue firmness, increase skin 
elasticity, decrease collagen stiffness and act as free radical scavengers). 
The assessor (95% CI: -2.10; -0.16), ptosis (95% CI; 0.03; 0.33), and amount of right-
sided breast tissue (95% CI: -0.01; -0.00) removed influenced the effectiveness of the 
Mesotherapy Eporex treatments (p=<0.05). The VSS is a subjective assessment tool 
explaining the influence of the assessor on the effectiveness of the treatment. Ptosis is 
an indication of the amount of breast tissue to be surgically removed and the more 
breast tissue removed the greater the chance of more aggressive scarring post-
operatively. 
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Conclusion 
In spite of the subjectivity and imprecision of the measurement system used, the 
effectiveness of the Mesotherapy Eporex treatment with active ingredients is not in 
question. There was a relative change in scar appearance over time in favour of the 
breast receiving Mesotherapy treatment at that time. 
KEY WORDS: Female breast, Mammary reduction surgery, Healing, Scarring, 
Mesotherapy Eporex treatment, Vitamin C, Hyaluronic acid, Asian Centella. 
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CHAPTER 1 
INTRODUCTION 
1.1  Background 
The visual appearance of female breasts differs considerably between individuals. These 
differences are associated with the amount of adipose tissue found below the breast tissue 
and the surrounding lobules. Women presenting with mammary hypertrophy, gigantomastia 
(extremely large breasts) and ptosis (nipple sagging) usually suffer psychological symptoms 
like stress, depression and feelings of shyness or embarrassment (Saariniemi et al., 2009), 
as well as physical discomfort including persistent neck, upper back and shoulder pain 
(Fernandes et al., 2007; Setälä et al., 2009; Sofianos et al., 2015). The goal of mammary 
reduction surgery is to improve breast weight-related symptoms while achieving acceptable 
breast shape and symmetry. 
Mammary reduction surgery is the treatment method of choice for enlarged breasts and is 
one of the top 10 elective surgeries performed on both male and female patients worldwide. 
In 2010, 4645 adolescent girls underwent breast reduction surgery to treat macromastia or 
juvenile breast hyperthrophy (Crerand and Magee, 2013). In 2011 mammary reduction was 
one of the top ten reconstructive procedures in the UK (Draelos and Pugliese, 2011).The 
frequency of this surgery is observed in all racial groups, although it is predominant in 
African-Americans (Plastic Surgery Statistics Report, 2011).  
However, mammary reduction surgery is not without complications or risks. Complications 
associated with mammary reduction surgery may include partial and superficial wound 
dishiscence, infection and sebsequent scarring (Setälä et al., 2009; Saleem and John, 
2013). From an aesthetic perspective, post-operative scarring is most probably one of the 
major concerns for female patients receiving mammary reduction surgery (Monstrey et al., 
2014; Purohit, 2008). According to Abu-Nab and Grunfeld (2007) scarring can be a major 
source of dissatisfaction after aesthetic breast surgery. 
© Central University of Technology, Free State
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Besides surgical technique, numerous pre-operative risk fators can contribute to post-
operative complications (Brown et al., 2012, Saleem and John, 2013; Pierpont et al., 2014). 
Age, obesity, the amount of breast tissue removed usually indicated by the degree of ptosis 
are variables considered by the plastic surgeon before opting to perform breast reduction 
surgery due to the impact on post-operative complications (Setälä et al., 2009; Ellsworth et 
al., 2009; Saleem and John, 2013; Hannson et al., 2014; Srinivasaiah et al., 2014). 
 
To address patient dissatisfaction with regard to post-operative scarring several treatment 
modalities have been introduced namely; massages, silicone gels or plasters, creams/gels, 
peels, pressure garments, steroid injections, radiotherapy and camouflage makeup 
(Monstrey et al., 2014; Garg et al., 2014). Fortunate, for us as technology improves, new 
treatment techniques are developed. 
 
Mesotherapy was introduced by a French physician, Dr. Michel Pistor, in 1952. A new 
modification of mesotherapy by which both ionised and neutral drugs can be transported 
into the dermis and subcutaneous tissue is known as no needle Mesotherapy (Sivagnanam, 
2010). The Mesotherapy Eporex machine is used for both medicinal and aesthetic 
treatments and promotes the absorption of medicines, vitamins, minerals and amino acids. 
The treatment modality encourages the active gel to penetrate more deeply into the 
epidermis, dermis and hypodermis. Deeper active ingredient penetration is accomplished 
by applying a dual wavelength laser light and then four (4) components; electroporation, 
active current, hydrophoresis and cryophoresis (Latha and Vandana, 2011; Konda and 
Thappa, 2013). Although the application of the Mesotherapy Eporex treatment is well 
established for cellulite, wrinkles, muscle spasms and firming of skin (Konda and Thappa, 
2013); its effectiveness to reduce the appearance of surgical scarring still needs to be 
scientifically investigated. 
 
In this study Mesotherapy Eporex with active ingredients was selected as treatment method 
to reduce scar appearance after bilateral mammary reduction surgery by forcing active 
ingredients into the skin. The Mesotherapy Eporex treatment with active ingredients was 
applied over a period of one (1) month, with two (2) sessions weekly for a total of eight (8) 
treatments. The purpose of the active ingredients was to supply the skin with antioxidants 
and moisture, to aid in wound healing, promote formation of mature collagen fibres and to 
act as anti-inflammatory agents in an attempt to improve scar appearance both in texture 
© Central University of Technology, Free State
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and colour. During and after the application of the Mesotherapy Eporex treatments the 
Vancouver scar scale (subjective assessment) was the scar rating scale used by the 
researcher (not blinded), independent assessor (blinded) and plastic surgeon (blinded) to 
assess scar appearance. The VSS assess four (4) skin characteristics namely pliability, 
vascularity, pigmentation and scar height. 
1.2 Aim and objectives 
1.2.1 Aim 
The aim of the research study was to assess if Mesotherapy Eporex treatment with active 
ingredients could effectively reduce scar appearance after bilateral mammary reduction 
surgery. 
1.2.2 Objectives 
The objectives of the study were: 
To determine the effectiveness of the Mesotherapy Eporex treatment with active 
ingredients by comparing the scar appearance of the experimental breast 
(Mesotherapy Eporex treatment with active ingredients) with the control breast (no 
Mesotherapy Eporex treatment) using the VSS. 
To determine the percentage of improvement of scar appearance after applying the 
Mesotherapy treatment for each of the four (4) categories included in the VSS by 
subtracting the endpoint measurements [after treatment eight (8] from the baseline 
measurements [prior to treatment one (1)]. 
To determine if scar appearance (wound healing) differ between the right and left 
breast by randomizing the application of the Mesotherapy Eporex treatment between 
the right and left breast. 
To determine if the amount of breast tissue removed, ptosis, age, and BMI 
influenced the effectiveness of the Mesotherapy Eporex treatment while accounting 
© Central University of Technology, Free State
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for a possible difference between the assessors (plastic surgeon and independent 
assessor). 
 
1.3 Dissertation Outline 
 
Chapter 1 outlines the research problem concerning scar appearance after bilateral 
mammary reduction surgery, Mesotherapy Eporex treatment with active ingredients as a 
treatment option, and rationale for performing the research study. 
 
Chapter 2 reviews the literature pertinent to the understanding of the anatomy and 
physiology of the female breast, developmental changes, bilateral mammary reduction 
surgery, complications associated with bilateral mammary reduction surgery with special 
emphasis on scar formation, treatment modalities used to reduce scar formation and 
assessment tools used to evaluate scarring. Chapter 2 also formed the basis for the 
research design outlined in Chapter 3. 
 
Chapter 3 outlines the research design, data collection, special investigations, statistical 
analysis and ethical considerations applied in the research study to produce scientific data. 
 
Chapter 4 presents results, starting with demographic, anthropometric and clinical data 
followed by VSS assessment results of scar appearance. The percentage of improvement 
for each skin characteristic included in the VSS after Mesotherapy Eporex treatment was 
evaluated as well as factors that might have an impact on the effectiveness of the 
treatment. 
 
Chapter 5 is a discussion of the results. 
 
Chapter 6 concludes the study with an account of the implications of the results obtained 
including the limitations of the study and possible recommendations for future studies. 
 
Chapter 7 lists the references cited in the study. 
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Chapter 8 includes all the appendices comprising ethical clearance documents, 
Mesotherapy Eporex instruction manual, and photographs of surgical wound healing before 
and after Mesotherapy Eporex therapy. 
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CHAPTER 2 
 
LITERATURE REVIEW 
 
 
2.1 The mammary integumentary system 
 
Human skin is composed of three heterogeneous layers: epidermis (outer layer), dermis 
(medial layer) and the hypodermis (inner layer) ( Kolarsick et al., 2011;Sutradhar and Miller, 
2013). The epidermal layer forms a protection barrier against injury, contamination and 
moisture loss. The epidermal layer is made up of epithelial cells that are continually 
displaced towards the surface to be shed, encouraging cell regeneration. Structures, such 
as hair follicles, sebaceous and sweat glands, start in the dermis and extend through to the 
epidermal surface. These structures assist with the bodies‟ heat and cold regulation without 
interrupting the epidermo-dermal junction. The second layer, known as the dermis, is a 
network of collagen and elastin fibres supplied by blood capillaries, which supports the 
epidermis (Kolarsick et al., 2011; McLafferty et al., 2012). The epidermal appendages found 
in the dermis provide strength to the skin (Verhaegen et al., 2012). Lying below the dermis 
is the hypodermis/subcutaneous fatty tissue layer which is comprised of nerve fibres, 
sensory organs, blood vessels, hair follicles and lymphatic glands (Sutradhar and Miller, 
2013). Any damage to the dermal and hypodermal layers could result in skin stiffness. The 
stiffness is a result of collagen and elastic fibres getting orientated in the direction of stress, 
possibly interrupting the nerve and blood supply of the surgical area (Gauglitz et al., 2011; 
Son and Harijan, 2014). 
 
Skin thickness varies across the human body ranging from thin skin on the eyelids to thick 
skin on the hands and feet. The thicker the dermis the higher the volume of collagen and 
elastin found in that specific area. The thickness of breast skin tissue ranges from 0.83mm 
to 2.35mm (Sutradhar and Miller, 2013). According to a Sutradhar and Miller (2013) skin in 
the medial breast region was thicker than skin in the lateral region of the breast, however 
no difference in thickness was found between the superior and inferior regions of the breast 
dermal layers. Due to the thicker skin on the medial side of the breast, compared to the 
lateral side, the elastic properties are higher which could contribute to an increased 
possibility for developing abnormal scarring in that region. 
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2.2 Anatomy and physiology of the female breast 
In the female breast, dimension and mass can vary substantially between individuals 
(Gefen and Dilmoney, 2007). Anatomic variation can occur in volume, width, length, 
projections, shape, and positions on the chest wall (Avsar et al., 2010). 
The breast is composed of glandular (secretory) and adipose (fatty) tissue supported by a 
loose framework of fibrous connective tissue called Cooper‟s ligaments. The glandular 
tissue contains 15–20 lobes with lobules that contain 10-100 alveoli, each approximately 
0.12mm in diameter, situated beneath the adipose tissue. Each breast lobe is considered to 
be a single entity (Kopans, 2007; Hassiotou and Geddes, 2013). Adipose fat is interspersed 
between and above the lobules providing support and contributing to the rounded 
contouring of the breasts. 
The glandular tissue is drained by a ductal system that stores and transports milk to the 
nipple during lactation. The ductal system found in the breast is comprised of numerous 
small ductules that drain to the alveoli. The ductules merge to culminate in one main duct 
that dilates slightly to form a lactiferous sinus (2.0–4.5mm) (Hammond and Loffredo, 2012). 
The main duct then narrows at the „waist‟ before it passes through the nipple and connects 
at the centre of the nipple. The nipple is surrounded by a dark pigmented area known as 
the areola (Jesinger, 2014).The areola is composed of longitudinal and horizontal smooth 
muscle fibres adhering to the nipple base and is often aligned with the nipple ducts 
(Hassiotou and Geddes, 2013). The areola has oil glands which extend through to the 
surface of the skin to provide lubrication during breastfeeding (Jesinger, 2014). 
The vascular anatomy of the breast includes the auxiliary artery, internal thoracic and 
intercostal arteries (Ellis and Mahadevan, 2013). The internal thoracic artery accounts for 
60% of the total blood supply to the breast. This thoracic artery supplies rich oxygenated 
blood to the breasts supporting various reduction techniques without the risk of nipple and 
areolar (loose connective tissue) necrosis (Gabriel, 2011). The motion/bounce of the female 
breast is the result of the elasticity of connective tissue fibres present within the breast 
tissue itself (Hassiotou and Geddes, 2013). 
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2.3 Breast developmental stages 
 
Breast development is split into the following stages: foetal growth, pubertal expansion, 
pregnancy and post-menopausal (Geddes, 2007). The time course of breast development 
initiates in the foundation phase, with mammary buds developing during embryonic life, it 
continues with minimal growth during infancy, and is followed by a rapid growth phase at 
puberty (Hassiotou and Geddes, 2013). 
 
When a female reaches puberty, hormones including oestrogen, progesterone, prolactin, 
insulin, thyroxine and growth hormones, are produced in moderation and may lead to the 
development of enlarged breast tissue (Javed and Lteif, 2013). The rapid breast growth is 
driven by the ovulation cycle and the body‟s pursuit to establish a regular menstrual cycle. 
The sudden increase in breast size can be attributed to an increase of adipose tissue within 
the mammary gland (Hassiotou and Geddes, 2013). When breast volume increases beyond 
physical comfort, it is not uncommon for women to become self-conscious about their 
breasts, leading to social withdrawal, and thus hindering the development of important 
social skills (Saariniemi et al., 2009) Furthermore, women with large breasts prior to 
pregnancy experience further breast tissue enlargement due to the release of pregnancy 
hormones (Hassiotou and Geddes, 2013). 
 
2.3.1 Factors influencing mammary gland development 
 
Various factors can influence mammary gland development such as age and BMI, 
hormonal changes, pregnancy and menopause (Mansel et al., 2009; Wade et al., 2010; 
Brown et al., 2012; Wolfswinkel et al., 2013). Women presenting with macromastia (breast 
hypertrophy) during menopause, due to hormonal changes, also experience weight gain. It 
is common for the breasts to enlarge as the weight of a patient increases (Hammond, 
2009). A patient‟s body mass index (BMI) is of great importance when considering a patient 
for breast reduction surgery. If the patient has a BMI of >35kg/m2, the patient is encouraged 
to lose weight and maintain the loss for six (6) months to one (1) year before mammary 
reduction surgery is performed. This approach ensures that unexpected weight changes do 
not influence the post-operative size and shape of the breast ( Hammond, 2009; Solorzano 
and McCartney, 2010). 
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During the pregnancy and lactation cycle the mammary gland undergoes complete 
remodelling, maturating into a functional milk secretory organ (Hassiotou and Geddes, 
2013). After pregnancy, women usually experience an increase in breast size due to 
breastfeeding leading to the development of post-lactation ptosis (drooping of the nipple) 
(Purohit, 2008; Rinker et al., 2008). Therefore, women are more likely to consider 
mammary reduction surgery, due to enlarged breasts, after pregnancy. Once the pregnancy 
and lactation stage is complete the mammary alveolar cells clear, encouraging the breasts 
to regress into non-functional organs until the next pregnancy and lactation stage. However, 
if a subsequent pregnancy does not occur, the glandular epithelium regresses and adjacent 
connective tissue is gradually replaced by fat. This process continues into menopause 
(Hassiotou and Geddes, 2013). 
Post-menopausal mammary changes are associated with ovarian functional decay and are 
characterized by the reduction of glandular breast tissue and an increase in the surrounding 
adipose tissue ( Hassiotou and Geddes, 2013; Savolainen-Peltonen et al., 2014). Post-
menopausal breasts may be heavy and large, leading to physical breast abnormalities 
(hypertrophy, gigantomastia and ptosis). Women who experience secondary enlargement, 
due to fatty infiltration of their breasts after menopause, usually require the removal of more 
than 1800g of adipose tissue (per breast) during mammary reduction surgery (Purohit, 
2008). 
2.4 History of mammary reduction surgery 
Mammary reduction surgery was developed by Theodor Billroth from 1869 to 1876 followed 
by Alfred Pousson in 1897. Billroth and Pousson believed that removing the entire breast 
rather than performing a reduction was the procedure of choice (Purohit, 2008). However, 
during the late 19th century, the “natural breast” concept was introduced by Galliard to 
salvage part of the breast tissue, and thus mammary reduction went from reconstructive 
surgery to aesthetic surgery (Shiffman, 2010). In 1928, Biesenbergers performed breast 
reduction surgery on patients by separating skin from the lateral half of the breast gland and 
transporting the nipple to markings made in line with the inframammary crease. 
Biesenbergers‟ mammary reduction technique is still the procedure of choice to create 
proportionate, youthful-looking breasts with minimal scarring (Saleem and John, 2013). In 
1956 Dr RJ Wise used Biesenbergers mammary reduction technique which included: 
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a) The separation of the skin from the mammary gland. 
b) Resection of the lateral half of the mammary gland. 
c) The transposition of the nipple on the retained gland (Purohit, 2008). 
 
However, Wise modified the technique through the development of improved excision 
techniques, hence the Wise pattern technique (Figure 1.2). Robbins (1977), Courtiss (1977) 
and Goldwyn (1977) contributed to the development of the inferior pedicle technique, which 
aimed to reduce visible scarring (Purohit, 2008; Shiffman, 2010). 
 
2.4.1 Applications for mammary reduction surgery 
 
Mammary reduction (MR) surgery is a common cosmetic and oncological surgical 
procedure not only restricted to bringing down the size of the breast proportionate to the 
build of the individual, but also to overcome the discomfort caused by massive, ill-shaped 
and hanging breasts. Through the years MR surgery has evolved from mere reduction of 
breast mass to the enhancement of aesthetic appeal producing minimum scar load (Saleem 
and John, 2013; Sofianos et al., 2015). 
 
Breast size are reduced by surgically removing excess glandular, skin and adipose tissue in 
order to improve the patient‟s psychological, aesthetical and physical wellbeing (Crerand 
and Magee, 2013). 
 
Mammary reduction surgery aims to modify the breasts size to be in proportion to the 
patient‟s body structure, be symmetrical, and retain the breasts‟ rounded and natural shape 
with excellent nipple projection, without losing blood supply to the nipple. Therefore, the 
goal of mammary reduction surgery is once-off surgery, with the preservation of breast 
function and minimal scarring (Copcu, 2009; Saleem and John, 2013). 
 
The most frequent causes associated with requests for mammary reduction surgery are 
medical, namely increased breast size, weight, discomfort or gravitational force (Karaaslan 
et al., 2013). These causes are usually associated with complications such as backache 
(cervical and upper thoracic back discomfort), neck pain causing headaches, skin 
irritation/rashes, poor posture, shortness of breath (dyspnoea), shoulder grooves and the 
inability to exercise (Table 2.1) (Fernandes et al., 2007; Setälä et al., 2009; Sofianos et al., 
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2015; Strong and Hall-Findlay, 2015). Breast reduction surgery can also result in 
physiological benefits for the patients which include improvements in self-esteem and 
depression (Cerand and Magree, 2013). 
© Central University of Technology, Free State
  
 
12 
Table 2.1 Complications associated with mammary hypertrophy 
Complication Description 
Back and neck pain 
Discomfort and pain in the back muscles are the result of the 
surrounding muscles (upper back and chest) not being strong 
enough to support the weight of the breasts. Without the 
support of the surrounding muscles, the shoulders 
automatically roll forward causing stress on the back and neck, 
as well as compression on the thoracic vertebrae‟s and 
thereby exaggerating a natural thoracic lordosis. This poor 
posture creates a snow ball effect, since the larger the breasts, 
the more pressure is exerted on the vertebrae, often leading to 
compressed nerve fibers causing discomfort, pain and 
headaches (Fernandes et al., 2007;Karaaslan et al., 2015). 
Skin irritation/rashes 
Skin irritations and rashes are caused by trapped moisture and 
body heat generated underneath and in-between the breasts. 
The moisture can encourage fungal infection development 
resulting in personal hygiene concerns (Mistiaen and Van 
Halm-Walters, 2010; Wolfswinkel et al., 2013). 
Poor posture 
Poor posture is associated with the excess weight of the 
breasts and the poor strength of the surrounding muscles 
(Lapid et al., 2013; Sahin et al., 2013). 
Dyspnea 
(shortness of breath) 
The large amount of breast tissue may exert pressure on the 
thoracic cavity resulting in shortness of breath (Nafae et al., 
2013). 
Shoulder grooving 
Patients tend to wear smaller sized bras due to a lack of 
knowledge regarding proper bra fitment, for example, a patient 
requiring an F size bra chooses to wear a DD sized bra. Thinly 
sized shoulder straps pull down into the shoulders resulting in 
wheals on the shoulders (Radosa et al., 2013; Coltman et al., 
2015). 
Inability to exercise 
The larger the breasts, the more difficult it is to exercise. The 
inability to exercise may potentially encourage inactivity and 
obesity (Scurr et al., 2016). Thus, the muscles are weaker and 
more problems are experienced with posture and back/neck 
pain. 
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2.4.2 Mammary reduction surgery 
Numerous operative techniques are available for mammary reduction surgery and the 
choice of technique depends on the surgeon‟s preference and estimated resection volume 
(Nelson et al., 2008; Wong et al., 2014). To qualify for breast reduction surgery the 
minimum amount of breast tissue that has to be removed is 500g or more per breast 
(depending on health insurance plans and countries). The estimated volume of breast 
tissue to be removed can be determined using the Schnur scale, which utilizes the body 
surface area, determined by height and weight (Wolfswinkel et al., 2013). Other methods 
used by surgeon‟s to estimate the amount of breast tissue remove during surgery includes; 
water displacement and the Grossman-Roudner device, mammograms, ultrasound, 
magnetic resonance imaging, three-dimensional computed tomography and three-
dimensional photography. Furthermore, anthropometric measurements have also been 
used to estimate resection amounts (Murray et al., 2008; Kececi and Sir, 2014). 
Sternal notch-to-nipple distance (ptosis) is one way to assist plastic surgeons 
preoperatively, to estimate the amount of breast tissue removed during surgery (Hernanz et 
al., 2014; Ikander et al., 2014). Breast ptosis was originally categorized by Regnault (1976) 
and is classified based on the position of the nipple relative to the inframammary fold and 
the breast base in the standing position (Liu, 2009). These objective measurements are 
categorized according to grade 0-3. Grade 0 signifies no ptosis, in which the nipple lies 
above the inframammary fold. Grade I is known as mild ptosis that occurs when the nipple 
is at the same level or up to 1cm below the inframammary fold. Grade II (moderate) ptosis 
refers to when the nipple falls 1 to 3cm below the inframammary fold. Grade III (severe) 
ptosis becomes apparent when the nipple falls 3cm below the inframammary fold (Liu, 
2009;  Andrades and Prado., 2007). 
The patients‟ requirements, ptosis degree, breast size, skin and gland quality, including the 
surgeons experience and preferences are taken into consideration when deciding on the 
appropriate pedicle technique for the nipple areola in reduction mammaplasty (Murray et 
al., 2008; Castro et al., 2013). Grade 1 ptosis would be best to utilize a superior based 
pedicle. Moderate to severe ptosis requires greater elevation of the nipple-areola complex 
and larger amounts of skin need to be excised. Severe breast hypertrophy and a type III 
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ptosis, a safer pedicle is recommended (inverted T resection with an inferior pedicle) in 
spite of a longer scar (Andrades and Prado. 2007).  
 
Table 2.2 Selecting the breast reduction technique based on hypertrophy and ptosis degree 
(Andrades and Prado, 2007) 
  PTOSIS 
  Mild Moderate Severe 
H
Y
P
E
R
T
R
O
P
H
Y
 
Mild 
(< 500g) 
Shorter Scars 
Upper pole based pedicles 
 
 
 
 
 
 
 
 
 
 
 
Longer Scars 
Lower pole based pedicles 
Moderate 
(500g-1000g) 
Severe 
(>1000g) 
 
 
2.4.3 Surgical procedures/techniques used during mammary reduction surgery 
 
Mammary reduction surgery entails two technical procedures, namely resection and the 
placement of the pedicle to retain the nipple areola (Purohit, 2008; Saleem and John, 
2013). A skin resection pattern is the removal of skin, whereas a pedicle placement refers 
to a technique developed to ensure continuous blood supply to the nipple by maintaining its 
connection to the underlying breast tissue. An inferior pedicle is mostly associated with an 
inverted T skin resection whereas a superior pedicle is associated with a vertical skin 
resection (Purohit, 2008; Wong et al., 2014). 
 
2.4.3.1  Placement of pedicles 
 
Skin resection patterns can be combined with most pedicles (Purohit, 2008; Wong et al., 
2014). Pedicle techniques include the inferior, superior, central, lateral and lastly the medial 
pedicle technique (Figure 2.1). Pedicles situated around the breast, are named according to 
their position on the breast, and are used to maintain blood supply to the nipple areola 
complex (Andrades and Prado, 2008). According to Saleem and John (2013), the inferior 
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pedicle technique is reproducible across a range of breast sizes with varying ptosis. 
Utilizing this technique allows easy access to the different breast quadrants, precision in 
shaping of the breast, and the retention of parenchyma, including the skin envelope 
(Saleem and John, 2013). 
Figure 2.1 Blood supply of pedicles (A) blood supply of the inferior pedicle (B) blood supply of the superior pedicle
(C) blood supply of the central pedicle (D) blood supply of the lateral pedicle (E) blood supply of the medial pedicle 
(Purohit, 2008) 
2.4.3.2 Skin resection patterns 
Skin resection patterns include the following techniques: inverted T resection (Wise 
pattern), vertical resection, circumareolar resection and lateral skin resection (Purohit, 
2008; Wong et al., 2014). 
Plastic surgeons seem to prefer the Wise pattern (inverted T resection) approach with an 
inferior pedicle technique (69%), also referred to as a keyhole pattern (Chopra et al., 2013). 
The Wise pattern technique removes glandular tissue and excess skin, and includes nipple 
transportation (Purohit, 2008). The Wise pattern (inverted T resection) with an inferior 
pedicle technique facilitates wide access to the breast parenchyma, and is thus effective for 
a variety of breast reduction sizes, including unusually large breasts and patients with 
excess skin due to substantial weight loss (Cutress et al., 2013; Wong et al., 2014). In 
addition, this technique yields predictable results, including the preservation of nipple 
sensitivity (Chopra et al., 2013).  
In this research study, emphasis will be placed on the Wise pattern with an inferior pedicle 
technique for this is the surgical methods of choice used by the plastic surgeon when 
performing bilateral mammary reduction surgery. 
A B C D E 
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2.4.4 The Wise pattern with inferior pedicle surgical technique used for mammary 
reduction surgery 
 
2.4.4.1 Marking the skin resection pattern 
 
Enlarged breasts tend to sag as one ages often causing breasts to sag past the 
inframammary fold, adding to nipple ptosis. The ideal anatomical nipple height is 21cm from 
the sternum-bone notch to the nipple (Khan and Bayat, 2008). Therefore, a plastic surgeon 
makes measured markings on a patient‟s breasts before surgery commences. The 
markings determines the amount of skin and breast tissue to be resected as well as breast 
asymmetry (Barbosa et al., 2010). 
 
Prior to mammary reduction surgery the patient is placed in an upright position and the 
suprasternal notch and midclavicular points are marked. A vertical line is drawn between 
the suprasternal point and the xiphoid. The proposed nipple level is marked according to 
the inframammary crease using the finger method; referred to as point A (Figure 2.2) (Moio 
and Schonauer, 2015). Secondly, the vertical limb angles are marked by placing the thumb 
and index finger 6.5cm equally adjacent to the nipple in a pinching motion to create marking 
B (lateral) and C (medial), which will assist in determining the volume of resection required. 
The medial (E) and lateral (D) limits of resection are marked on the breast by displacing the 
gland medially and laterally in the opposite directions (Figure 2.2) (Purohit, 2008). The 
breast is elevated, the inframammary crease is marked and the point where the 
inframammary crease joins the breast is marked F. Markings of point C to E, and B to D are 
then connected with straight lines. The medial and lateral lines should be adjusted so that 
they are equidistant from the breast meridian and marking F to ensure equal distance 
between the nipple height and inframammary crease (Cutress et al., 2013). 
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Figure 2.2 Markings of the inferior skin resection pattern (Jatoi et al., 2006) 
2.4.4.2 Inverted T resection technique with inferior pedicle 
The term inferior pedicle refers to an inverted U-shaped incision based at the 
inframammary fold, moving up and around the nipple area. The pedicle is 6-8cm wide, is 
centred on the breast meridian, and extends for about 2cm above the nipple areola 
complex. The areola is stretched and by using a cookie cutter, a marking is made around 
the areola. The marking is about 3.5 to 4.5cm in diameter and is incised into the dermis. 
The inferior pedicle skin is de-epithelialized (Figure 2.3 and 2.4 A). Incisions are then made 
on the lateral and medial sides of the breast. The superior flaps are thinned out to achieve 
the natural breast shape (Figure 2.4 B). The Wise pattern with inferior pedicle surgical 
technique (inverted T) is used to keep the nipple “alive”, keeping it connected to the arterial 
and venous blood supply, thus maintaining circulation and sensation (Purohit, 2008; 
Khondoker and Ahmed, 2012). 
Medial angle 
point 
Suprasternal 
notch 
Medial 
Resection 
marking 
Lateral 
Resection 
marking 
A 
Proposed 
nipple height 
Midclavicular 
line 
Lateral angle 
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F 
C 
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Figure 2.3 De-epithelialized skin of the inferior pedicle operative technique (Jatoi et al., 
2006) 
 
The superior flaps (Figure 2.4 B, points B and C) are pulled towards each other and one 
suture is inserted to ensure an adequate opening for the „new‟ nipple areola complex 
(Figure 2.4 C). Once the nipple areola complex is in position it is sutured, following the 
vertical line down to the inframammary fold, using continuous intra-dermal sutures and 
sterri-strips, creating an inverted T (Figure 2.5C) (Purohit, 2008; DeGeorge et al., 2013). 
 
 
 
 
 
 
 
 
 
Figure 2.4 Wise pattern with inferior pedicle operative technique (A) De-epithelialized skin (B) B and 
C pulled together (C) One surture to ensure adequate opening for nipple areola complex (Jatoi et al., 2006) 
 
2.4.4.3  Advantages of the Wise pattern inferior pedicle technique 
 
The Wise pattern inferior pedicle technique can be used for all breast sizes and for varying 
degrees of ptosis (Saleem and John, 2013). The technique ensures sufficient blood supply 
to the nipple areola complex, promoting good circulation and retains both the fine sensation 
in the area and the possibility of breast-feeding after mammary reduction surgery (Wong et 
al., 2014). 
A B C 
C B 
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2.4.4.4 Disadvantages of the Wise pattern inferior pedicle technique 
The Wise pattern inferior pedicle technique may result in “dog ears” being created during 
the suturing process. “Dog ears” are prominent lateral bulges on both ends of the 
transverse scar (Weissman et al., 2014; Hansen, 2016). Other disadvantages associated 
with the technique are, a hypo-pigmented patch of the nipple, delayed healing and webbing 
(no cleavage/breast separation) of the pre-sternal region of the breast. The webbing of the 
pre-sternal region includes damage to the peripheral nervous system, intercostal nerves 
and the thoracic spinal nerves. The nerve damage leads to a loss of sensation in the breast 
area (Saleem and John, 2013). Hypertrophic and keloid scarring are both associated with 
mammary reduction surgery (thus the Wise pattern with an inferior pedicle technique may 
result in a long unsightly scar running along the inverted incision) (Hansen, 2016). 
2.5 Complications associated with mammary reduction surgery 
Complications and risks associated with mammary reduction surgery include, bleeding, in 
conjunction with or without, hematoma formation, breast sensitivity accompanied by breast 
numbness, delayed wound healing, breast asymmetry, hyper-pigmentation, fat and tissue 
necrosis, infection and scarring irregularities (Baker et al., 2009; Saleem and John, 2013; 
Weissman et al., 2014). The possibility of a bacterial infection at the incision site of the 
breast exists, and such an infection could contribute to swelling, redness, pus discharge 
and pain ( Purohit, 2008; Nezhadhoseini et al., 2015). 
2.5.1 Bleeding with or without the formation of a hematoma 
Bleeding during surgery increases the risk of a patient receiving a blood transfusion 
whereas bleeding after surgery causes the breast to swell, turn purple/blue and slow down 
the healing process (Hardy et al., 2008). Swelling due to bleeding usually occurs within the 
first 24 hours after surgery and often requires a second surgery to drain and stop the 
bleeding in the breast. Extensive swelling prevents blood perfusion to the skin causing 
oxygen (O2) delivery to the skin to be compromised. The lack of O2 may result in 
complications such as infection, localized death of skin cells (necrosis) and wound 
separation (Pierpont et al., 2014).  
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Excessive bleeding from broken blood vessels can disrupt wound healing causing the 
formation of a hematoma (which is a form of bruising). Hematomas are identified by the 
acute asymmetry of the breast, presenting with pain, and can occur up to nine (9) days 
post-operatively (Seth and Kim, 2010). Once a hematoma is detected it is important to 
remove it as the hematoma separates healthy tissue from the blood supply, creating a 
medium for bacterial growth (Saleem and John, 2013). 
 
2.5.2  Loss of sensation/sensitivity and numbness 
 
Loss of sensation and numbness in the breast area are experienced by many patients after 
mammary reduction surgery (von Sperling et al., 2011). The loss of sensation could be 
permanent, especially in the areola area, as this is where the nerves converge. However, 
normal sensation (dysaesthesia) in the nipple and the surrounding tissue could return within 
a few months or up to a year after the surgery. The sensation may return once the nervous 
system has healed the synapses connections between the nerve endings (Saleem and 
John, 2013). 
 
2.5.3 Infection and wound healing complications 
 
Infection and poor wound healing can occur at the junction of the two scar lines that join the 
medial and lateral flaps with the inframammary fold (inverted T). This complication is more 
frequent when the flaps are excessively thinned (Saleem and John, 2013). Poor wound 
healing due to compromised blood supply frequently occurs in patients with an elevated 
BMI (>25kg/m2), diabetes and/or myocardial injury (Setälä et al., 2009). Although patients 
are scrubbed with an antimicrobial solution prior to the surgical procedure to prevent 
bacterial infections, infections still occur. If infection occurs due to compromised blood 
supply at the injured site, it can contribute to excessive scar formation (Garvey et al., 2006).  
 
2.5.4 Breast asymmetry 
 
Breast symmetry is considered important for both emotional and physical self-acceptance 
and for spousal acceptance (Khondoker and Ahmed, 2012). Surgical procedures where 
large amounts of breast tissue are removed are usually accompanied by the risk of breast 
distortion (one breast being higher than the other), as well as a height difference in the 
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positioning of the nipples (Garcia, 2016). Patients with extremely large breasts are made 
aware of the risk of asymmetrical breasts after surgery and the possibility of a second 
operation in an attempt to restore breast symmetry. However, the number of surgical 
interventions increases the likelihood of more severe scarring (Purohit, 2008). 
2.5.5 Hypo-pigmentation 
Hypo-pigmentation can be seen as a surgical complication linked to the operative technique 
used by the plastic surgeon (DeGeorge et al., 2013). After surgery or trauma to a patient‟s 
mammary gland, inflammation can cause the melanin (skin pigment) production to be 
reduced or damaged causing hypo-pigmentation (Figure 2.10) (Vachiramon and 
Thadanipon, 2011). 
2.5.6 Fat and tissue necrosis 
Fat necrosis usually results from surgical trauma and is recognized as a sterile 
inflammatory process in which fat filled macrophages are surrounded by interstitial 
infiltration of plasma cells (Tan et al., 2006) . Necrosis can present as single or multiple 
smooth, round firm nodules/masses associated with pain, erythema, inflammation and skin 
thickening. The destruction of the intra-cellular framework of the breast causes extensive 
cell death, resulting in necrosis. Nipple necrosis is a dreaded complication (Handel and 
Yegiyants, 2016) emanating from the decreased vascularity of either the skin flaps or the 
pedicle in which the nipple areola complex is based. Nipple necrosis can be avoided by 
ensuring that the pedicle of choice has been incised in a pyramidal shape (Saleem and 
John, 2013). It is important to note that all the complications mentioned above can 
contribute to, or worsen, scarring after mammary reduction surgery. 
2.6 Scar formation 
Scarring is classified as either normal or abnormal, depending on the patient‟s lifestyle, 
medical history, healing ability, genetics, incision depth, length and location of the surgery 
performed (Hess, 2011; Son and Harijan, 2014). Scarring is the body‟s natural healing 
mechanism, creating a “plaster” at the site of injury. Surgery or any physical trauma to the 
skin could result in scar formation. Some scars heal quickly while others may take many 
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years to heal (Kaartinen et al., 2011). Most mammary reduction patients can expected 
scarring after surgery (Monstrey et al., 2014). Scarring can occur in all ethnic groups, 
presenting more often in African Americans, Hispanic and Asian ethnic groups than in 
Caucasian skin (Bian et al., 2013;). In some cultures scars are seen as being symbolic of 
heroism, for others the symbolism is religious, and for many patients scars are a reminder 
of hostile events (Oultram, 2009).  
 
2.6.1  Normal versus abnormal scarring 
 
Different types of scars can develop from an injury, and the scars are classified as normal 
or abnormal. Normal scarring is the result of an uncomplicated healing process and 
presents as a flat, unrecognizable scar in contrast to the surrounding skin. Injuries 
penetrating only the epidermis will heal without a resulting scar. Healing of a normal scar 
usually takes 24 hours once the basal cell layer in injured healthy skin begin to proliferate, 
re-creating an intact epidermal layer (Hill and Pickart, 2009). Abnormal scarring develops 
when the healing process of a wound does not follow the normal process. An inflamed 
wound could take longer to heal due to an extended inflammatory phase. Abnormal 
scarring includes atrophic, hypertrophic and keloid scarring (Son and Harijan, 2014; Gozali 
et al., 2015). It is attributed to delayed epithelisation in areas of high tension for example 
the sternal regions, deltoid and other areas of movement (Penn et al., 2012). 
 
Scars, in the early wound healing stages, are classified as being red, swollen and sensitive, 
and over time, as the redness dissipates exposing the true colour of the scar, as darkened 
(hyper-pigmentation) or lightened (hypo-pigmentation) (Chadwick et al., 2012). Scar tissue 
has reduced hydration (amount of moisture) and less elasticity than the surrounding skin 
and is identified by its colour, texture and contours (Monstrey et al., 2014). Damage to the 
skin encourages the skin‟s protection mechanism to respond by thickening and stimulating 
elastin and excess collagen production, causing abnormal scarring (Hill and Pickart, 2009). 
 
2.6.2 The pathophysiology of scarring 
 
A wound is a disturbance of normal tissue that occurs from either physical or pathological 
processes (Hill and Pickart, 2009), but luckily with damage comes repair. Healing is a 
process by which the damaged tissue repairs itself to join the surrounding healthy tissue of 
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the body through three phases known as the inflammatory, proliferative and remodelling 
phases (Figure 2.5) (Reinke and Sorg, 2012).  
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2.6.3 The inflammatory phase 
Healing starts with inflammation at the site of injury which is characterized by redness, pain 
and swelling from constricted lacerated vessels (LeBert and Huttenlocher, 2014). 
Inflammation takes place within the first three (3) days (0-3 days) at the injured wound site, 
to prevent infection (Brown, 2015). An injury to the tissue is followed by gradual 
haemostasis. During haemostasis, the microcirculation creates thrombocytes (platelets) and 
fibrinogen (blood-clotting protein) to start the formation of a haemostatic plug in the area to 
prevent further bleeding and encourage healing. Once the haemostatic plug has formed, 
the next process addresses the removal of dead tissue from the wound in order to prevent 
infection (Velnar et al., 2009). 
The process of dead tissue removal is assisted by phagocytic cells which are produced by 
the inflammatory cells. Within 24 hours and continuing for the first five (5) days after injury, 
neutrophils (rich in fibrin) enter the area to assist in killing local bacteria and removing dead 
tissue (Young and McNaught, 2011). Leucocytes increase within 24 hours of the 
inflammatory phase and, together with lymphocytes, are critical for the removal of necrotic 
tissue (Franz et al., 2007). Macrophages are released and are responsible for scavenging 
debris, secreting growth factors (chemokine‟s and cytokines) (Figure 2.6) and for initiating 
the transition from the inflammatory phase to the proliferative phase (Velnar et al., 2009). 
Figure 2.6 The inflammatory phase of wound healing (Gurtner et al., 2008) 
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2.6.4 Proliferative phase 
The proliferative phase starts at day 4 or 5 (Son and Harijan, 2014), of the healing process, 
and continues to day 21. During this phase, the haemostatic plug is replaced by granulation 
tissue (macrophages, fibroblasts and endothelial cells). Both type I and type III collagen are 
associated with the proliferative phase. Type I collagen is the most abundant type of 
collagen found in the normal dermis. However, during the proliferative phase of healing 
fibroblast cells multiply, encouraging collagen type III to be laid down, creating a structural 
framework for endothelial cells. Type III collagen is quickly produced by young fibroblasts 
before the tougher type I collagen is synthesized (Van den Broek et al., 2012). The 
restoration of the epithelium is of importance for tissue integrity as it re-strengthens the skin. 
Keratinocytes found in the follicles of skin and below the scab, migrate across the 
granulation tissue causing a separation of the scab from underlying tissue. During the 
migration of the keratinocytes, plasminogen activators release plasmin to assist in 
dissolving the scab. As the keratinocytes continue to migrate, new epithelial cells are 
formed, completing the healing process of the damaged tissue (Figure 2.7). If the 
proliferative phase of cell death does not start, hypertrophic and keloid scars can develop 
(Velnar et al., 2009). 
Figure 2.7 The proliferative phase of wound healing (Gurtner et al., 2008) 
© Central University of Technology, Free State
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2.6.5 Remodelling phase 
 
The remodelling phase starts around day 21 and continues to day 365. Wound remodelling 
occurs once the proliferative phase comes to an end by means of programmed cell death. 
Type III collagen formed during the proliferative phase degenerates and is replaced with 
stronger type I collagen, which accounts for 10-20% of the collagen in the dermis of adults 
(Hill and Pickart, 2009). In an unwounded dermis the collagen fibre bundles are arranged in 
a basket-weave pattern whereas in an acute wound the matured collagen fibres are 
oriented in overlapping arrays parallel to the wound surface and usually along lines of 
maximum tension, thereby contributing to scar appearance (Figure 2.8) (Velnar et al., 
2009). 
 
 
 
 
 
 
 
 
 
 
Figure 2.8  The remodelling phase of wound healing (Gurtner et al., 2008) 
 
2.6.6  Different types of scar formations 
 
Depending on the extent of wound injury and genetic factors, various scars can develop 
during wound healing for instance atrophic, hypertrophic and keloid scars.  Atrophic, 
hypertrophic and keloid scars are most often associated with acne (Gozali et al., 2015) 
while) hypertrophic and keloid scars are usually seen after breast reduction surgery 
(Monstrey et al., 2014). All ethnic groups are prone to keloid and hypertrophic scarring; 
however, it is most frequently seen in African Americans, Hispanics and Asians;  possibly 
due to collagen type III production and melanocyte stimulating hormone anomalies (Juckett 
and Hartman-Adams, 2009; Hunasgi et al., 2013). 
 
© Central University of Technology, Free State
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2.6.6.1 Atrophic scars 
Atrophic scars (AS) are typically rounded, flat or inverted and present in patients that have 
suffered from acne or chickenpox, leaving a pit-like appearance (Levy and Zeichner, 2012). 
Endogenous factors including involuntary stretching due to surgery or excessive tension on 
the wound edges, could lead to dermal dehiscence, which can result in the development of 
striaedistensae (SD). SD is formed after excessive dermal stretching and presents with a 
scar like appearance, showing hypo-pigmentation and dermal fibrosis, due to a prolonged 
inflammatory phase (Figure 2.10) (Ud-Din and Bayat, 2014). Increased melanisation has 
been noted to be more severe in African American women compared to Caucasian women 
(Ud-Din and Bayat, 2014). Treatments for AS include chemicals peels, micro-dermabrasion, 
laser therapy and surgery (Levy and Zeichner, 2012). A treatment specifically mentioned for 
SD is treatment with the Mesotherapy Eporex machine. The machine is used in 
combination with active ingredients, such as Vitamin C which is an antioxidant and assists 
in healing, skin elasticity and promotes fibroblast stimulation (Vedamurthy, 2007). 
2.6.6.2 Hypertrophic scars 
Hypertrophic scarring (HTS) presents as a red, warm, hard, pruritic (itchy), painful/tender 
and lumpy scar due to uneven collagen production and it is raised above the skin level but 
does not exceed the original lesion‟s boundary (Figure 2.9) (Ud-Din and Bayat, 2014). HTS 
is mostly caused by surgical incisions and these scars usually appear within one (1) month 
of injury, but can continue to develop over a few years (Juckett and Hartman-Adams, 2009). 
After surgery, the human body heals itself by producing collagen which is deposited in the 
skin to provide protection. In the case of hypertrophic scarring the collagen accumulation is 
arranged in whorls and nodules rather than a basket-weave pattern resulting in a 
hypertrophic appearance (Huang et al., 2013,). HTS gradually matures taking anything from 
12-18 months to form (Donovan et al., 2016). 
© Central University of Technology, Free State
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Figure 2.9 Hypertrophic breast scarring at the inframammary crease (Chopra et al., 2014) 
 
2.6.6.3 Keloid scars 
 
A keloid scar conforms to a hypertrophic scar except that it extends beyond the natural 
architecture of the injured area (original lesion‟s boundary) (Hunasgi et al., 2013). A keloid 
scar is red in colour, raised in height, large in shape and reflects a shiny appearance 
(Figure 2.10) (Monstrey et al., 2014). The pathophysiology of keloid scarring is not fully 
understood, and Van der Veer et al. (2009) suggested that during the proliferation phase, 
fibroblasts, which form connective tissue, develop larger quantities of collagen fibres than is 
considered normal. This type of scarring does not subside, rather it continues to mature 
over time as collagen synthesis in keloids is 20 times greater than in normal unscarred skin 
(Shen et al., 2015). Keloid scarring is difficult to treat and due to its unsightly exterior, 
patients may resort to surgical interventions to improve the visual appearance of the scar 
(Hill and Pickart, 2009). 
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Figure 2.10 Keloid scarring at the nipple areola (Davalia et al., 2008) 
2.6.7 Factors delaying wound healing that can contribute to scar formation 
Various factors have an impact on wound healing and the amount of scar tissue formed 
after mammary reduction surgery. These factors are associated with improved or poor 
wound healing. In general, these factors include genetics, medical history (for example 
medication, diabetes, post-surgical care and disease or illness), physical stress, active 
lifestyle and ethnicity (Hill and Pickart, 2009; Huang et al., 2013).  
2.6.7.1 Genetics 
Genetics and aging have an effect on scar formation (Shermak et al., 2011; Thompson et 
al., 2013). A genetic factor could be, for example, being born with a suppressed immune 
system which in turn affects the inflammatory phase of healing,  making it difficult for the 
body to heal at the required rate, thus resulting in keloid scarring (Brown et al., 2008; Shih 
and Bayat, 2010). 
Wound healing may occur in older patients, mainly due to co-morbidities and inadequate 
nutritional intake, altered hormonal responses, poor hydration and compromised immune, 
circulatory, and respiratory systems which increase the risk of skin breakdown causing a 
delay in wound healing (Hess, 2011). 
© Central University of Technology, Free State
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2.6.7.2 Medical history 
 
A. Disease or illness 
Chronic diseases that cause immune suppression such as diabetes, coronary artery 
disease, peripheral vascular disease, cancer to name a few can negatively affect wound 
healing (Hess, 2011). The impaired vascular flow causes poor tissue oxygenation and 
decreases epithelialisation, thereby prolonging healing which could encourage abnormal 
scar formation (Guo and Dipietro, 2010). 
 
B. Smoking 
 
Smoking is a preventable lifestyle factor that affects both the rate and quality of wound 
healing, and significantly increases the risk of postoperative, wound-related complications 
(Ahn et al., 2008; Cope, 2014). Smoking could have an adverse effect on healing as it 
causes vasoconstriction of the blood vessels resulting in low oxygen levels (Sørensen et al., 
2009). Carbon monoxide, found in the blood of smokers, preferentially binds to 
haemoglobin, reducing the delivery of O2 to the wound. The lower O2 levels cause a delay in 
the inflammatory phase by diminishing the function of neutrophils and macrophages, 
resulting in poor wound healing (Deliaert et al., 2012). In cosmetic surgery outcomes in 
smokers appear to be worse, and plastic surgeons and reconstructive surgeons are often 
reluctant to perform cosmetic surgeries on individuals who refuse to quit smoking (Guo and 
Dipietro, 2010). 
 
C. Post-surgical care and active lifestyle 
 
Post-surgical care is of great importance as this can determine the speed of wound healing 
(Anderson and Hamm, 2012). Vigorous treatments or resuming physical activity too early 
can stimulate inflammation and oedema, prolonging the inflammatory phase, and can result 
in wound disruption. An inflamed wound results in increased collagen deposition. By being 
gentle during the early stages of healing, rehabilitation can progress faster at later stages of 
healing (Gantwerker and Hom, 2012). However, being active is also of great importance as 
this improves blood circulation; increases O2 delivery, assists in lymph removal and 
supports the body‟s response to emotional and physical stress (Guo and Dipietro, 2010). 
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Because physical activity has a positive influence on immunity, being physically active 
before/after surgery within limits could encourage wound healing.  
D. Physical stress 
Stress has an impact on overall health and social behaviour. Stress lowers the strength of 
the immune system and since the immune system plays a vital role in wound healing, high 
stress levels result in delayed wound healing (Godbout and Glaser, 2006; Vileikyte, 2007). 
In addition to the direct influences of anxiety and depression on immunity, stress also 
affects an individual‟s daily habits. Daily stress can contribute to poor sleeping patterns, 
inadequate nutrition, lower levels of exercise and possible susceptibility to alcohol or drug 
abuse (Guo and Dipietro, 2010). 
E. Nutrition and hydration 
Nutrition and hydration are the construction blocks for tissue repair, therefore a patient‟s 
diet should contain proteins, carbohydrates, fat and vitamins to promote wound healing 
(Arnold and Barbul, 2006; Hill and Pickart, 2009). Vitamin C is a vitamin essential for wound 
healing and should be supplemented on a daily basis.  Vitamin C provides tensile strength 
to newly formed collagen and is required for proper immune function (Collins, 2013). 
Vitamin E maintains and stabilizes cellular membrane integrity and has anti-inflammatory 
properties (Guo and Dipietro, 2010). 
F. Medication 
Medications can affect the healing process; negatively or positively. Common medications 
known to compromise the healing process include chemotherapeutic drugs, glucocorticoid 
steroids and non-steroidal anti-inflammatory drugs. These drugs have a tendency to destroy 
the cell structures that are required for cell reproduction (Guo and Dipietro, 2010; Wigston 
et al., 2013). Medications can also affect the body by lowering the immune system which in 
turn results in poor wound healing (Kidd et al., 2016). 
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G. Ethnicity 
 
When comparing the structure of white skin to dark skin, in general dark skin has a thick, 
compact dermis with prominent and numerous fibre fragments which could complicate the 
healing process. Keloid scarring is more prominent in black skin due to higher levels of 
compacted collagen bundles (Czerkasij, 2013). Melanocyte-stimulating hormone anomalies, 
familial predisposition, with autosomal dominant and recessive genetic variants is 
recognized as possible causes for why darkly pigmented skin carries a 15- to 20-fold 
increased risk for keloid formation (Kose and Waseem, 2008; Juckett et al., 2009; Ahuja et 
al., 2015). 
 
2.6.7.3 Amount of breast tissue removed 
 
The chance of skin loss and delayed wound healing increases as the quantity of resection 
increases (Andrades and Prado, 2007). Hypertrophic breast with moderate to severe ptosis 
require greater elevation of the nipple-areola complex and larger amounts of skin excised. 
This could result in closure of the surgical site to be tight or excessively thinned flaps 
increasing chances of wound breakdown. This usually occurs at the junction of two scar 
lines and in this case the Wise pattern junction of the inverted T (Saleem and John, 2013). 
 
Overweight and obese women usually have large breasts, which logically explain the 
connection between large resections and local complications (Murray et al., 2008; Setälä et 
al., 2009). Ayadin et al. (2016) found a strong correlation between breast resection weight 
and the risk of complications to surgery such as delayed wound healing, wound 
dehiscence, nipple/areola necrosis, haematoma, sarcoma, fat necrosis, hypertrophic 
scarring and infections. In order to prevent delayed wound healing and dehiscence in 
patients with high BMI, antibiotic coverage for a period of five (5) days could be regarded as 
useful (Saleem and John, 2013).  
 
Ptosis is another method to determine the amount of breast tissue removed during surgery.  
The higher the grade of ptosis the more breast tissue is being removed leading to longer 
scars with the disproportionate skin and excessive dog ears (Andrades and Prado, 2007; 
Shiffman, 2009). 
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2.6.8 The assessment of scar tissue formation post-mammary reduction surgery 
A deep wound could potentially lead to excessive scar formation, whereas a superficial 
wound should heal without leaving a scar. According to Brusselaer et al. (2010) several 
scar scales have been developed over the last 30 years of which the Vancouver Scar Scale 
(VSS) and the Patient and Observer Scar Assessment Scale (POSAS) are the most widely 
used (Brusselaers et al., 2010). An instrument used to measure any health status, in this 
case the amount of scar hypertrophy or activity, is required to include four (key) features, 
namely validity, reliability, consistency and feasibility (Duncan et al. 2006). To date, no ideal 
objective measurement tool has been developed or identified to assess scar tissue 
formation post mammary reduction surgery.  However, the Vancouver Scar Scale (VSS) 
remains the most frequently used scar rating scale by doctors when assessing linear 
surgical scars, burn scars and skin grafts (Fearmonti et al., 2010; Ferriero et al., 2015). The 
VSS scale was used in this research study to evaluate scar formation. 
2.6.8.1 Vancouver Scar Scale (VSS) 
The VSS (Table 2.5) was first described by Sullivan in 1990 as a tool for the monitoring of 
changes in scar quality over time (Gankande et al., 2013). The VSS assessment evaluates 
the treatment response by evaluating scar vascularity, pigmentation, pliability and the 
height of a scar (Fearmonti et al., 2010; Wei et al., 2015). Truong et al. (2005) tested the 
VSS scale in the assessment of linear scars after breast cancer surgery. They concluded 
that the VSS scale is valid and reliable when assessing linear scars, although the level of 
reliability in their study was lower than what is usually considered acceptable (r=0.64). 
Despite its poor reliability, subjective assessment is still considered the gold standard in 
scar assessment (Kaartinen et al., 2011). 
A. Vascularity 
Vascularity of a scar is related to the stage of wound healing. Highly active scars have a 
greater blood supply leading to red and raised scarring whereas mature scars have fewer 
and smaller capillaries leading to a paler and flatter scar surface (Perry et al., 2010; Wei et 
al., 2015). Scar vascularity is divided into normal colour (old scar), which is in turn the exact 
same colour as the healthy skin surrounding the scar, and pink, red and purple (in the case 
of a recent scar). The colour of a scar is assessed by visual inspection Hallam et al., 2013). 
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B. Pigmentation  
Pigmentation is tested by blanching the skin to remove any blood supply to the area (Levy 
and Emer, 2012). Pigmentation refers to the number of melanocytes, bile and carotene 
pigments found in the scar. Normal pigmentation implies the same skin colour surrounding 
a scar. Hyper-pigmentation is the increase of melanocytes that creates darkening of the 
scar in contrast to the adjacent skin, whereas hypo-pigmentation is a decrease in 
melanocytes creating a lighter appearance of the scar opposed to the adjacent skin 
(Chadwick et al., 2012; Czerkasij, 2013). 
 
C. Pliability 
The pliability of a scar is measured by the normal movement, glide and stretch of the skin. 
The term pliability is highly subjective and describes suppleness, texture, skin tone and skin 
hardness (Ferriero et al., 2015). The skin‟s firmness and extensibility reflects both the 
morphological and physiological properties of a scar, revealing the equilibrium between the 
intra- and intermolecular cross-links of collagen, elastin and reticulin fibres embedded in the 
dermis. Range of motion is the simplest method for measuring the functional effect of the 
skin‟s pliability (Morien et al., 2008). 
 
D. Height 
Changes in the height of a scar could reflect the maturity of a scar and also the relation to 
the overabundance of collagen deposition (Gauglitz et al., 2011). Scar height is defined as 
the elevation of the scar raised above the surrounding tissue (Thompson et al., 2015). 
Rulers are used to measure the external size of a scar, for example the length, width, height 
and elevation (Ferriero et al., 2015). 
 
The VSS has zero (0) to five (5) possible scores for each characteristic being assessed 
(Table 2.5). The scores are achieved by comparing each characteristic with the adjacent 
healthy skin. The scale is scored on a range of 0-13, where 0 reflects normal skin healing 
and 13; poor skin healing (Kaartinen et al., 2011). The emphases of the subjective 
measurements are on the appearance and cosmetic aspects of scarring. The scoring 
should depend on the severity of the scar area being assessed (Gankande et al., 2013). 
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Table 2.4 Vancouver Scar Scale (VSS) (Kaartinen et al., 2011) 
2.6.9 Treatment modalities for post-operative scar formation 
The treatment of scar tissue formation is not a spontaneous decision as scars respond 
differently to various treatment techniques, and usually more than one scar treatment is 
required. A scar treatment technique cannot guarantee the removal of scar tissue without 
any visible marks remaining. It is possible to improve the visual appearance of a scar and 
surrounding skin through various methods of surgical and non-surgical treatments (Levy 
and Zeichner, 2012). These methods aim to reduce inflammation, increase hydration and 
assist in collagen synthesis (Rabello et al., 2014). 
2.6.9.1 Re-surgical and radiation treatment 
Re-surgery can be used to treat keloid scarring by changing the appearance of the scar 
shape by altering its position (Rabello et al., 2014). The process is risky as it can trigger a 
PARAMETER DESCRIPTOR POINTS 
Vascularity 
Normal 0 
Pink 1 
Red 2 
Purple 3 
Pigmentation 
Normal 0 
Hypo-pigmentation 1 
Hyper-pigmentation 2 
Pliability 
Normal 0 
Supple 1 
Yielding 2 
Firm 3 
Ropes 4 
Contracture 5 
Height 
Flat 0 
<2mm 1 
2-5 mm 2 
>5 mm 3 
Total score /13 
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larger formation of keloid scarring in the same area. New scars could take up to 2 years to 
mature (Ogawa and Chin, 2008). 
 
Surgery and radiation can also be used in conjunction with one another to treat keloid 
scars. Radiotherapy is commonly used to suppress the overgrowth of scar tissue (Shen et 
al., 2015). Low doses of superficial radiation can be applied to the operation site from the 
first day after surgery, aiming to alter the fibroblast formation and increase the breakdown of 
collagen production (Velnar et al., 2009). 
 
2.6.9.2 Non-surgical treatments 
 
Numerous non-surgical treatment modalities can be used against scar formation. These 
treatment options include message, steroid injections, laser, silicone gel or sheets, 
cryotherapy, peels, gels and creams, onion extracts, interferon etc. to name just a few 
(Velnar et al., 2009; Monstrey et al., 2014). 
 
Di-Ud and Payat (2014) stated that tissue healing could be enhanced through electrode 
stimulation and, more recently, electrode stimulation in the treatment of abnormal raised 
dermal scarring, alleviating the symptoms of pain, pruritus, and inflammation. 
 
A modern technique used to treat a variety of clinical conditions (cellulite, wrinkles/aging, 
acne and muscle aches) is non-invasive Mesotherapy Eporex (Figure 2.13). The treatment 
encompasses the use of modulated electrical wave lengths and ionized ingredients that are 
propelled into the skin at varying depths (Konda and Thappa, 2013). For the purpose of this 
research project emphasis will be placed on the effectiveness of Mesotherapy Eporex 
treatments on scar appearance. 
 
2.7 Isophoresis via the Mesotherapy Eporex machine 
 
The skin is the largest, most important organ of the human body covering 2m² of surface 
area and is 1-2mm thick (Panzade and Puranik, 2012). The skin has three (3) layers 
namely the epidermis, dermis and hypodermis. Transdermal systems have been developed 
over the years for the purpose of delivering ionic and non-ionic agents into the different skin 
layers at variable depths (Herwadkar and Banga, 2012). The Mesotherapy Eporex machine 
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uses the new innovative isophoresis technique which is a transdermal delivery system, 
bringing about the synergy of known techniques such as iontophoresis, ionophoresis and 
electroporation (Figure 2.11) (Vedamurthy, 2007). 
Figure 2.11 Mesotherapy Eporex machine (A) Mesotherapy Eporex control board (B) Ultrasonic spatula (C)
Electrical pad (D) Mesotherapy Eporex apparatus (hand piece) with active ingredients 
Iontophoresis gained popularity at the beginning of the 20th century. Leduc introduced this 
method for administering pharmacological agents into the skin in the 1900's , 2008). The 
iontophoresis technique utilizes a continuous direct electrical current (galvanic), to repel 
charged molecules across a cellular membrane. Iontophoresis increases blood and 
lymphatic circulation as well as cellular metabolism (Rawat et al., 2008) 
Iontophoresis makes use of two (2) electrodes to complete an electrical circuit; one of the 
electrodes is referred to as the active electrode and the other as the indifferent electrode. 
The electrodes, in conjunction with a pulsed direct current, cause an acidic or alkaline 
chemical reaction to occur at the electrode site. Depending on the polarity an acidic effect is 
produced under the anode (positive pole) causing vasoconstriction of blood vessels, an 
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astringent effect on the pores, tissue firmness and soothing of nerve endings. The cathode 
(negative pole) on the other hand produces an alkaline effect causing vasodilatation, 
relaxation of pores, tissue softness and stimulation of nerve endings (Dhote et al., 2012; 
Panzade and Puranik, 2012). 
 
The ionophoresis current is similar to the iontophoresis current, encouraging movement of 
charged ions in an electrical field, with positively charged ions moving towards the cathode 
and negatively charge ions to the anode. Ionophoresis uses a direct current without 
modulated waves (Dhote et al., 2012). Due to the fixed frequency used by ionophoresis, 
there is limited ingredient penetration which may lead to chemical burns at the treatment 
site due to prolonged skin exposure. Other disadvantaged of ionophoresis includes difficulty 
in stabilizing the therapeutic agent in the application vehicle and the complexity of the drug 
release system (Krueger et al., 2014). 
 
Electroporation uses high voltage pulses for short durations (Ma et al., 2014; Ita, 2016). 
Electroporation is best known as a physical transfection method where the skin cells are 
exposed to a brief electrical pulse, thereby opening the pores in the cell membrane, 
allowing micro-molecules to enter the cell (Santra and Tseng, 2013).  
 
Isophoresis uses a synergy of the 3 penetration methods (Figure 2.12) expanding the 
scope of transdermal delivery (Dhote et al., 2012). The electrical pulses created by the 
Mesotherapy Eporex machine induce a structural re-arrangement of the semi-permeable 
cell membranes encouraging the increased uptake of macro and micro molecules. 
Isophoresis uses a low frequency modulated (non-continuous) alternating current, which is 
a pulse, released with a low frequency elasto-modulated profile with an intensity that can be 
adjusted on the system by the operator. The low frequency modulated alternating current 
allows hydro-soluble molecules to enter the extra-cellular compartments of the skin during 
the “on” phase. During the “off” phase no current flows through the electrode, preventing 
the tissues from absorbing too much energy thus avoiding possible thermal damage 
[Mesotherapy Eporex K69 User Manual (Appendix A1)]. 
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Figure 2.12 Combination of three (3) different currents, forming isophoresis 
The Mesotherapy Eporex machine differs from other electrical currents and machines with 
respect to the wave modularity it uses and the presence of an ionization chamber (Figure 
2.14). The isophoresis transmission can be summarized into three (3) processes. Firstly, 
the low frequency modulated alternating current ionises the molecules in the chamber, 
secondly ingredients are propelled to different depths of the skin and lastly electroporation 
occurs via osmosis. The ionization chamber prepares active ingredients by ionizing them 
and, in combination with an electrical current, up to 90% of the active ingredients can be 
delivered to depths of 0.1cm to 10cm in the treatment area (Goldman and Hexsel, 2010; 
Mammucari et al., 2011). 
Isophoresis 
Low frequency  
Pulsated alternating current 
Ingredients are ionised by the ionising chamber 
Macro and micro molecules 
No possibility of burns 
Depths of 9-10cm  
Iontophoresis 
Continuous direct current 
Modulated wave impulses 
Low voltage (10 V or less) 
Pushes ingredients through the 
skin 
Small molecular weight 
molecules 
Polarised ingredients needed 
Increased pulse for short periods 
Possibility of burns 
Limited depth of penetration 
Ionophoresis 
Continuous direct current 
No modulated wave impulses 
Pushes ingredients through the 
skin 
Small molecular weight 
molecules 
Polarised ingredients needed 
Continuous pulse  
Possibility of burns 
Limited depth of penetration 
Electroporation 
High voltage (>100 V) in a short 
duration 
Breaking down of stratum 
corneum 
Changes of cell membrane = 
opening  of pores 
Small molecular weight 
molecules 
Lipophilic, hydrophilic charged 
and neutral molecules 
© Central University of Technology, Free State
  
 
42 
2.7.1 Ultrasound for exfoliation of corneocytes and improved skin tone 
 
In conjunction with the Mesotherapy Eporex treatment, an ultrasonic spatula is used for skin 
exfoliation, healing and improved product penetration. The ultrasonic spatula is held at a 
45° angle allowing ultrasonic waves to cover a large surface, exploiting the principle of 
cavitation (transfer of liquid molecules to vapour) (Figure 3.2). Cavitation encourages the 
removal of corneocytes and improves blood circulation in the area. The application of low-
frequency ultrasound enhances the stratum corneum‟s (SC) permeability for a variety of 
water soluble ingredients. The ultrasound prepares the skin for the transdermal delivery of 
active ingredients prior to the main treatment by promoting the exfoliation of 20-50% of 
corneocytes (D‟Angelo, 2009; Tekchandani, 2016). 
 
After the completion of the main treatment the ultrasound spatula can be used to encourage 
healing and assist in the deeper penetration of ingredients utilized during a treatment. The 
ultrasound spatula is held at a 45° angle facing upward with the flat side on the area of 
treatment (Figure 3.4). The ultrasound waves created by the ultrasound spatula cause 
vibrations in the molecules which create heat and further encourage cellular stimulation and 
deeper product penetration (MacGregor and Tanzi, 2013). 
 
2.7.2 Intracellular absorption/transdermal delivery 
 
One of the skin's primary functions is that of protection. The skin is covered with a natural 
barrier, preventing exogenous substances such as molecules or ions from entering the 
body. The route of penetration for active ingredients into the skin is to cross the stratum 
corneum and pass through the epidermis (Panzade and Puranik, 2012), to reach the dermis 
(middle layer of the skin) and subcutaneous tissue. The channels (trans-cellular route) 
responsible for water transport into the cells, allow for the transport of substances such as 
water, salts and molecules through the cellular membrane via chemical impulses. The 
chemical impulses induce the flow of active ingredients from cell to cell (osmosis), resulting 
in a macroscopic distribution (Sharma et al., 2015). The electrical impulses created by the 
current, allow for a temporarily confused cellular membrane - a vibration allowing the 
ingredients to pass through the cell layers (Figure 2.13). Once the electrical current is 
removed, the cells return to normal and the penetrated ingredients are retained within the 
cell (Rawat et al., 2008). 
© Central University of Technology, Free State
43 
 
Figure 2.13 Intracellular penetration through the skin barrier by hydrophilic keratinocytes 
(Tosti and De Padova., 2007). 
2.7.3 The Mesotherapy Eporex hand piece 
The Mesotherapy Eporex hand piece (Figure 2.14) has an internal stainless steel ionization 
chamber, responsible for the electrical preparation of molecules. A plastic bottle, containing 
clear conductive gel and active ingredients chosen for the treatment, is shaken to combine 
the ingredients and connected to the hand piece. The active gel is squeezed into the 
chamber ensuring constant contact with the ionization chamber and thus allowing ionization 
of the ingredients through the elasto-modulated current. The application of the front 
stainless steel roller to the skin creates a constant and graduated transmission of active 
ingredients into the skin. The continuous transmission provides optimal depth transmission, 
creating electro-pores and encouraging osmosis (transferring of ingredients between cells) 
[Tosti and De Padova., 2007; Mesotherapy Eporex K69 User Manual (Appendix A1)]. 
Water Channel Cell Membrane Ion Channel 
Skin Cell 
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Figure 2.14 Mesotherapy Eporex hand piece and the ionization chamber 
 
Electro-pores are channels used to transport active ingredients at a specific phase of 
electrical induction (on phase) and can preserve the active ingredients until the correct 
depth in the skin is reached to induce the diffusion of high weighted molecular structures 
(Konda and Thappa, 2013). 
 
Electrolytes (therapeutic ingredients from herbs, plants, flowers and fruits) contain both 
acids and salts which increase electrical conductivity. With the assistance of iontophoresis 
the skin‟s resistance is broken down and a chemical change occurs within the skin. When 
electrolytes are dissolved in a water base, the electrolytes partly split and form ions carrying 
a negative (cation) or positive (anion) charge. When these electrolytes come into contact 
with the direct current, movement between the ions occurs, encouraging like charges to 
repel and opposite charges to attract (electrical principle) (Dhote et al., 2012 Bhatia and 
Banga, 2014). In the human body the tissue fluids possess electrolytic properties, thus 
allowing a current to pass through the skin and propel ingredients to the deeper layers of 
the skin (Panzade and Puranik, 2012). 
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2.7.4 Active ingredients used in conjunction with Mesotherapy Eporex treatments 
Numerous active ingredients can be utilized with the Mesotherapy Eporex machine to treat 
scar appearance. These active ingredients include Asian Centella, Hyaluronic Acid, 
Vitamins A, B, C, organic silica, poly nucleotides-DNA, soybean extract, polyphenols and 
mineral salts (Latha and Vandana, 2011; Konda and Thappa, 2013) . However, the 
suppliers (Mesoskin Therapy Worldwide, Orlando, Florida) of the Mesotherapy Eporex 
ingredients recommended the use of three (3) active ingredients for the treatment of 
scarring (namely Asian Centella, Hyaluronic Acid and Vitamin C). Based on this information 
Asian Centella, Hyaluronic Acid and Vitamin C were used in conjunction with the 
Mesotherapy Eporex machine for the treatment of scarring in this research study.  
2.7.4.1 Asian Centella (Centella asiatica (L.)) 
Asian Centella is an aromatic herb found in abundance on moist, sandy/clay, damp fields in 
India. This herb is a faintly aromatic, stoloniderous, perennial creeper which attains a height 
up to 15cm (Tripathi et al., 2015). The chemical constituents of the Centella plant have an 
important role in both medicinal and nutraceutical applications (Seevaratnam et al., 2012; 
Bylka et al., 2013).  
Asian Centella has positive attributes which include: 
Figure 2.15 Positive attributes of Asian Centella 
Asian Centella is a water soluble ingredient aiding in wound healing by stimulating type I 
collagen and by increasing antioxidant levels (Song et al., 2012). Oral and topical 
administration of Asian Centella used from week six (6) to eight (8) may increase wound 
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strength. Asian Centella extract contains asiaticosides and madecassosides (purified 
molecule of Asian Centella) which have a stimulating action, through collagen and elastin 
biosynthesis in the dermal fibroblasts and vein walls, thus improving the tone and elasticity 
of the skin, aiding in early treatment of keloid formation and they exhibit anti-inflammatory 
properties (Song et al., 2012; Somboonwong et al., 2013). 
 
2.7.4.2 Hyaluronic Acid (HA) 
 
HA is a natural compound found in the human body. However, with age the quantities of HA 
deteriorate dramatically which makes the skin susceptible to wrinkles, dehydration and 
infection (Papakonstantinou et al., 2012). HA is hygroscopic and increases the permeability 
of the skin by hydrating the stratum corneum as it binds with water molecules found in 
between the intercellular spaces of tissues, thus allowing the receptors found in HA to be 
distributed in the skin tissue facilitating the localization of HA (Yang et al., 2012). HA is a 
linear polysaccharide with more than 50% of the body‟s HA found in skin tissue. The 
application of iontophoresis has been limited to the delivery of small molecules with a 
charge, whereas ionophoresis disrupts the lipid structure of the stratum corneum to 
enhance the skin‟s permeability allowing deeper product penetration (Konda and Thappa, 
2013). 
 
In conjunction with ionophoresis, HA absorbs an additional 500 water molecules, swelling in 
size and allowing the transport of essential nutrients from the blood stream to the skin cells, 
contributing to dermis renewal and removal of harmful compounds. HA aids in wound 
healing (Konda and Thappa, 2013), through the stimulation of agents required for collagen 
synthesis, as HA can enhance the proliferation of fibroblasts through receptors on the cell 
membrane. HA also acts as a humectant and protects against free-radical scavengers 
(Papakonstantinou et al., 2012; Yang et al., 2012). 
 
HA is likely to play a multifaceted role during the stages of healing. A variety of cell 
functions are essential for tissue repair and this may be the result of the HA rich network. 
These functions include facilitation of cell migration into the provisional wound matrix, cell 
proliferation and organization of the granulation tissue matrix (Necas et al., 2008;Xu et al., 
2012). HA was observed to enhance cellular infiltration (Necas et al., 2008). Wound tissue 
in the early inflammatory phase of wound repair is abundant in HA thus an increased 
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synthesis of HA plays a crucial role in the skin wound healing process. These benefits 
contribute to smoothing of the skin and improving the appearance of scars (Yang et al., 
2012). 
2.7.4.3 Vitamin C (Ascorbic Acid) 
Vitamin C is an essential nutrient for human beings and is a water soluble antioxidant that 
can be delivered topically or transdermally (Telang, 2013). Vitamin C acts as a co-factor for 
hydroxylation of the proline and lysine residues of pro-collagen and thereby promotes the 
formation of the triple-helical conformation of mature collagen fibres (Michels and Frei, 
2013). Vitamin C assists in wound healing by decreasing oxidative stress; causing skin to 
remain radiant and bright. Vitamin C also acts as a natural antihistamine contributing to the 
release of histamine, therefore aiding in wound healing (Lima et al., 2009). 
Vitamin C is found in high concentrations in immune cells, and is consumed quickly by the 
body during infections. It is not certain how with the immune system; it has been 
hypothesized to modulate the activities of phagocytes, the production of cytokines and 
lymphocytes, and the number of cell adhesion molecules in monocytes encouraging faster 
healing phases (Velnar et al., 2009; Guo and DiPietro, 2010; Paiva et al., 2013). 
Topical and Mesotherapy intradermal applications of Vitamin C concentrations vary from 
5% - 30%, the higher the percentage of Vitamin C concentration the lower its absorption 
rate in the skin, rendering the antioxidant effect ineffective. A study conducted by Michels 
and Frei (2013) explains that a 20% Vitamin C concentration has the highest absorption 
rate in the dermal layers, helping to stimulate the formation of the epidermal barrier and re-
establish the SC. Thus the application of 20% Vitamin C would allow maximal antioxidant 
absorption (Telang, 2013). After being delivered into the skin, Vitamin C is stabilized and 
remains in the tissue for a period of four (4) days (Michels and Frei, 2013). Thus, the re-
application of Vitamin C could possibly enhance the healing process during all three (3) 
healing phases.  
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2.7.5 Indications and advantages of the Mesotherapy Eporex treatment 
 
The Mesotherapy Eporex treatment is non-invasive, painless and provides a range of 
benefits which include the alleviation of inflammatory conditions, skin conditions, muscular 
aches and pain relief (Latha and Vandana, 2011; Konda and Thappa, 2013). The treatment 
enhances ingredient penetration with a strict control of transdermal penetration rates. 
Ingredients used during this treatment aid in healing, collagen stimulation, increased 
moisture levels, improved skin elasticity and texture. The main advantages of no needle 
Mesotherapy is that it is completely painless, no bruising, erythema or swelling, materials 
can penetrate to deeper levels, immediate rapid response and it is cost effective and larger 
areas can be treated in comparison with injection Mesotherapy (Konda and Thappa, 2013; 
Bagwe and Sarawade, 2014). 
 
2.7.6 Contra-indications and disadvantages of the Mesotherapy Eporex treatment 
 
Contra-indications for Mesotherapy Eporex (non-invasive) treatment is based on contra-
indications applicable to the application of electrical currents and includes; pregnancy, 
breast feeding, open wounds, cardiac pacemakers, allergy to active ingredients (Kopitar et 
al., 2012). As the Mesotherapy Eporex treatment is time consuming, it could be considered 
a disadvantage to both the participant and therapist.  
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CHAPTER 3 
METHODOLOGY 
3.1 Introduction 
The objectives identified for this research study were four-fold. The first objective was to 
determine the effectiveness of the Mesotherapy Eporex treatments with active ingredients 
by comparing the scar appearance of the experimental breast to that of the control breast. 
Secondly, to determine the percentage of improvement of scar appearance after applying 
the Mesotherapy treatment for each of the four (4) categories included in the VSS. Thirdly 
to investigate whether scar appearance (wound healing) differs between the right and left 
breast by randomizing the application of the Mesotherapy Eporex treatment between the 
right and left breast. Lastly, to investigate the possible influence that the variables ptosis, 
breast tissue removed, BMI and age have on scar appearance, thus Mesotherapy Eporex 
treatment effectiveness after receiving bilateral mammary reduction surgery. 
3.2 Study design 
A randomized, experimental study was used to assess the effectiveness of the 
Mesotherapy Eporex therapy with active ingredients. 
3.3 Study location 
The research study was conducted at the medical practice of a private plastic surgeon 
situated at a private hospital in Bloemfontein, Free State, South Africa. 
3.4 Study population and sampling 
A research population is also known as a well-defined collection of individuals known to 
have similar characteristics. All the individuals within a certain population usually have a 
common, binding characteristic or trait. Therefore, female participants that received bilateral 
mammary reduction surgery that met the inclusion criteria were recruited to participate in 
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the study to ensure a homologous population. All participants were recruited from a single 
plastic surgery practice to ensure standardized surgical procedures and post-operative 
care. 
 
3.4.1 Sample size 
 
Thirty female participants (n=30) that received bilateral mammary reduction surgery were 
recruited for the research study. The 30 participants were randomly divided into 2 (two) 
groups of 15 participants each (P1-P30). 
 
3.4.2 Sample selection 
 
A biostatistician randomized the 30 participants into equal groups consisting of 15 
participants each in which the Mesotherapy Eporex treatments were performed on the right 
breast (experimental breast) and the left breast served as the control breast (not receiving 
Mesotherapy Eporex treatments). Simultaneously, in the other 15 participants, the 
Mesotherapy Eporex treatments were performed on the left breast (experimental breast) 
and the right breast served as the control breast (not receiving Mesotherapy Eporex 
treatments). This was done to evaluate if healing differs between the right and the left 
breast. 
 
3.4.3 In- and exclusion criteria 
 
To address the objectives of the study, the selection criteria for the patients were based on 
two main variables namely bilateral mammary reduction surgery and Mesotherapy Eporex 
treatment. The specific requirements for the inclusion and exclusion of patients in this study 
are outlined in the inclusion and exclusion criteria. 
 
3.4.3.1 Inclusion criteria 
Participants were included in the study if they met the following criteria: 
 
i. Female participants from the age of 20 years. 
ii. Participants that qualified to received bilateral mammary reduction surgery. 
iii. The Wise pattern approach with inferior pedicle surgical technique. 
© Central University of Technology, Free State
51 
iv. Female participants willing to avail themselves for Mesotherapy Eporex treatment six
(6) weeks after receiving bilateral mammary reduction surgery.
v. Female participants of all ethnic groups.
vi. Participants fully literate in English.
3.4.3.2 Exclusion criteria 
The following participants were excluded from the study: 
Male participants. 
Contra-indications include chronic diseases (diabetes, HIV, auto-immune 
diseases and epilepsy), pregnancy and cardiac pace makers. 
Patients with the chronic diseases mentioned above were excluded because 
chronic diseases can interfere with the process of wound healing. HIV patients 
were excluded because these patients suffer from severe forms of common skin 
diseases (seborrheic dermatitis and psoriasis) which can increase skin sensitivity 
(Halder et al., 2012). The application of an electrical current via the Mesotherapy 
Eporex machine on already sensitive skin will increase patient discomfort. 
Patients with cardiac pacemakers and pregnancy were excluded because the 
application of electrical current (Mesotherapy Eporex) can interfere with cardiac 
pacemakers and can be harmful to the unborn child (Rukari and Alhat, 2014). 
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3.5 Conceptual framework for data collection 
The data was collected according to the conceptual framework summarized in figure 3.1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1 Conceptual framework for data collection 
Bilateral Mammary Reduction Surgery (n=30) 
Experimental Breast 
(n=30) 
Control Breast 
(n=30) 
Demographic data 
- Ethnicity (Black, White,  
Caucasian/Asian) 
- Age (years) 
Anthropometry 
- Weight (kg) 
- Height (m) 
- BMI (kg/m2) 
Clinical data 
- Bra size (A-DD) 
- Ptosis (cm) 
- Amount of breast tissue 
removed (g) 
- Concomitant medication 
VSS assessments VSS assessments 
Plastic 
surgeon 
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- Prior to 
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Statistical Analysis 
Mesotherapy Eporex treatment with active 
ingredients six (6) weeks after surgery 
Collect data from medical records 
in Microsoft Excel ® 2013 
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3.6 Data collection 
Demographic, anthropometric and clinical data were extracted from patients’ medical 
records supplied by the plastic surgeon. Six (6) weeks post-operatively the Mesotherapy 
Eporex treatment commenced and scar appearance was evaluated using the VSS. A client 
information card was used to record the demographic, anthropometric and clinical data of 
each participant (Appendix B). 
3.6.1 Demographic, anthropometric and clinical data 
Demographic data [ethnicity (Black/White/Caucasian/Asian) and age (years)], 
anthropometric data [weight (kg), length (m) and body mass index (BMI-kg/m2)] and clinical 
data [bra size (cup A-DD), ptosis (cm), amount of breast tissue (g) removed from each 
breast during surgery, and concomitant medication] were recorded for each participant prior 
to the commencement of the Mesotherapy Eporex treatment. 
BMI (kg/m2) was calculated according to the following formula and interpreted according to 
Table 3.1. 
(Corbin et al., 2016) 
Table 3.1 Rating scale for body mass index (BMI) (Corbin et al., 2016) 
Classification BMI kg/m
2 
Low less than 17 
Normal (good fitness zone) 17-24 
Overweight 25-30 
Obese (high risk) over 30 
[BMI = Body Mass Index; kg = kilogram; m
2 
= meter square] 
Breast ptosis was determined by measuring the distance from the supra sterna notch down 
to the nipple in cm. If this measurement exceeds 21cm then a patient is presenting with 
breast ptosis (Khan and Bayat, 2008). The grade of breast ptosis was determined using the 
Regnault classification system (Castro et al., 2013) (Table 3.2). The grade of ptosis is 
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determined by the proximal measurement from the nipple to the inframammary crease 
measured in cm. Plastic surgeons use the grade of ptosis as estimation for the amount of 
skin resection and breast tissue to be removed during surgery. 
 
Table 3.2 Regnault classification system for breast ptosis (1976) 
 
 
3.6.2 Wise pattern with inferior pedicle surgical technique 
 
The surgical procedure was standardized and only the Wise pattern approach with an 
inferior Pedicle was used on all patients that received bilateral mammary reduction surgery. 
The Wise pattern approach with an inferior pedicle is also the surgical method of choice 
used by the plastic surgeon when performing bilateral mammary reduction surgery. The 
surgical technique is summarized in Appendix C. 
 
3.6.3 Mesotherapy Eporex treatment 
 
The aim of the research study was to determine the effectiveness of Mesotherapy Eporex 
treatment using specific active ingredients on linear scars produced by bilateral mammary 
reduction surgery. The Mesotherapy Eporex treatment commenced six (6) weeks after 
surgery to allow sufficient wound healing to take place and to reduce skin sensitivity. 
 
Each participant received eight (8) treatments lasting about thirty (30) minutes each using 
the Mesotherapy Eporex machine (serial number I472OT3787, Bester Medical Aesthetics, 
Cape Town, South Africa) for the introduction of active ingredients into the incision site. The 
treatments were scheduled three (3) days apart to allow for skin sensitivity to subside. 
In group one (1) (n=15), the right breast was treated with the Mesotherapy Eporex machine 
(experimental breast) and the left breast did not receive any treatment (control breast). In 
group two (2) (n=15), the left breast served as the experimental breast and the right breast 
served as the control breast. 
 
Grade 1 
(Minor ptosis) The nipple is at or up to 1cm below the inframammary crease. 
Grade 2  
(Moderate ptosis) The nipple is at 1cm up to 3cm below the inframammary crease. 
Grade 3 
(Major ptosis) The nipple ptosis is more than 3cm below the inframammary crease. 
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The Mesotherapy Eporex treatment was performed by making use of three (3) active 
ingredients and a water based gel:  
2ml Asian Centella ampoule (Mesotherapy Eporex worldwide, BE corporation, Bodi 
junction, Australia), 
5ml 20% Vitamin C ampoule (Mesotherapy Eporex worldwide, BE corporation, Bodi 
junction, Australia), 
5ml Hyaluronic Acid ampoule (Mesotherapy Eporex worldwide, BE corporation, Bodi 
junction, Australia) and 
60ml clear water based conductive gel (Bester medical aesthetics, Cape Town, 
South Africa). 
The active ingredients provided beneficial effects such as skin rejuvenation, hydration, 
strengthening of capillary walls, stimulation of collagen and elastin, anti-inflammatory 
properties and decrease myofibroblast production. 
3.6.3.1 Mesotherapy Eporex treatment protocol 
Each Mesotherapy Eporex treatment procedure was divided into three (3) steps: 
Step 1: Exfoliation using the ultrasonic spatula with the water based ultra-peel. 
Step 2: Scar treatment using the Mesotherapy Eporex machine with active   
ingredients set on the stretch mark programme. 
Step 3: Enhanced product penetration using the ultrasonic spatula. 
Step 1 
Pre-Treatment– Exfoliation 
The first step of the treatment procedure focused on desquamation of the treatment area. 
Each participant’s treatment commenced with a pre-treatment using the ultrasonic 
spatula.  
A water based ultra-peel solution (Bester Medical Aesthetics, Cape Town, South 
Africa), containing lactic acid and denatured alcohol, was applied to the scar by 
means of a facial brush.  
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 The derma-purification program was selected and pre-set for a maximum of three (3) 
minutes. The ultrasound spatula was placed facing downward at a 45° angle (Figure 
3.2) on the scar. Movements were made in an upward motion, thus allowing the 
spread of ultrasonic waves to create a high pressure peeling, removing skin sebum 
and lifting of keratinized cells from the scar surface, including a 1cm radius 
surrounding the scar tissue.  
 Due to the high liquid concentration of the water based ultra-peel solution, no residue 
was left on the skin after the exfoliation process. However, warm water with gauze 
was used to cleanse the skin further. 
 
 
 
 
 
 
 
Figure 3.2 Correct use of the ultrasonic spatula designed for exfoliation [Mesotherapy 
Eporex Manual, 2007 (Appendix A2)] 
 
Step 2 
Main Treatment – Active ingredients 
 
The second step of the treatment procedure focused on the penetration of the active 
ingredients into the skin. 
 
The active gel for the main treatment was prepared as follows: 
A 2ml Asian Centella ampoule, 5ml 20% Vitamin C ampoule and 5ml Hyaluronic acid 
ampoule were pre-mixed with 60ml clear conductive gel in a clear plastic bottle. 
 
 The main treatment commenced by placing an electrical pad, covered with a sponge 
and saturated with tap water under the participant’s scapula to complete the electrical 
current. 
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The Mesotherapy Eporex ball applicator (Bester Medical Aesthetics, Cape Town, 
South Africa) was connected to the stainless steel hand piece.  
A plastic bottle dispenser, containing the active gel, was connected to the 
Mesotherapy Eporex stainless steel hand piece (Bester Medical Aesthetics, Cape 
Town, South Africa). Through the application of pressure on the plastic bottle, the 
active gel was released into the stainless steel chamber of the hand piece where 
ionization of the ingredients occurred. 
The researcher applied a small amount of active gel onto the scar via the ball 
applicator without any current.  
On the Mesotherapy Eporex machine, the stretch mark program was selected and 
treatment time was set at 14 minutes. 
According to the participant’s comfort threshold, the intensity of the treatment was 
determined, starting at zero (0) and increasing the intensity until the participant was 
comfortable with the sensation felt on the treatment area.  
With each treatment thereafter, the treatment intensity started at the previously 
recorded intensity. An increase in intensity was allowed with each treatment received.  
Continuous criss-cross movements were performed over the scar, lateral to medial, 
medial to lateral and around the nipple area (Figure 3.3).  
Continuous application of the active gel via the ball applicator during the criss-cross 
movements ensured that the skin remained moisturised. 
The active gel was left on the skin in order to complete step 3. 
Figure 3.3 Criss-cross action of the Mesotherapy Eporex ball applicator 
Step 3 
Post Treatment – Enhancing product penetration 
The third step of the procedure focused on enhanced penetration of the active gel and 
supported the healing process by using an ultrasonic spatula. 
Scar 
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 The skin reactivation tone-up program was selected and pre-set for a maximum of 14 
minutes.  
 An electrical wrist strap, saturated with tap water, was placed around the participant’s 
wrist to complete the electrical current. 
 The ultrasonic spatula was placed (facing upwards) at a relatively flat 30° angle 
(Figure 3.4), moving over the scar tissue, including up to 1cm surrounding the scar 
tissue, using a slow up and down motion to encourage further penetration of the 
active gel into the scar tissue.  
 
 
 
 
 
Figure 3.4 Correct use of the ultrasonic spatula designed for the skin reactivation tone-up 
settings [Mesotherapy Eporex Manual, 2007 (Appendix A2)] 
 
 The treatment was completed with the removal of the excess active gel from the 
treatment area, with warm water and gauze.  
 The skin was left clean. No creams or gels were applied to the surgical scar upon 
completion of the Mesotherapy Eporex treatment. 
 
3.6.4 Assessment of scar appearance using Vancouver Scar Scale (VSS) 
3.6.4.1 Data collectors 
 
The Mesotherapy Eporex treatment on the 30 participating women that received bilateral 
mammary reduction surgery commenced six (6) weeks after surgery. The researcher, 
plastic surgeon and independent assessor (laser therapist), each assessed both of the 
participants’ breasts by evaluating the linear scars produced by bilateral mammary 
reduction surgery using the VSS (Appendix D). All the assessments post-operatively were 
individually recorded by the researcher, plastic surgeon and independent assessor on a 
pre-set assessment table (Appendix E). 
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3.6.4.2 Biasness 
Biasness was addressed by keeping both the plastic surgeon and independent assessor 
blind to which breast was receiving the Mesotherapy Eporex treatment. Both breasts were 
evaluated using the VSS before the Mesotherapy Eporex treatment with active ingredients 
commenced (baseline) and then before the 3rd, 5th, 7th and after the 8th treatment. The 
researcher applied the treatment and was not blinded to the breast receiving treatment. 
Although the researchers’ results was not taken into consideration when conclusions were 
made, results of the relative change observed over time of the VSS measurement for the 
researcher is displayed in Chapter 4 to show how the researcher’s results compared with 
the plastic surgeon and independent assessor. 
It is important to note that the researcher’s results were also not  taken into account when 
any recommendations were made about the effectiveness of Mesotherapy Eporex 
treatment with active ingredients on scar appearance after bilateral mammary reduction 
surgery because biasness could not be excluded. 
3.6.4.3 Vancouver Scar Scale measurements 
Each experimental breast was subjected to eight (8) Mesotherapy Eporex treatments with 
active ingredients. The researcher and independent assessor performed scar assessment 
measurements using the VSS on all participants before the 1st (baseline), 3rd, 5th, 7th and 
after the 8th treatment. The plastic surgeon only assessed the participants before the 1st 
(baseline) and after the 8th Mesotherapy Eporex treatment. Figure 3.5 summarize the 
assessment schedule followed during the treatment period. The VSS measurements were 
only done before the 1st (baseline), 3rd, 5th, 7th and after the 8th treatment because it was 
deemed to provide sufficient data to observe a trend to establish whether Mesotherapy 
Eporex treatment was effective in reducing scar appearance after bilateral mammary 
reduction surgery. 
Although assessments were done throughout the course of the Mesotherapy Eporex 
treatments the assessment prior to treatment one (1) and the assessment after treatment 
eight (8) were statistically the most important measurements. 
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Figure 3.5 VSS assessment schedule prior to and after Mesotherapy Eporex treatments 
[Open – Researcher aware of which breast was receiving the experimental treatments, Blind – plastic surgeon and 
independent assessor blinded to which breast was receiving the treatment] 
Bilateral Mammary 
Reduction Surgery 
patients (n=30) 
Experimental 
Breast  
(n=30) 
Control 
Breast  
(n=30) 
Right 
Breast (n=15) 
Left 
Breast (n=15) 
Left 
Breast (n=15) 
Right 
Breast (n=15) 
Prior to treatment 3 
Assessors: 
 Researcher (open) 
 Independent assessor (blind) 
 
Prior to treatment 5 
Assessors: 
 Researcher (open) 
 Independent assessor (blind) 
 
Prior to treatment 7 
Assessors: 
 Researcher (open) 
 Independent assessor (blind) 
 
After treatment 8 
Assessors: 
 Researcher (open) 
 Plastic surgeon (blind) 
 Independent assessor (blind) 
 
Baseline assessment 
 
Prior to treatment 1 
Assessors: 
 Researcher (open) 
 Plastic surgeon (blind) 
 Independent assessor (blind) 
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The VSS has four (4) categories with possible scores of zero (0) to between two (2) and 
five (5) depending on the characteristic being assessed (vascularity 0-3, pigmentation 0-2, 
pliability 0-5 and height 0-3). Scores are allocated by comparing each characteristic with the 
adjacent healthy skin. The scale is scored on a range of 0-13, where zero (0) reflects 
normal skin healing and 13, poor skin healing. Thus, the lower the VSS score, the better the 
scar appearance (Table 3.3). 
Table 3.3 Vancouver Scar Scale (VSS) (Kaartinen et al., 2011) 
For the purpose of this research study the vascularity of the surgical scars (pink, red and 
purple) was supported by utilising a colour index (Table 3.4). The colour index chart was 
provided to each assessor as a guideline for the assessment of the scar vascularity to 
ensure that the assessors’ perception of the colours did not vary greatly. 
PARAMETER DESCRIPTOR POINTS/SCORES 
Vascularity 
Normal 0 
Pink 1 
Red 2 
Purple 3 
Pigmentation 
Normal 0 
Hypo-pigmentation 1 
Hyper-pigmentation 2 
Pliability 
Normal 0 
Supple 1 
Yielding 2 
Firm 3 
Ropes 4 
Contracture 5 
Height 
Flat 0 
<2mm 1 
2-5 mm 2 
>5 mm 3 
TOTAL SCORE /13 
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Table 3.4 Colour index assessing vascularity using the Vancouver Scar Scale 
Pink Red Purple 
 
 
 
 
 
  
Pink refers to a light shade of red Red refers to a colour or pigment; 
the chromatic colour resembling 
the hue of blood. 
An intermediate colour between 
red and blue, however more red 
than blue. 
 
*The amount of redness assessed in scar tissue is dependent on the presence of blood vessels in the area, which is tested by how 
quickly the skin turns red after blanching (pressure applied to the scar using the pointer finger and then releasing allowing blood flow to 
return to the area) (Hallam et al., 2013). 
 
Scar height was measured from the natural skin surface to the elevated point of the scar 
with a ruler. The same ruler was used by all three (3) assessors. 
 
A) Validation of Vancouver Scar Scale 
 
Scar assessment is part of the evaluation process of patients requiring rehabilitation after 
surgery. The efficacy of these assessments is based on the use of validated tools, 
important to ensure reliable outcome measurements. Literature on the VSS focuses 
predominantly on burn scars, but has also been validated for rating post-surgical scars 
(Truong et al., 2005; Ferriero et al., 2010; Kaya et al., 2015). In scientific scar studies, 
subjective assessment with scar rating scales, the VSS in particular, remains the most well-
known and mostly used (Idriss and Maibach, 2009; Kaartinen et al., 2011; Nguyen et al., 
2015). Although it has been reported that subjective assessment is unreliable, it has been 
considered the gold standard in scar assessment. The VSS scale has an acceptable 
internal consistency of 0.79 (Cronbach’s alpha) and 0.66 inter-observer reliability 
(Spearman’s correlation coefficients) for overall scores (p< 0.001) (Truong et al., 2005; 
Ferriero et al., 2010). 
 
The VSS is also the assessment tool of choice used by the plastic surgeon that formed part 
of the research team in this study to assess post-operative scarring in women receiving 
bilateral mammary reduction surgery. 
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3.6.5 Breast photography 
 
Photographic images were taken to visually compare the control breasts to the 
experimental breasts prior to the first, and after the last, treatment. Note that these 
photographs are not regarded as a scientific result but only added for illustration purposes 
(Appendix F).  
 
3.7 Statistical analysis 
 
On completion of all eight (8) Mesotherapy treatments the demographic-, anthropometric-, 
clinical data and results generated from the VSS were captured in Microsoft ® Excel ® 
2013 (Microsoft Corporation, Redmond, USA) for data cleaning. All numerical data such as 
age, weight, height, ptosis, amount of breast tissue removed were checked for validity using 
the following formulae: 
 
=IF (data is outside normal range) OR (cell contains sting data), check data validity 
 
The data were then exported to R (R Core Team, 2014) for analysis. The data was further 
summarised and transformed using R scripts. Numeric and graphical data summaries were 
provided as a starting point. The data was summarised using means, percentages and 
frequencies for categorical data and medians and percentiles for continuous data. 
Significant differences were noted at p < 0.05. This is equivalent to a one (1) in 20 rate of 
false discovery and is the standard in clinical trials. A p<5% indicates that the observed 
statistic (from the data) is unlikely to occur (less than 5% chance) if the assumption of no 
improvement after treatment was true. It thus provides evidence against the assumption 
that the treatment is not effective. 
 
 
For the VSS assessments the data measurement scale was given as less is better, and this 
was maintained through all transformations. The first transformation was that the baseline 
[prior to treatment one (1)] was subtracted from the endpoint [after treatment eight (8)]. This 
gave a measurement of the change observed over time. The second transformation was 
that the control breast measurements were subtracted from the experimental breast 
measurements. This gave relative change observed over time, relative to the baseline 
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value. This relative change observed over time (RCOOT) is what was analysed going 
forward using a paired t-test. We will refer to this as the treatment effect from here on. 
 
The difference in scar appearance between the right and the left breast was determined by 
generating p-values from the Two Sample version of Hotelling's T2 test. 
 
The assumption was that there is no treatment effect. The natural, commonly used 
statistical test for this is the t-test. However, there is a dependence structure present in the 
data caused by multiple observations belonging to the same patient effect. To account for 
this the multivariate equivalent test, known as Hotelling’s T2 test was used. 
 
After we have established whether the Mesotherapy treatment was effective, independent 
variables (plastic surgeon relative to independent assessor, age, ptosis, BMI and amount of 
breast tissue removed) that could play a role in the effectiveness of the treatment 
(dependent variable) were investigated, while accounting for the difference between the two 
(2) assessors (plastic surgeon and independent assessor). A linear model was fitted using 
the Ordinary Least Squares (OLS) methodology taking into account the factors (plastic 
surgeon relative to independent assessor, age, ptosis, BMI, amount of breast tissue 
removed) that might have an impact on the treatment effectiveness.  
 
The internal consistency of the VSS was tested by means of Cronbach’s alpha and the 
inter-observer reliability of the VSS was tested by means of the interclass correlation 
coefficient. 
 
3.8 Ethical aspects and good clinical practice 
3.8.1 Ethical clearance 
 
Ethical clearance (ECUFS NR 185/2012) was obtained from the University of the Free 
State’s Ethics Committee before the study commenced (Appendix G). 
 
Upon completion of the study the researcher availed herself to treat the control breast in 
exactly the same manner as the experimental breast. 
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3.8.2 Good Clinical Practice (GCP)/Quality assurance 
All clinical work conducted during this research project was subjected to the Good Clinical 
Practice guidelines. The Declaration of Helsinki’s basic principle number three (3), states 
that research should be conducted only by scientifically qualified people and under the 
supervision of adequately qualified personnel involved (South African Good Clinical 
Practice guidelines, 2006 ; World Medical Association Declaration of Helsinki, 2013). 
Fundamentally GCP requires oversight of the local ethics committee, verification of the 
investigator’s qualifications, a study protocol, informed consent and essential 
documentation needed to undertake the study, monitoring, submission of reports and 
maintenance of records. By applying the GCP guidelines in this research study, public 
assurance is provided that the rights, safety and wellbeing of the participants are protected 
and that the research data are credible. 
3.8.3 Confidentiality 
Participants were assigned a study identification number between P1–P30 to ensure 
confidentiality at all times and non-disclosure of personal details. 
At no time during the research study was any of the participants’ identification or 
information made known to any individual(s) that were not part of the research team. All the 
information regarding this study is kept confidential and kept in secured storage for a period 
of five (5) years. 
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CHAPTER 4 
 
RESULTS 
 
 
4.1 Introduction 
 
This chapter presents the demographic, anthropometric and clinical results recorded for the 
30 women receiving bilateral mammary reduction surgery that participated in the research 
study. This is followed by the results obtained from the VSS measurements (plastic surgeon 
and independent assessor) determining the effectiveness of the Mesotherapy Eporex 
treatments. The percentage of scar appearance for each of the four (4) categories included 
in the VSS was calculated for both the blinded assessors and for the independent assessor 
only. The independent assessor, ptosis, age, amount of breast tissue removed and BMI 
were investigated as independent variables that might impact the effectiveness of the 
Mesotherapy Eporex treatment. The chapter concludes with the validity and reliability 
results of the VSS. 
 
4.2 Demographic, anthropometric and clinical data 
4.2.1 Demographic data 
 
The mean age of the 30 participating women was 42 years; the youngest being 21 years 
and the oldest, 73 years of age. Advanced age is known to affect the wound healing 
process, but every participant acted as her own control. Age was considered only as an 
independent variable to assess whether age would be a factor that could influence the 
effectiveness of the Mesotherapy Eporex treatment. 
 
Most (n=17) of the participants were African Americans (57%) whereas 12 were Caucasian 
(40) and only 1 participant was Asian (3%). 
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4.2.2 Anthropometric data 
The 30 participants had a mean weight and height of 77.2kg and 1.62m, respectively, and 
the mean BMI for all participants was 23.9kg/m2 ranging between 18kg/m2 and 30 kg/m2 
(Table 4.1). 
Table 4.1 Anthropometric data 
Variable 
(Unit) 
25th 
percentile 
Minimum 
75th 
percentile 
Maximum 
Standard 
deviation 
Mean Minimum Maximum 
Height (m) 1.58 1.65 0.06 1.62 1.52 1.75 
Weight (kg) 70.5 87.3 10.8 77.2 57.0 100.0 
BMI (kg/m
2
) 22.0 26.7 3.3 23.9 18.0 30.0 
[BMI = Body Mass Index; m = meter; kg = kilogram; m
2 
= meter square] 
Sixty three percent (63.0%) of the participants presented with a normal BMI and the 
remaining 37.0% of participants were classified as overweight according to their BMI 
(Corbin et al., 2016). None (0%) of the participants that received breast reduction surgery 
presented with a low (good fitness zone) or obese (high risk) BMI (Figure 4.1). 
Figure 4.1 Participants (n=30) BMI rating scale classification (<17 = low; 17-24 = normal; 
25-30 = overweight and >30 = obese) (Corbin et al., 2016) 
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4.2.3 Clinical data 
4.2.3.1 Concomitant Medication 
 
Prescription and over-the-counter drugs and supplements taken by the participants along 
with the study intervention were recorded as required by regulatory bodies. This information 
was only collected as a history item and at no time during the study were participants 
requested to discontinue any of the medication taken due to their participation in the study. 
Because every participant acted as her own control the influence of medication on the scar 
appearance after the Mesotherapy Eporex treatment was not investigated in this study. 
Twelve (40.0%) of the participants took concomitant medication which continued during the 
study if need be. Eight (26.6%) of the participants took multivitamins and five (5) 
participants (16.6%) took anti-depressants (Table 4.2). 
 
Table 4.2 Concomitant medication 
Variable 
Yes 
n (%) 
No 
n (%) 
Concomitant medication 12 (40.0) 18 (60.0) 
Multivitamins 8 (26.6) 22 (73.4) 
Anti-depressants 5 (16.6) 25 (83.4) 
Hypertension medication 4 (13.4) 26 (86.6) 
Iron 4 (13.4) 26 (86.6) 
Asthma inhaler 3 (10.0) 27 (90.0) 
Magnesium 3 (10.0) 27 (90.0) 
Vitamin C 2 (6.6) 28 (93.4) 
Primrose oil 2 (6.6) 28 (93.4) 
Aloe salt 1 (3.4) 29 (96.6) 
Calcium 1 (3.4) 29 (96.6) 
Altroxin 1 (3.4) 29 (96.6) 
Controloc 1 (3.4) 29 (96.6) 
Pro-biotic 1 (3.4) 29 (96.6) 
Coxflam 1 (3.4) 29 (96.6) 
Equidin 1 (3.4) 29 (96.6) 
Cholesterol 1 (3.4) 29 (96.6) 
Omega 3's 1 (3.4) 29 (96.6) 
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4.2.3.2 Bra size 
Bra size was recorded by the plastic surgeon prior to surgery, six (6) (20.0%) of the 
participants wore a 34D bra size, five (5) (16.7%) a 38DD, and a further five (5) (16.7%) a 
44DD (Table 4.3). The average BMI for the participants with a 34D bra size was 20.6 kg/m2, 
for 38DD; 22.1kg/m2 and for 44DD; 27.4kg/m2. The bigger bra sizes were reported for the 
overweight participants as can be seen from the BMI values. Obesity is a known indication 
for increased breast size and post-operative complications after breast reduction surgery. 
None (0%) of the participants presented as obese according to their BMI classification. 
Therefore, obesity was not the determining factor for increased breast size in this study 
population. Besides obesity an increase in breast size can also be attributed to genetics 
and the result of hormones produced during the participants different life stages. 
Table 4.3 Bra sizes of mammary reduction participants prior to surgery (n=30) 
Bra size n (%) 
34C 2 (6.6) 
34D 6 (20.0) 
36C 2 (6.6) 
36E 1 (3.4) 
38C 2 (6.6) 
38D 2 (6.6) 
38DD 5 (16.7) 
40DD 1 (3.3) 
42D 1 (3.3) 
42DD 3 (10.0) 
44DD 5 (16.7) 
4.2.3.3 Breast ptosis 
If the distance measured from the supra sterna notch down to the nipple exceeds 21cm 
then a patient is regarded as having breast ptosis (Khan and Bayat, 2008). Breast ptosis 
was measured prior to surgery and a median of 32.0cm was recorded for all the 
participants. The minimum ptosis was 24.0cm and the maximum was 45.0cm (Table 4.4). 
Therefore all the participants (100%) in this study presented with breast ptosis. 
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Table 4.4 Breast ptosis of participants prior to surgery (n=30) 
Ptosis (cm)  
Median 32.0 
Standard deviation 5.0 
25
th
 Percentile  30.0 
75
th
 Percentile 36.5 
Minimum ptosis 24.0 
Maximum ptosis 45.0 
 
It is also important to know the degree of ptosis because it provides an indication to the 
plastic surgeon of the amount of breast tissue to remove during surgery and it is also one of 
the most objective ways to decide what surgical technique (besides surgeon preference) is 
suitable for each individual because ptosis can be clinically measured (Andrades and 
Prado, 2008). The grade of ptosis was determined using the Regnault classification system 
(1976) (Castro et al., 2013). To determine the grade of ptosis, a proximal measurement 
from the nipple to the inframammary crease was measured in cm. Ninety seven percent 
(97%) of the participants presented with Grade 3 (major ptosis) meaning that the nipple is 
more than 3cm below the inframammary crease (Table 4.5). 
 
Table 4.5 Degree of ptosis according to the Regnault classification system (1976) 
Variable 
Grade 1 
(Minor ptosis) 
Grade 2 
(Moderate ptosis) 
Grade 3 
(Major ptosis) 
Degree of ptosis 
(n=30) 
0 (0%) 1(3%) 29 (97%) 
 
4.2.3.4 Amount of breast tissue removed 
 
The weight of breast tissue removed from each breast was measured intra-operatively. The 
median weight of breast tissue removed from the right breast during mammary reduction 
surgery was 674.0g and from the left breast, 673.5g. The minimum weight of breast tissue 
removed from both breasts combined during surgery was 317.0g and the maximum 
combined weight of breast tissue removed was 5761.0g (Table 4.6). 
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Table 4.6 Breast tissue removed during mammary reduction surgery (n=30) 
Breast Tissue Removal (g) Right Breast (g) Left Breast (g) Total (R+L) 
Median 674.0g 673.5g 1347.5g 
Standard deviation 737.8g 634.0g 1371.7g 
25
th
 Percentile 503.7g 457.2g 961.0g 
75
th
 Percentile 1038.0g 1021.2g 2059.2g 
Minimum breast tissue removed 121.0g 196.0g 317.0g 
Maximum breast tissue removed 3273.0g 2488.0g 5761.0g 
[g = gram; R = right; L = left] 
4.2.4 Vancouver Scar Scale measurements 
4.2.4.1 Experimental breast versus control breast 
Only the experimental breast was treated with the Mesotherapy Eporex machine. Both 
breasts were assessed by the independent assessor (before the 1st, 3rd, 5th, 7th and after 
the 8th treatment) and plastic surgeon (before the 1st and after treatment 8). 
Keeping in mind that less is better the mean VSS score of the plastic surgeon and 
independent assessor improved when the mean endpoint VSS score [after treatment eight 
(8)] was compared with the mean baseline [prior to treatment one (1)] VSS score for both 
the experimental and control breast (Table 4.7). 
Table 4.7 Mean VSS assessment results for plastic surgeon and independent assessor 
Assessment: Plastic Surgeon Independent Assessor 
Exp Breast Con Breast Exp Breast Con Breast 
1
st
 visit assessment 6.2 6.2 5.1 5.3 
3
rd
 visit assessment - - 4.2 4.7 
5
th 
visit assessment - - 3.6 4.0 
7
th
 visit assessment - - 2.7 3.7 
After 8
th
 visit
assessment 
2.6 4.3 2.7 3.5 
[Exp = experimental; Con = control; - =no assessment done during that time interval] 
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The scar characteristics of the experimental breast (▲) appear to improve more with 
treatment compared to the control breast (■) (not receiving treatment) for both the plastic 
surgeon and independent assessor (Figure 4.2A and B). The mean VSS score of the 
independent assessor showed an improvement from baseline to treatment seven (7) 
reaching a plateau at treatment eight (8) for the experimental breast. Whereas, the control 
breast showed a gradual improvement from baseline to end point (Figure 4.2B). Figure 
4.2B showed that the improvement in scar appearance was the greatest between the mean 
baseline [prior to treatment one (1)] VSS score and the mean 3rd visit assessment VSS 
score for the independent assessor for both the experimental (5.13 vs. 4.23) and control 
breast (5.3 vs. 4.73). 
 
 
 
 
 
 
 
 
 
 
 
 
© Central University of Technology, Free State
73 
Figure 4.2 Mean VSS for the experimental and control breast over time (n=30) [(A-B) – mean
individual VSS assessments by assessor 
Before 1st 
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ass 
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4.2.4.2 Effectiveness of Mesotherapy Eporex treatment using VSS 
measurements 
 
The data measurement scale was given as less is better, and this was maintained 
through all transformations. The first transformation was that the starting 
measurements were subtracted from the ending measurements. This gave a 
measure of the change observed over time. The second transformation was that the 
control measurements were subtracted from the experimental measurements. This 
gave relative change observed over time, relative to the baseline value [prior to visit 
one (1)]. This relative change observed over time (RCOOT) is what was analyzed 
going forward using a paired t-test. We will refer to this as the treatment effect from 
here on. 
 
The assumption was that there is no treatment effect. The natural, commonly used 
statistical test for this is the t-test. However, there is a dependence structure present 
in the data caused by multiple observations belonging to the same patient effect. To 
account for this the multivariate equivalent test, known as Hotelling’s  test was 
used. 
 
When considering the experimental phase, which was the primary focus of the 
experiment, then there were 30 complete participant observations. All three 
assessors (plastic surgeon, independent assessor and researcher’s) VSS 
measurements indicated an improvement for the treatment breast, relative to the 
control breast, over time (Table 4.8). When the baseline to endpoint change in the 
experimental breast was compared to the baseline to endpoint change in the control 
breast, the plastic surgeon VSS measurements indicated the highest level of 
improvement, an average difference of -1.700, indicating better healing or less 
scarring for the experimental breast compared to the natural healing of the control 
breast. Because the researcher was not blinded to the breast receiving treatment the 
researcher’s results will be excluded from all the statistical analysis going forward. 
 
The p-value for the blinded assessors (plastic surgeon and independent assessor) 
was 0.0002. According to this value it is safe to conclude that the treatment is 
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effective, based on this sample (p<0.05). Therefore, if the results were extended to 
other populations we are 95% certain that the same treatment effect will be obtained. 
Table 4.8 Relative change observed over time for all 3 assessors (n=30) 
Independent assessor 
(p-value) 
Plastic surgeon 
(p-value) 
Researcher 
(p-value) 
-0.567 -1.700 -1.433 
The results were further broken down for interest sake. If only the plastic surgeons’ 
assessments were considered then again a highly significant p-value of 0.0002 was 
obtained, if only the assessments of the independent assessor was considered then 
the p-value was 0.0842. This was close to being significant but not conclusive. When 
using a non-inferiority methodology a p-value of <0.1 is considered statistically 
significant. 
A comparison was made between the plastic surgeon and independent assessor in 
terms of correlation, variability and average values. There was no evidence of 
correlation (p-value=0.3705) between the results of the independent assessor and 
plastic surgeon. With regard to variability there was no difference (p-value=0.1950) 
and in terms of average values, there was a borderline no difference (p-
value=0.0501) between the plastic surgeon and independent assessor. The VSS is a 
subjective measurement tool and is known for its inter-observer variability, and it is 
no surprise that there is no evidence of correlation between the assessments made 
by the plastic surgeon and independent assessor. Although there was a difference 
with regard to the VSS measurements between the plastic surgeon and independent 
assessor, both indicated an improvement in scar appearance (VSS measurements) 
after the completion of the Mesotherapy Eporex treatment. 
Due to the evidence of no correlation of the results between the independent 
assessor and plastic surgeon and because the independent assessor performed 
assessments throughout the treatment process only the independent assessors 
results was further statistically analyzed. 
The total scores (per participant) for the control and experimental groups were 
expressed as percentages and the change from baseline was calculated. The scores 
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reported for visit one (1) were defined as the baseline value and the last visit (visit 
eight (8) was the endpoint value. The changes were therefore calculated as visit 8 - 
visit 1. These changes were subjected to a t-test and the 95% confidence interval 
(CI) was calculated for the total VSS score. The individual values for change from 
baseline for the control and experimental breast are available in Table 4.9. 
 
Table 4.9 Change from baseline (%) for the control and experimental groups per 
participant 
Subject Change_Control Change_Experimental 
p1 -7.69 -30.77 
p2 7.69 -30.77 
p3 0.00 -15.39 
p4 -7.69 -15.39 
p5 -46.15 -30.77 
p6 0.00 -15.39 
p7 -7.69 -7.69 
p8 23.08 0.00 
p9 0.00 -15.39 
p10 -23.08 -38.46 
p11 -30.77 -30.77 
p12 -15.39 -15.39 
p13 -15.39 -15.39 
p14 -23.08 -23.08 
p15 -15.39 -23.08 
p16 0.00 -15.39 
p17 -23.08 -23.08 
p18 -38.46 -38.46 
p19 -7.69 -7.69 
p20 -7.69 -23.08 
p21 -15.39 -23.08 
p22 -7.69 -23.08 
p23 -30.77 -30.77 
p24 -23.08 -23.08 
p25 -61.54 -23.08 
p26 -7.69 -7.69 
p27 -7.69 0.00 
p28 -7.69 -15.39 
p29 -7.69 -15.39 
p30 -7.69 -7.69 
[Change_control = change from baseline for control group/per participant; Change_Exprimental = change from baseline for 
experimental group/per participant] 
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Descriptive statistics for the change from baseline for the experimental and control 
breast are depicted in Table 4.10. 
Table 4.10 Descriptive statistics: change from baseline 
Variable Min 1st Qu Median Mean 3rd Qu Max 
Change_Control -61.538 -23.077 -7.692 -13.333 -7.692 23.077 
Change_Experimental -38.462 -23.077 -19.231 -18.974 -15.385 7.692 
[Change_control = change from baseline for control group; Change_Experimental = change from baseline for experimental 
group; Min = minimum; 1st Qu = 1st quadrant; 3rd Qu = 3rd quadrant; Max = maximum] 
The 95% CI for the change in baseline for the experimental and control group is 
-10.70 to -0.58 (Table 4.11). Therefore, in this trial, the change from baseline in the 
experimental group is at most 11% more and at least 0.6% more than in the control 
group, with an average of -5.64% (Table 4.11). Statistical significance is confirmed 
by the fact that the 95% confidence interval exclude zero. Thus taking the individual 
baselines in consideration, the endpoint score (visit 8) in the experimental group is 
overtly lower than the endpoint score of the control group (Table 4.11). 
Table 4.11 Statistical analysis result: change from baseline 
Variable t df 
95% confidence 
interval 
Sample estimates: mean 
difference 
Change_Experimental 
and Change_ Control -2.2817 29 -10.70 ;  -0.58 -5.64 
[Change_Experimental and Change_Control = change from baseline for experimental group and change from baseline for 
control group] 
4.2.4.3 VSS scores: vascularity, pigmentation, pliability and height 
The total VSS score is divided into four (4) categories assessing vascularity, 
pigmentation, pliability and height. Table 4.12 summarizes the mean results of the 
experimental and control breast recorded by the two (2) blinded assessors (plastic 
surgeon and independent assessor) for each of the four (4) categories included in 
the VSS. 
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Table 4.12 Mean VSS score categories: experimental versus control breasts (n=30) 
Assessment: Plastic Surgeon Independent Assessor 
 Exp Breast Con Breast Exp Breast Con Breast 
1
st
  visit 
assessment 
6.2 6.2 5.1 5.3 
Vascularity 1.4 1.4 1.4 1.2 
Pigmentation 1.4 1.3 1.3 1.3 
Pliability 2.7 2.7 1.7 1.8 
Scar Height 0.8 0.8 0.8 0.9 
3
rd
  visit 
assessment 
- - 4.2 4.7 
Vascularity - - 1.1 1.2 
Pigmentation - - 1.2 1.2 
Pliability - - 1.3 1.5 
Scar Height - - 0.6 0.8 
5
th  
visit 
assessment 
- - 3.6 4.0 
Vascularity - - 0.9 1.0 
Pigmentation - - 1.2 1.2 
Pliability - - 1.0 1.2 
Scar Height - - 0.5 0.6 
7
th
  visit 
assessment 
- - 2.7 3.7 
Vascularity - - 0.7 0.9 
Pigmentation - - 1.0 1.1 
Pliability - - 0.6 1.2 
Scar Height - - 0.3 0.5 
After 8
th
  visit 
assessment 
2.6 4.3 2.7 3.5 
Vascularity 0,5 0,8 0.7 0.8 
Pigmentation 0.9 1.3 0.9 1.0 
Pliability 1.0 1.7 0.8 1.1 
Scar Height 0.2 0.5 0.3 0.5 
[Exp = experimental; Con = control; - = no assessment done during that time interval] 
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A Line (scatter graph with only points, no lines) was created to illustrate the 
vascularity, pigmentation, pliability and scar height improvements for both the control 
and experimental breast by comparing the baseline levels with the results obtained 
after the 8th treatment for the plastic surgeon and independent assessor combined 
(Figure 4.3). Although an improvement can be seen in all four (4) of the categories 
included in the VSS, scar pliability decreased the most when comparing the baseline 
assessment with assessment eight (8) in both the experimental and control breast 
(Figure 4.3).  
Figure 4.3 VSS assessment of scar characteristics for experimental and control 
breast (n=30) [commencement of treatment = 6 weeks post-operative]
A mean percentage of improvement of the control and experimental breast for each 
category of the VSS was calculated using the results of the plastic surgeon and 
independent assessor (both blinded) (Figure 4.4A). The percentage of improvement 
for all four (4) categories of the VSS was also calculated by including just the results 
of the independent assessor (Figure 4.4B). The mean percentages for each of the 
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four (4) VSS categories were calculated by subtracting the mean results from 
treatment eight (8) from the mean baseline results.  
 
Statistical method calculating mean percentage of improvement for both 
assessors (example for vascularity): 
 
 1st treatment = [Sum of vascularity score per participant (plastic surgeon) + 
sum of vascularity score per participant (independent assessor) / 2 = mean 
vascularity score per participant] 
 Sum of mean vascularity score per participant / 30 = mean vascularity score 
 8th treatment = [Sum of vascularity score per participant (plastic surgeon) + 
sum of vascularity score per participant (independent assessor) / 2 = mean 
vascularity score per participant] 
 Sum of mean vascularity score per participant / 30 = mean vascularity score 
  Mean 8th treatment vascularity score – mean 1st treatment vascularity score 
100/1 = - value (the negative value is ignored because less is better). 
 
Statistical method calculating mean percentage of improvement for 
independent assessor (example for vascularity): 
 
 1st treatment = (sum of vascularity score per participant / 30 = mean 
vascularity score) 
 8th treatment = (sum of vascularity score per participant / 30 = mean 
vascularity score) 
 Mean 8th treatment vascularity score – mean 1st treatment vascularity score 
100/1 = - value (the negative value is ignored because less is better). 
 
The percentage of improvement for pliability was the highest for both the control and 
experimental breast, 81% and 132%, respectively (plastic surgeon and independent 
assessor’s results combined) (Figure 4.4A). Pliability also improved the most when 
only the result of the independent assessor was taken into account (90% 
experimental breast and 67% control breast) (Figure 4.4B). Besides pliability the 
percentage of improvement seen in the other three (3) categories (vascularity, 
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pigmentation and scar height) was also higher in the experimental breast than in the 
control breast for plastic surgeon and independent assessors results combined and 
for only the results of the independent assessor. 
Figure 4.4 Mean percentage of improvement of each VSS category: experimental 
and control breast (n=30)  
[A) Mean percentage of improvement of VSS results for plastic surgeon and independent assessor 
combined B) Mean percentage of improvement of independent assessor’s VSS results] 
75% 
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Again, due to the evidence of no correlation between the results of the independent 
assessor and plastic surgeon and because the independent assessor performed 
assessments throughout the treatment process only the independent assessor’s 
results was statistically analyzed using the following transformations and analyses. 
The individual baseline scores (visit 1) and mean follow-up scores (visits 3, 5, 7 and 
8) were transformed to percentages by dividing the scores by 13 (total of the scores 
over the four (4) parameters) and expressing these scores as percentages. The 
individual scores are depicted in Table 4.13. 
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The baseline scores (per category) for the control and experimental groups were 
subjected to a t-test, testing for the difference in means for paired data. Ninety five 
percent (95%) confidence intervals were calculated and reported (Table 4.14). No 
statistically significant differences were reported for any of the four (4) categories 
(vascularity, pliability, pigmentation and height) included in the VSS. This is confirmed 
by the fact that the 95% confidence intervals (CIs) include zero. 
Table 4.14 Baseline values (per category) for the control and experimental 
group 
Variable t df 95% confidence interval 
Sample estimates: mean 
difference 
Baseline vascularity 
(experimental) and baseline 
vascularity (control) 
1.44 29 -0.22 ; 1.24 0.51 
Baseline pigmentation 
(experimental) and baseline 
pigmentation (control) 
Not 
calculated 29 
Not calculated (due to equal 
means and variance) 0.00 
Baseline pliability 
(experimental and baseline 
pliability (control) 
-0.24 29 -2.45 ; 1.94 -0.26 
Baseline scar height 
(experimental) and baseline 
scar height (control)
0.25 29 -1.81 ; 2.32 0.26 
Then, the mean follow-up (visit 3, 5, 7, and 8) scores (per category) for the control and 
experimental groups were subjected to a t-test, testing for the difference in means for 
paired data. Ninety five percent (95%) confidence intervals were also calculated. 
Statistically significant differences were seen for the parameters pliability (CI: -3.88; -
0.87) and scar height (CI: -2.58; -0.11) as is confirmed by the fact that the 95% 
confidence interval exclude zero (Table 4.15). Therefore, in this trial, pliability improved 
at most 4% more and at least 0.9% more in the experimental group than in the control 
group, with an average of -2.37% (Table 4.11). Scar height improved at most 3% more 
and at least 0.1% more in the experimental group than in the control group, with an 
average of -1.35% (Table 4.11). 
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Table 4.15 Mean follow-up VSS score (per category) for control and 
experimental group 
Variable t df 95% confidence interval 
Sample estimates: mean 
difference 
Mean vascularity 
(experimental) and mean 
vascularity (control) 
-1.23 29 -1.82 ; 0.45 -0.68 
Mean pigmentation 
(experimental) and mean 
pigmentation (control) 
-1.43 29 -1.40 ; 0.25 -0.58 
Mean pliability 
(experimental) and mean 
pliability (control) 
-3.22 29 -3.88 ; -0.87 -2.37 
Mean scar height 
(experimental) and mean 
scar height (control) 
-2.22 29 -2.58 ; -0.11 -1.35 
 
The individual mean follow-up (visit 3, 5, 7, and 8) scores (per category) transformed to 
percentages for the control and experimental groups are presented in Figure 4.5-4.8. 
Because less is better the majority of the individuals showed lower percentage values 
for the experimental breast compared to the control breast for all four (4) VSS 
categories. 
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Figure 4.5 Mean vascularity follow-up scores (3rd, 5th, 7th and after 8th visit) for 
the control and experimental groups (if no bar is displayed for either the 
control or experimental breast it means that the value = 0) 
[MVas_C = Mean Vascularity Control; MVas_E = Mean Vascularity Experimental] 
 
Figure 4.6 Mean pigmentation follow-up scores (3rd, 5th, 7th and after 8th visit) for 
the control and experimental groups (if no bar is displayed for either the 
control or experimental breast it means that the value = 0) 
[MPig_C = Mean Pigmentation Control; MPig_E = Mean Pigmentation Experimental] 
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Figure 4.7 Mean pliability follow-up scores (3rd, 5th, 7th and after 8th visit) for the 
control and experimental groups (if no bar is displayed for either the 
control or experimental breast it means that the value = 0) 
[MPli_C = Mean Pliability Control; MPli_E = Mean Pliability Experimental] 
Figure 4.8 Mean scar height follow-up scores (3rd, 5th, 7th and after 8th visit) for 
the control and experimental groups (if no bar is displayed for either the 
control or experimental breast it means that the value = 0) 
[MHeig_C = Mean scar Height Control; MHeig_E = Mean scar Height Experimental] 
 
4.2.5 Scar appearance of the right breast versus the left breast 
 
The appearances of the mammary reduction scars were compared between the right 
and left breast to determine if there is a difference between the healing ability of the left 
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between the right and left experimental breasts (p=0.3288). The p-values were 
determined from the Two Sample version of Hotelling's T2 test. 
 
4.2.6 Factors impacting the effectiveness of Mesotherapy Eporex treatment 
 
After establishing that the treatment was effective, it was important to investigate which 
factors played a role in the effectiveness of the Mesotherapy Eporex treatment, while 
accounting for a possible difference between the assessors (plastic surgeon and 
independent assessor). This information can be used to advise a patient in advance of 
the treatment and what level of treatment effect to expect. 
 
It is important to note that the dependent variable was not healing but treatment 
effectiveness, i.e. how much more healing occurred under treatment than under control. 
First, a complete linear model was fitted, taking into account many factors (plastic 
surgeon relative to the independent assessor, age, ptosis, breast tissue removed from 
right breast, breast tissue removed from left breast and BMI) that might, hypothetically, 
have an impact on the treatment effectiveness (Table 4.16). 
 
Table 4.16 Factors impacting the effectiveness of Mesotherapy Eporex treatment 
Independent 
Variable 
Estimate Error t-stat p-value Significance 
Intercept -5.233 2.550 -2.052 0.045 * 
Plastic surgeon  
(relative to 
independent 
assessor) 
-1.133 0.490 -2.313 0.025 * 
Age -0.006 0.022 -0.257 0.798  
Ptosis 0.203 0.084 2.405 0.020 * 
Breast tissue removed 
right -0.002 0.001 -2.129 0.038 * 
Breast tissue removed 
left 0.002 0.001 1.543 0.129  
BMI -0.059 0.093 -0.636 0.527  
Signif. codes:  0 ‘***’ 0.001 ‘**’ 0.01 ‘*’ 0.05 ‘.’ 0.1 ‘ ’ 1 
 
Residual standard error: 1.897 on 53 degrees of freedom 
Multiple R-squared:  0.2335,    Adjusted R-squared:  0.1467 
F-statistic: 2.691 on 6 and 53 DF,  p-value: 0.02354 
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Statistical significant differences were observed for the intercept (p=0.045), plastic 
surgeon relative to the independent assessor (p=0.025), ptosis (p=0.020) and the 
amount of breast tissue removed from the right breast (p=0.038) (Table 4.16). The 
intercept was the treatment effectiveness indicated by the independent assessor for a 
patient with 0 age, ptosis, breast tissue removed and BMI (kg/m2). Remember that the 
data measurement scale was given as less is better. The independent assessor was 
considered the baseline, and then the plastic surgeon observed significantly greater 
treatment effectiveness (estimate = -1.133), after adjusting for the other factors. 
Therefore, on average the plastic surgeon observed 1.133 more treatment effectiveness 
(improvement in scar appearance) relative to the independent assessor (Table 4.16). 
The treatment is less effective the higher the ptosis value (estimate = 0.203). Interesting 
results were obtained for the amount of breast tissue removed from the right breast 
because the more breast tissue removed from the right breast the more the treatment 
effectiveness (estimate = -0.002). A possible reason could be that the patients receiving 
right treatment first may have randomly had more right (or left) breast tissue removed in 
general, leading to bias. The model as a whole is significant, indicating that the given 
factors do explain variation in treatment effectiveness (23% to be precise) (Table 4.16). 
 
Table 4.17 appears to be the best model for factors impacting the effectiveness of the 
Mesotherapy Eporex treatment since it does not include the confounding effect of the 
highly insignificant variables. There is little difference between this model (Table 4.17) 
and the model provided in Table 4.16. 
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Table 4.17 Significant factors impacting the effectiveness of Mesotherapy Eporex 
treatment 
Independent 
Variable 
Estimate Error t-stat p-value 95% CI 
Intercept -6.117 2.219 -2.757 0.008 -10.56 ; -1.67 
Plastic surgeon  
(relative to 
independent 
assessor) 
-1.133 0.483 -2.344 0.023 -2.10 ; -0.16 
Ptosis 0.180 0.077 2.324 0.024 0.03 ; 0.33 
Breast tissue 
removed right -0.003 0.001 -2.288 0.026 -0.01 ; -0.00 
Breast tissue 
removed left 0.002 0.001 1.705 0.094 -0.00 ; 0.01 
Signif. codes:  0 ‘***’ 0.001 ‘**’ 0.01 ‘*’ 0.05 ‘.’ 0.1 ‘ ’ 1 
 
Residual standard error: 1.872 on 55 degrees of freedom 
Multiple R-squared:  0.2255,    Adjusted R-squared:  0.1692 
F-statistic: 4.004 on 4 and 55 DF,  p-value: 0.006384 
 
After excluding the highly insignificant factors from the model the p-values were; 
intercept (p=0.008), plastic surgeon relative to the independent assessor (p=0.023), 
ptosis (p=0.024) and breast tissue removed from the right breast (p=0.026) (Table 
4.17). The intercept was the treatment effectiveness indicated by the independent 
assessor for a patient with 0 ptosis and breast tissue removed. According to the CI in 
Table 4.17 the plastic surgeon observed at most 2% more and at least 0.1% more 
improvement in scar appearance, after adjusting for the other factors. The higher the 
ptosis value the less the treatment effectiveness. The CI showed that ptosis caused at 
most a 0.03% and at least a 0.16% decrease in scar appearance (treatment 
effectiveness). The CI for the amount of breast tissue removed right showed at most a 
0.01% and at least a 0.00% more improvement in scar appearance (Table 4.17). This 
percentage of improvement or decline is very low. 
 
Again, the model as a whole is significant, indicating that the given factors do explain 
variation in treatment effectiveness (23% to be precise) (Table 4.17). 
 
4.2.7 Reliability of the VSS measurement tool 
 
The internal consistency of the VSS was tested by means of Cronbach’s alpha and the 
inter-observer reliability of the VSS was tested by means of the interclass correlation 
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coefficient. An interclass correlation coefficient of one (1) indicates that measurements 
carried out by different numbers of observers produce the same results. The inter-
observer reliability was tested when two (2) observers (plastic surgeon and independent 
assessor) assessed the scar areas and for a single observer (independent assessor). 
The internal consistency of the VSS appeared to be lower than acceptable (Cronbach’s 
alpha, 0.4355). The corresponding interclass correlation coefficient value for the VSS 
was 0.2888 with a 95% confidence interval of -0.069 to 0.583.  
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CHAPTER 5 
 
DISCUSSION 
 
 
5.1 Introduction 
 
After cosmetic breast surgery the final breast appearance is the most important result that 
ultimately determines patient satisfaction. In patients with mammary hypertrophy, 
(extremely large breasts) and ptosis (nipple sagging) a decrease in psychological and 
physical discomfort are contributing factors why patients opt for mammary reduction 
surgery (Setälä et al., 2009). The operative procedure has evolved from a mere reduction of 
breast mass to enhanced aesthetic appeal with a minimum scar load (Saleem and John, 
2013; Crerand and Magee, 2013). However, post-operative scarring can be a major source 
of dissatisfaction after aesthetic breast surgery (Monstrey et al., 2014). 
 
In most mammary reduction surgery cases, normal scarring is the result of an 
uncomplicated healing process. However, abnormal scarring develops when the healing 
process of a wound does not follow the body’s expected healing phases; known as the 
inflammatory, proliferative and remodelling phases. The healing process follows a specific 
time sequence with temporary overlapping; and abnormal scarring can occur due to 
prolonging of the inflammatory and proliferative phases (Reinke and Sorg, 2012). The 
majority of non-healing wounds fail to progress through these phases of wound repair and 
remain in a chronic inflammatory state which ultimately leads to abnormal wound repair and 
the development of hypertrophic or keloid scars (Velnar et al., 2009; Reinke and Sorg, 
2012). 
 
To promote wound healing and reduce scarring, several treatment methods have been 
introduced, for example, invasive Mesotherapy (injection), lasers, compression therapy, 
cryotherapy, corticosteroids, topical silicone gel, radiation and Bleomycin (Gauglitz, 2013; 
Son and Harijan, 2014). A new non-invasive technique namely Mesotherapy with active 
ingredients applied by the Mesotherapy Eporex machine was used in this study to evaluate 
whether the treatment could improve the scar appearance six (6) weeks after bilateral 
mammary reduction surgery. The Mesotherapy Eporex machine assists in the transdermal 
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delivery of active ingredients (with varying molecular weight) via an electrical pulse 
(isophoresis) which stimulates a structural re-arrangement of the skin’s semi-permeable cell 
membranes. The process of structural re-arrangement is necessary to allow water soluble 
ingredients to penetrate the skin’s protective sebum layer found in the upper epidermis 
(Fabbrocini et al., 2007). The Mesotherapy Eporex technique by which both ionised and 
neutral drugs can be transported into the dermis and subcutaneous tissue are mainly used 
for the treatment of cellulite, skin rejuvenation, hyper-pigmentation, reduction of wrinkles, 
pores and skin lifting/tightening (Konda and Thappa, 2014). 
 
Therefore, the aim of the research study was to evaluate the effectiveness of Mesotherapy 
Eporex treatments on scar appearance in participants receiving bilateral mammary 
reduction surgery. Each participant received eight (8) treatments and scar appearance was 
evaluated using the VSS prior to the 1st, 3rd, 5th, 7th and after the 8th treatment. 
 
5.2 Demographic, anthropometric and clinical data 
 
The mean age of the 30 participants was 42 years with a mean weight and height of 77.2kg 
and 1.62cm, respectively. Each participant served as her own control, as healing in each 
individual occurs differently. 
 
Only thirty seven percent (37.0%) of the participants were classified as being overweight 
(25-30kg/m2) and none of the participants in this study were classified as obese (over 
30.0kg/m2) according to the BMI (kg/m2)  rating scale (Corbin et al., 2016) (Figure 4.1). The 
BMI results corresponded with literature because mammary reduction surgeries are not 
recommended for obese patients (Brown et al., 2012). In the case of obese patients the 
plastic surgeon would request the patient to lose weight and to keep it off for a period of six 
(6) months to one (1) year prior to mammary reduction surgery to prevent and limit possible 
surgical complications (Chopra et al., 2013). Lapid et al. (2013) contradicts this statement 
regarding BMI stating that macromastia (hypertrophy and gigantomastia) is usually 
correlated with a higher BMI (kg/m2), however he does support the fact that more thin 
patients with large breasts present for mammary reduction surgery (Lapid et al., 2013). 
 
The bra size prior to surgery ranged from a 34D-44DD. The average BMI (kg/m2) for the 
participants with a 34D bra size was 20.6kg/m2 (normal), for 38DD; 22.1kg/m2 (normal) and 
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for a 44DD; 27.4kg/m2 (overweight). Because none of the participants in the study were 
obese, the increase of bra sizes could not be attributed to obesity. If obesity is not related to 
increased breast size, the reason for enlarged breasts could be the result of hormones 
produced during the participants different life stages (foetal growth, pubertal expansion, 
pregnancy and post-menopausal). During these life stages fluctuations in hormones such 
as oestrogen, progesterone, prolactin, insulin, thyroxine and growth hormones, can 
contribute to the development of macromastia (Wolfswinkel et al., 2013). 
 
Breast ptosis was determined by measuring the distance from the supra sterna notch down 
to the nipple in cm. If this measurement exceeds 21cm then a patient has breast ptosis 
(Khan and Bayat, 2008). The minimum breast ptosis value recorded for all participants were 
24cm therefore, all participants in the study presented with breast ptosis (median =32cm) 
(Table 4.4). An increased ptosis value provides an indication for the breast tissue and 
amount of skin resection required during surgery and to estimate the correct nipple height 
and breast shape (Andrades and Prado, 2008). However, limited literature is available on 
the reliability of standard breast measurements, such as ptosis and suprasternal notch-
nipple distance (Hansson et al., 2014). 
 
Using the Regnault classification system (1976) breast ptosis can also be classified as 
Grade I (minor), Grade II (moderate) and Grade III (major) based on the proximal 
measurement from the nipple to the inframammary crease measured in cm (Castro et al., 
2013). The degree of ptosis is determined by the plastic surgeon prior to surgery for it can 
provide an indication for the surgical technique (skin resection amount) and the amount of 
breast tissue to be removed during surgery. Ninety seven percent (97%) of the participants 
in the study presented with Grade III ptosis. According to Andrades and Prado (2008) more 
than 1000g of breast tissue can be removed when a patient present with Grade III (major) 
ptosis. In this study less than 1000g of breast tissue was removed in nine of the participants 
(30%). This could be attributed to the plastic surgeon considering patient preference and 
expectation with regard to desired bra size post-operatively. Between 1000-1500g of breast 
tissue was removed in eight (27%) participants and more than 1500g of breast tissue was 
removed in 13 participants (43%). The larger the amount of breast tissue and skin removed 
during mammary reduction surgery the higher the risk of more aggressive scar formation 
post-operatively due to the substantial loss of skin, tissue structure and breast function 
(Andrades and Prado, 2008; Murray et al., 2008). 
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5.3 Vancouver Scar Scale measurements 
 
The researcher was not blinded to the breast receiving treatment therefore, the 
researcher’s results were excluded from all the statistical analysis and only the plastic 
surgeon and independent assessor’s results were included. The data measurement scale 
for the VSS (less is better) was maintained throughout all the statistical analysis. 
 
The baseline [prior to treatment one (1)] to endpoint change [after treatment eight (8)] in the 
experimental breast was compared to the baseline to endpoint change in the control breast 
for the plastic surgeon and independent assessor. Both the plastic surgeon (-1.700) and 
independent assessor (-0.567) VSS measurements indicated an improvement (better 
healing or less scarring) for the experimental breast compared to the natural healing of the 
control breast (p=0.0002) (Table 4.8). This p-value (p<0.05) indicates a statistical 
significance therefore the Mesotherapy Eporex treatment was effective. If only the plastic 
surgeons’ assessments were considered then again a significant p-value of 0.0002 was 
obtained, if only the assessments of the independent assessor was considered then the p-
value was 0.0842. 
 
A comparison was done between the VSS results of the plastic surgeon and independent 
assessor in terms of correlation, variability and average values. Although no evidence of 
correlation was found between the assessors (p=0.3705), their VSS results did not differ in 
terms of variability (p=0.1950) and average values (p=0.0501). Inter-observer reliability of 
the VSS is known to be unacceptably low and can be attributed to the fact that the VSS is a 
subjective assessment tool (Kaartinen et al., 2011, Nguyen et al., 2015). Subjective 
evaluation is known to be unreliable when done by a single observer, as is usually the case 
in clinical practice. By increasing the number of observers it is possible to increase the 
reliability of the results. However, in a study conducted by Kaartinen et al. (2011) they still 
reported that the reliability of the VSS was low even with three observers. Evidently, no 
matter how complicated the scar rating scales or how many observers used, we cannot 
overcome human limitations when fulfilling the role of an observer. Despite all the negative 
attributes of the VSS, the VSS remains the most well-known and mostly used scar rating 
scale (Idriss and Maibach, 2009; Kaartinen et al., 2011; Nguyen et al., 2015). 
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Because the results of the independent assessor and plastic surgeon did not correlate, the 
results of the plastic surgeon was excluded and a t-test and 95% CI was calculated for the 
total VSS score by subtracting the endpoint VSS score [after treatment eight (8)] from the 
baseline VSS score (prior to the 1st Mesotherapy Eporex treatment). The 95% CI for the 
change in baseline for the experimental and control group is -10.70 to -0.58 demonstrating 
that the change from baseline is at least 11% more and at least 0.6% more in the 
experimental group than in the control group (Table 4.11). This means that if a participant 
received Mesotherapy Eporex treatments she can expect a maximum of 10% improvement 
and a minimum of 0.6% improvement in scar appearance. 
 
The improvement in scar appearance can be attributed to the application of the 
Mesotherapy Eporex treatment in combination with active ingredients [2ml Asian Centella 
(Centella asiatica), 5ml Vitamin C (20%) and 5ml Hyaluronic acid]. These aforementioned 
ingredients promote the proper formation of pro-collagen and a triple helix necessary for 
healing (Michels and Frei, 2013). The positive effects of the active ingredients include; 
reducing inflammation, assisting in collagen synthesis, restoring tissue firmness, increasing 
skin elasticity, decreasing collagen stiffness and acts as free radical scavengers (Guo and 
DiPietro, 2010; Papakonstantinou et al., 2012; Neuman et al., 2015). 
 
The Mesotherapy Eporex machine makes use of transdermal delivery of active ingredients 
via isophoresis (a low frequency modulated alternating current) (Dhote et al., 2012; 
Panzade and Puranik, 2012). Transdermal delivery is when a water retaining medium 
encapsulates an ingredient and controls the release thereof into the skin. When the 
encapsulated ingredient enters the skin, it hydrates the area, allowing faster absorption of 
the ingredient into the blood stream via electroporation. Electroporation is a pulsating 
current which increases skin temperature and cell permeability which in turn temporarily 
disorganizes the temporary water pathways of the cellular membranes (Ita, 2016; Ma et al., 
2014). The application of pulses stimulates the creation of new and/or creates enlargement 
of existing aqueous pathways in the stratum corneum. The skin’s resistance decreases and 
water/oil soluble active ingredients are able to penetrate into the skin. Once the active 
ingredients have penetrated, the molecules (active ingredients) bind to natural enzymes 
within the body (Santra and Tseng, 2013). 
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5.3.1 VSS scores: vascularity, pigmentation, pliability and height 
 
The VSS evaluate four (4) scar characteristics namely vascularity, pigmentation, pliability 
and scar height. A mean percentage of improvement for all four (4) categories included in 
the VSS was calculated using the results of the plastic surgeon and independent assessor 
and only the results of the independent assessor for both the control and experimental 
breasts. The mean percentages for each of the four (4) VSS categories were calculated by 
subtracting the mean results from treatment eight (8) from the mean baseline results. 
 
All four (4) scar characteristics of the control and experimental breast improved over time 
but the highest percentage of improvement was seen in the experimental breast receiving 
Mesotherapy Eporex treatment. 
 
5.3.1.1 Vascularity 
 
The mean percentage of improvement (VSS results of plastic surgeon and independent 
assessor combined) for vascularity in the experimental breast was 75% compared to the 
53% improvement seen in the control breast. The independent assessor reported a mean 
percentage vascularity improvement of 37% for the experimental breast and 23% for the 
control breast (Figure 4.4). 
 
Blood supply is a common problem in injured skin and Goldberg et al. (2013) demonstrated 
that sufficient blood supply can increase the rate of wound healing, prevent infection and 
restore skin function. Improved blood supply in the area is important as it increases oxygen 
delivery and nutrient uptake to the injured area and assists in the removal of toxins 
facilitating increased cell metabolism and renewal. The improvement in vascularity can be 
attributed to the Mesotherapy Eporex current which creates friction (via electroporation) 
between the stainless steel hand piece and the skin in combination with the three (3) active 
ingredients selected (Asian Centella, Vitamin C and Hyaluronic acid). One of the 
characteristics of Asian Centella and Vitamin C is to assist in the development of blood 
vessels in the skin through collagen angiogenesis and epithelisation (Song et al., 2012). 
 
The application of Vitamin C on incisional scars has beneficial effects on skin tissue 
healing, hydroxyproline levels, neovascularization, fibroblast maturation and collagen 
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disposition (Telang, 2013). The increase in hydroxyproline levels has the same effect as 
Asian Centella, the prevention of the over production of collagen and promotion of collagen 
angiogenesis epithelisation. In addition, Vitamin C connects to a hydroxylation enzyme in 
the skin, encouraging collagen to form a triple helix which is essential for the development 
and maintenance of scar tissue and blood vessels in the skin. Vitamin C stimulates dormant 
fibroblasts to divide and promote migration to the wound site. The fibroblasts are 
regenerated, promoting the healing of the skin tissue and ultimately improving the scar 
appearance (Sharma et al., 2008). 
 
When visually assessed, the vascularity prior to the Mesotherapy Eporex treatments 
presented as a purple or red colour. The skin colour faded to a pink/normal skin colour 
(same as the surrounding skin) on completion of the treatments. This could be attributed to 
Asian Centella and Vitamin C enhancing antioxidant release in the skin by supporting and 
shortening the inflammatory phase (Collins, 2013). Asian Centella contains active 
components called triterpenes which include: asiaticosides, madecassoside and Asiatic 
acid. Triterpenes enhance normal human skin cell migration encouraging wound healing. 
Asiaticosides enhance antioxidant release in the skin which supports and shortens the 
inflammatory phase. A longer inflammatory phase allows oedema (swelling) to restrict the 
blood flow and oxygen levels to the wound site which results in poor wound healing (Gohil 
et al., 2010; Song et al., 2012). 
 
The body’s ability to absorb iron is increased by Vitamin C, contributing to higher oxygen 
levels in the skin (Telang, 2013). Vitamin C also acts as a potent anti-oxidant and anti-
inflammatory ingredient (Guo and DiPietro, 2010). All these factors can contribute to the 
improvement of scar vascularity. 
 
5.3.1.2 Pigmentation 
 
The mean percentage of improvement (VSS results of plastic surgeon and independent 
assessor combined) for pigmentation in the experimental breast was 40% compared to the 
13% improvement seen in the control breast. The independent assessor reported a mean 
percentage pigmentation improvement of 67% for the experimental breast and 40% for the 
control breast (Figure 4.4). 
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Hyper-pigmentation is a consequence of melanocyte recruitment which occurs at the 
wound site and can persist after the wound has successfully healed. This can be attributed 
to the keratinocytes situated at the wound edge that communicate a gene signature 
reflecting partial proliferative activation with several cell-cycle genes. The recruitment of 
melanocytes is generally the result of a heavy inflammatory response, particularly of 
neutrophills, and these cells may be phenotypically different from their equivalents in 
healing wound (Davis and Callender, 2010; Chadwick et al., 2012). 
 
The use of Vitamin C as an active ingredient addresses pigmentation as it acts as a water 
soluble antioxidant protective reservoir. This action allows for the ability to lighten skin as it 
inhibits tyrosinase (enzyme for controlling melanin production) and assists in decreasing 
oxidative stress, resulting in radiant and bright skin (Lima et al., 2009). Copper ions at the 
wound site interact with Vitamin C inhibiting the action of the enzyme tyrosinase, thereby 
decreasing melanin formation and possible scar hyper-pigmentation (Telang, 2013). In this 
research study the use of Vitamin C as active ingredient in conjunction with the 
Mesotherapy Eporex treatment did not only contribute to wound healing but it also 
decreased pigmentation of scar tissue. 
 
5.3.1.3 Pliability 
 
The mean percentage of improvement (VSS results of plastic surgeon and independent 
assessor combined) for pliability in the experimental breast was 132% compared to the 
81% improvement seen in the control breast. The independent assessor reported a mean 
percentage pliability improvement of 90% for the experimental breast and 67% for the 
control breast (Figure 4.4). 
 
The increase in scar pliability could be attributed to the use of HA, because HA is known to 
improve tissue suppleness and contribute to the detanglement of collagen fibres formed 
during the healing process (Baspeyras et al., 2013). An investigation by Baspeyras et al. 
(2013) on the impact of HA in combination with Mesotherapy treatments showed a 
decrease in elastin and collagen fibre stiffness suggesting that the skin may regain 
suppleness by decreasing the entanglement of its collagen fibres thus restoring the 
mechanical behaviour of young skin. Neuman et al. (2015) utilized an injectable HA hydro-
gel that provided an adhesion barrier in rat models following midline abdominal incision, 
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and this resulted in facilitated wound healing. HA absorption into the skin occurs when the 
Mesotherapy Eporex machine releases the conductive gel filled with active ingredients onto 
the skin, and via osmosis the HA is then transported by CD44 receptors to the healing site 
(Neuman et al., 2015). When HA is found in the epithelial tissue, keratinocyte proliferation is 
promoted, increasing the presence of retinoic acid which provides hydration in the skin. 
Hydrated skin cells could improve scar pliability and appearance. In addition, HA assisted in 
the transport of Vitamin C and Asian Centella across the stratum corneum skin layer with 
the help of naturally produced HA in the skin, including the electroporation process created 
by the Mesotherapy Eporex (Konda and Thappa, 2013). 
 
Additionally, Asian Centella produces peptidic hydroxyproline which assists with collagen 
stabilization. Peptidic hydroxyproline prevents the over production of collagen which could 
contribute to keloid formation, and promotes collagen angiogenesis epithelisation (new 
blood vessel formation from pre-existing vessels). Collagen angiogenesis epithelisation 
assists in wound healing as the new vessels increase oxygen and nutrient delivery to the 
wound site resulting in improved wound healing (Song et al., 2012). 
 
5.3.1.4 Scar height 
 
The mean percentage of improvement (VSS results of plastic surgeon and independent 
assessor combined) for scar height in the experimental breast was 53% compared to the 
33% improvement seen in the control breast. The independent assessor reported a mean 
percentage scar height improvement of 47% for the experimental breast and 43% for the 
control breast (Figure 4.4). 
 
Scar height reflects the maturity of a scar and also the overabundance of collagen 
deposition (Gauglitz, 2011). During the inflammatory phase fibroblasts in the skin contribute 
to collagen formation in a scar which is usually circular and cyclical. Due to this process a 
thick, whitish collagen inside the provisional and collagen matrix results in an abundant 
production of packed collagen, giving rise to scars that are uneven in texture and height. 
Over time, during the proliferative phase the fibroblasts continue to rearrange the collagen 
fibres and the scar settles and becomes stiff (McDougall et al., 2006; Velnar et al., 2009). 
Vitamin C and Asian Centella prevent the overproduction of collagen, assisting in collagen 
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stabilization and they encourage antioxidants to be released thus improving scar 
appearance. 
 
Therefore, by taking all the properties and characteristics of Asian Centella, Vitamin C and 
HA into consideration it is clear that these agents, in conjunction with Mesotherapy Eporex 
treatments, should have a positive effect on all four (4) scar characteristics in participants 
receiving mammary reduction surgery. 
 
Due to the evidence of no correlation of the results between the independent assessor and 
plastic surgeon and because the independent assessor performed assessments throughout 
the treatment process the independent assessors results were subjected to a t-test, to 
determine the 95% CI. The baseline VSS scores per category for the control and 
experimental groups showed no statistically significant differences for vascularity (CI: 0.22; 
1.24), pigmentation (CI: not calculated due to equal means and variance), pliability (CI: -
2.24; 1.94) and height (CI: -1.81; 2.32) (Table 4.14). The CI was also calculated for the 
mean follow-up (treatment 3, 5, 7 and 8) VSS scores (per category) for the control and 
experimental groups. Statistically significant differences were seen for the categories 
pliability (CI: -3.88; -0.87) and height (CI: -2.58; -0.11) (Table 4.15). 
 
However, it must be stated that problems with the VSS scale included separating between 
pigmentation and vascularity (Idriss and Maibach, 2009). Reason being that changes in 
both vascularity and pigmentation occur in the scar at a time overlapping each other, 
making colour definition difficult for the observer. Colour changes are also usually unevenly 
distributed across the scar, and estimating a mean value for a certain area is not evenly 
done by a human observer (Kaartinen et al., 2011). 
 
5.4 Factors impacting the effectiveness of Mesotherapy Eporex treatment 
 
The intercept (p=0.008), assessor (p=0.023), ptosis (p=0.024) and amount of breast tissue 
removed from the right breast (p=0.026) showed statistical significance therefore 
influencing the effectiveness of the Mesotherapy Eporex treatment (Table 4.17). Because 
the VSS is a subjective measurement tool and because of human inconsistency it is 
expected that the assessor could have an influence when evaluating the effectiveness of 
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the treatment. Reliability of the VSS remains a problem throughout literature (Kaartinen et 
al., 2011, Nguyen et al., 2015). 
 
Ptosis, and the grade of ptosis is determine by plastic surgeons prior to surgery for it 
provides an estimate of the amount of skin resection and breast tissue to be removed 
during surgery (Andrades and Prado, 2007; Shiffman, 2009). Although ptosis alone is not 
the only confounding factor indicating the amount of breast tissue removed, patient 
preference to post-operative expected bra-size is also taken into account. All the 
participants in this study (100%) presented with breast ptosis. The larger the amount of 
breast tissue and skin removed during mammary reduction surgery the higher the risk of 
more aggressive scar formation post-operatively due to the substantial loss of skin, tissue 
structure and breast function (Andrades and Prado, 2008; Murray et al., 2008). In this study 
ptosis had a negative impact on the effectiveness of the Mesotherapy Eporex treatment. 
 
Although the amount of right breast tissue removed had a positive effect on the 
Mesotherapy Eporex treatment which is contradicting the statement above, a possible 
reason could be that the patients receiving right treatment first may have randomly had 
more right (or left) breast tissue removed in general, leading to bias. 
 
5.5 Reliability of the VSS measurement tool 
 
Cronbach’s alpha should be from 0.70 up to and including 0.90 to demonstrate consistency 
in a scale. An interclass correlation coefficient value of 0.70 is considered a minimum 
requirement for reliable results (Durani et al., 2009). The internal consistency of the VSS 
appeared to be not acceptable (Cronbach’s alpha, 0.4355). The corresponding interclass 
correlation coefficient value for the VSS was 0.2888 with a 95% confidence interval of  
-0.069 to 0.583. The lack of consistency of the Vancouver scale might be explained by the 
fact that it includes a variable that appears to be a nominal variable (pigmentation).  
Consistency can be improved by increasing the number of observers. Despite the 
inconsistency of the VSS it remains one of the most well-known and widely used scar 
scales in clinical practice. 
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CHAPTER 6 
 
CONCLUSION 
 
 
6.1 Introduction 
 
Enlarged breasts are a major concern for women all over the world impacting them both 
physically and emotionally. Mammary reduction is a well-known surgical procedure but not 
without complications. Various factors like age, obesity, medication, chronic diseases, 
nutrition, surgical procedure etc. can contribute to the development of post-operative 
complications. Post-operative scarring continues to be a reality and a lingering concern for 
many women and also one of the reasons why women sometimes opt not to go for surgery 
despite physical and psychological discomfort. For this reason women are continually 
seeking new treatment modalities to improve scar appearance post-operatively. A 
Mesotherapy Eporex treatment in combination with active ingredients is well established for 
treating cellulite, wrinkles, firming of the skin and muscle spasms. The effectiveness of the 
Mesotherapy Eporex treatment on post-operative scarring was assessed by evaluating scar 
appearance using the VSS during and after the treatment period. 
 
No statistical significant differences were observed for demographic, anthropometric and 
clinical data indicating that the sample population was comparable. No difference in healing 
ability was observed when comparing the right experimental breast with the left 
experimental breast (p=0.3288). Both, the independent assessor (-0.567) and plastic 
surgeon (-1.700) reported improvements in scar appearance when comparing the baseline 
VSS results with the endpoint VSS results after applying the Mesotherapy Eporex treatment 
(p=0.0002). However, inter-observer reliability remains a problem due to the subjective 
nature of the VSS. The internal consistency of the VSS was lower than acceptable 
(Cronbach’s alpha 0.4355). Therefore, emphasis was placed on the results of the 
independent assessor and because the independent assessor assessed the breasts 
throughout the treatment period. The independent assessor’s results revealed a maximum 
of 11% or minimum of 0.6% improvement in scar appearance in the experimental group 
than in the control group after treatment (95% CI: -10.70 ; -0.58). When evaluating the 4 
(four) categories if the VSS the independent assessor’s results showed a statistical 
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significant improvement for scar pliability (95% CI: -3.88; -0.87) and height (95% CI: -2.58; -
0.11) when comparing the experimental and control group after treatment. The 
improvement in scar appearance can be attributed to the application of the Mesotherapy 
Eporex treatment in combination with active ingredients for it establishes deeper product 
penetration into the skin to reduce inflammation, assist in collagen synthesis, restore tissue 
firmness, increase skin elasticity, decrease collagen stiffness and act as free radical 
scavengers. 
 
The assessor (95% CI: -2.10; -0.16), ptosis (95% CI; 0.03; 0.33), and amount of right-sided 
breast tissue (95% CI: -0.01; -0.00) removed influenced the effectiveness of the 
Mesotherapy Eporex treatments (p≤0.05). The VSS is a subjective assessment tool 
explaining the influence of the assessor on the effectiveness of the treatment. The higher 
the degree of ptosis the less effective the treatment. All the participants in the study 
presented with ptosis. Ptosis is an indication of the amount of skin resection and breast 
tissue to be surgically removed and the more breast tissue removed the greater the chance 
of more aggressive scarring post-operatively. 
 
In spite of the subjectivity and imprecision of the measurement system used, the 
effectiveness of the Mesotherapy Eporex treatment with active ingredients is not in 
question. There was a relative change in scar appearance over time in favour of the breast 
receiving Mesotherapy treatment at that time. 
 
6.2 Limitations 
 
The following limitations were identified in this research study: 
 
 BMI distribution was limited as none of the 30 participants were found to be classified 
as underweight or obese according to the BMI rating scale. 
 
 The VSS as a measurement tool assessing post-operative scar appearance. Internal 
consistency of the VSS is known to be lower than acceptable although the VSS has 
been validated as a post-operative assessment tool. 
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 The number of observers used. Reliability can be increased by increasing the 
number of observers however, in everyday clinical practice this is not always 
feasible. 
 
 The small population size. Although it was clear that the scar appearance of the 
experimental breast improved after applying the Mesotherapy Eporex treatment 
compared to the control breast not receiving treatment. An increase in sample size 
could account for the internal variations seen. 
 
6.3 Recommendations 
 
The following recommendations can be made from this research study: 
 
 Advanced scientific investigation into the application of Mesotherapy Eporex 
treatment with active ingredients to optimize the treatment effect on post-operative 
scar appearance. 
 
 Re-evaluating the use of the VSS as a measurement tool for post-operative scarring. 
Replace subjective scar measurement tools with objective scar measurement tools. 
 
 Incorporating more than one scar assessment tool to evaluate scar appearance (e.g. 
Patient Observer Scar Assessment Scale (POSAS), Wound Evaluation Scale 
(WES); Manchester Scar Scale (MSS). 
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Eporex 
      Delivering Wellbeing through Technology 
 
This  is not  just  a slogan, it represents the  aim  we  set  ourselves and  the  goal  finally  reached 
after  the incorporation of a variety of various synergies and  types of co-operation. In fact, 
modern research in the electro-medical field at the moment offers various tools for medical 
professionals using machines with varying degrees of innovative technology. 
 
Nowadays, much is being said regarding how skin and intracellular absorption takes place and 
there are various theories, even if they are not all sustainable. Herein, we will only discuss 
scientifically tested theories. 
 
Eporex is an optimized system of cutaneous transport based upon a large number of 
accredited studies and research, in particular the research in the  field of physical mechanisms 
that  increase the  penetration and  spread of active principles into the  epidermis: 
 
With  EPOREX we  are  creating a  new  generation of  transdermal delivery system, bringing 
about the synergy of already known techniques such as Ionophoresis, Iontophoresis, and  
Electroporation, through an innovative method for “active”  molecular transcutaneous transport 
that  we call: 
 
“ISOPHORESIS” 
 
The  electronic transdermal method has  been used for decades, beginning in the  medical 
field  for the administration of painkilling drugs and  for rehabilitative therapy, but recently it was  
found that  it could be applied in the  dermatology and  professional aesthetics fields. 
 
The main  difficulty for the  penetration of substances through the  human skin is the  external 
layer,  i.e. the corneal layer  that  is a tough barrier to the  transport of substances; its lipid-
corneocyte matrix has  been the  subject of studies regarding: 
 
• Variations of impedance of the dermis subject to impulse charges, and 
• The consequent variation of its permeability; 
• Determination of the wave shapes useful for transport purposes; creation of 
a wave shape generator 
 
 
SKIN BARRIER FUNCTION 
HYDROPHYLIC KERATINOCYTES 
 
 
 
With ISOPHORESIS  an  attempt has  been made to  optimize the  transport method and  avoid  
the  limits posed by techniques used in the past, i.e. the poor concentration of active principle 
delivered, the limited depth reached in the  tissue, & the  damage of the  tissue due  to the  
intense currents induced.  For these reasons, the Isophoretic method represents the avant-
garde in skin treatments: new research has already been carried out in various countries with 
outstanding results representing the future of this new  needle- free technique. 
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  IONOPHORESIS, IONTOPHORESIS, ELECTROPORATION   
 
Ionophoresis was first described by A. Volta and A. Galvani in 1707 and laws were formulated about 
1900 by  Leduc.  This technique exploits the electrical principle by which electrically charged “ions”  
move at variable speeds in an electrical field generated by a continuous galvanic current, but  it 
is limitations are: 
 
• Poor penetration for fixed frequency use (max  5 mm.) 
• The need for polarized products 
• High concentration of active principle required 
• “Saponification” of the skin and burns due  to the  use  of energy over  0.1 mA/cm 
• Formulation of substance: pH, viscosity, presence of other ions 
 
Iontophoresis uses the same electrical principles as ionophoresis, in as much as the substance 
is ionized by means of a continuous galvanic current using, however, a developed wave no  
longer continuous but modulated in impulse trains. This reduces the incidence of surface burns 
but has the same limited capacity for penetration due to the wave frequency. 
 
The limits are the same as for ionophoresis, especially in the need to use products that are 
already polarized but, above all, the limit is that only a low quantity of active principle can be carried 
and  the depth reached in the  corneal layer  is quite  limited. 
 
With iontophoresis, the  importance of using the  electronic transdermal method for the  
administration of drugs in medical therapy, in various specialties, was  recognised first of all in 
genetic-molecular therapy, as  demonstrated by more than  1400  U.S. patents and  more than  
5,600  articles in scientific journals and magazines. 
 
 
 
  ELECTROPORATION   
 
This  methodology is  employed in  medical therapy to  increase in  the  permeability of  the  skin  
tissue: Electroporation of  the  skin  occurs when, by  the  art  of  an  electric pulse between 0,5  
and  1,5  Volts,  a transmembrane potential is generated within  an epithelial cell structure. 
 
As a result, the  lipid layer  of the  cell membrane is subjected to  an  alteration: the  formation of 
the  well known aqueous vessels, hence called “electropores”. 
 
The  creation of electropores occurs at a subsequent time,  after  the  induction of the  electric 
pulse, and takes only  a few minutes, thus leading to a diffusive permeability of the  molecules, 
even of high  weight, that  enables them to penetrate through the  entire tissue ‘’targeted’’  by the  
electric pulse. 
 
The  aqueous vessels will preserve themselves for a period directly proportional to  the  wave 
length of the  pulse itself;  the  time-span ranges from  a few  seconds to about ten  minutes. This 
has  been recently established by  chemical-biological field  researches in the  well  known study 
on  “vessels dedicated to transport of water into cells’’. 
 
This  study was  awarded the  Nobel  Prize  for  Chemistry in 2003,  which  went to  two  eminent 
American researchers, Roderick MacKinnon and  Peter Agre.  In fact, thanks to this study, it was  
possible to discover the existence of molecular vessels which  enable the cellular  membrane to 
let in or out vital substances as water and  salts (membrane proteins). 
 
The control of the crossing-over of ions  and  molecules through these structures is regulated by 
chemical impulses that  allow  cell-cell  contacts. These impulses appear to be ions or small 
molecules that induce a series of “cascade reactions” inside the cell, this event leading to the  
emergence of a macroscopic effect, such as, muscular tension or biochemical or metabolic 
reactions in our  body or in the  brain. 
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SKIN BARRIER FUNCTION 
HYDROPHYLIC KERATINOCYTES 
 
 
 
 
In consideration of the above, thanks to the methodology developed with EPOREX, i.e. 
ISOPHORESIS, it is possible to transport water-soluble molecules through the epidermal barrier, 
which  it is known, shows an extremely low permeability to water-soluble substances, due  to its 
extracellular lipid matrix (cholesterol, fatty acids), thereby allowing the  introduction of active 
pharmacological principles at varied depths. 
 
  EPOREX AND ISOPHORESIS   
 
With the method we have tested called ISOPHORESIS,  a pulsed and  modulated current is 
used: i.e. a low frequency wave with  elastomodulated wave shape and  with  a modulated 
intensity which  is variable by the  operator. 
 
Its shape and particular trend is able in this way to electronically activate molecules with both low 
and high molecular weight and allows them to pass into the extra-cellular compartment at 
depths never reached before: up to 9 to 10 cm, while  introducing 90%  of the  active substance 
necessary for the  treatment.  In this way a double objective is achieved: the increase in the 
permeability of skin tissue even at the deepest levels of the dermis and the capacity of 
introducing active hydrosoluble substances with a high molecular weight (e.g. hyaluronic acid, 
collagen, etc.) 
 
EPOREX differs considerably from other  systems in two  essential 
features: 
1) THE WAVE MODULARITY: non  continuous negative/positive or alternate, constituted by a pulse 
train with  a sinusoidal mode separated by intervals that  can  be  modified in a frequency that  
accords to the wave equation Y=X – 180 + 2000. 
 
Where Y is the  frequency in Hertz and  X the  depth in cm,  the  product is carried without thermal 
damage for  several centimeters: in fact,  the  wave modulation avoids the  absorption of too  
much energy into tissue (maximum for human tissue is 0,1mA/cm2) in the time  of phase “off ”. 
The Eporex system makes it possible to automatically vary the wave length frequency in relation 
to the  set  penetration depth. 
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2) THE PRESENCE OF A IONIZATION CHAMBER in the hand piece that polarizes and prepares 
molecules electrically, with the possibility of thereby carrying any hydrosoluble substance through 
the opening of the so called “electropores” and easier intracellular penetration: the “in dissociate” 
molecules actively brought to and  into the cells will modulate the metabolism in relation to their 
characteristics and  concentration and they  will move towards the  dermal matrix by electro-
osmosis. 
 
In brief, in ISOPHORESIS, the transmission process occurs according to a synergy of steady 
processes: 
 
1. IONIZATION OF THE SUBSTANCE 
The elasto-pulsated current meets the molecule then it ionises it and makes it “active” and 
ready for transport. 
 
2. TRANSMISSION 
The ionised molecule is transferred to the optimal depth. 
 
3. ELECTROPORATION 
After a few minutes, electropores are created: the molecules transfer the substances from 
one cell to the other by osmosis. 
 
 
 
  EPOREX HANDPIECE & THE IONIZATION CHAMBER   
 
 
 
 
 
 
The ionization chamber is a true innovation; here the osmotic and conductive processes of the 
substances gradually take place. 
 
Attached to  the  ionization chamber,  a  bottle of  conductive gel  is  mixed with  dehydrated 
powder or mesotherapy  ampoules,  immediately before use.  This ensures the   freshness 
of the   product.  The 
conductive gel is free of preservatives, which might create allergies. 
 
EPOREX is supplied with   specifically prepared gel,   powders and   ampoules and   utilizes   
traditional mesotherapy protocols. 
 
The ionization chamber features structured metal armatures and the mix of actives is subjected 
to fixed and constant induction by the elasto-modulated current. 
 
The hand piece is in fact structured in such a way that the armature of the ionization chamber is 
fixed and constantly in contact with the mix of actives and ensures a constancy of ionisation of 
the active principle for transmission. 
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The Eporex hand piece can carry 
out: 
 
• Constant and graduated transmission of active 
substances, as its steel roller carries out the 
electroporation on the skin, with constant release of the 
mix, with perfect adhesion to the skin and at fixed distance 
 
• No dispersion or concentration of the ingredients is 
created. It ensures a constant quantity of electric power 
and thereby, of ionised substance 
 
• Furthermore, the hand piece ensures all sanitary standards, 
in compliance with health regulations. In fact, its special 
stainless steel parts are removable and can be cleaned and 
sterilized. 
 
 
 
Methodology‘s 
objective: 
 
• Transmission of the active principle directly and in depth, into the  target tissue 
• Extended action of active principles 
• Reduced quantity of active principle used 
• Higher concentration in treated site 
• Less systemic absorption and toxicity 
• Total absence of any pain or discomfort during treatment 
• Hygiene 
 
  BRIGHT SKIN ULTRASOUND   
 
Eporex is successful in  combining different   methodologies and  is  able  to  enhance the  
efficacy   of Isophoresis treatments through ultrasound waves combined with galvanic current 
by means of BRIGHT SKIN. This technological device is patented and supported by 
registered protocols. 
 
The BRIGHT SKIN ultrasound device promotes the rejuvenation of the skin and the prevention of 
cutaneous ageing through the use of Ultrasound waves: It consists of a metal strip in the shape of 
a spatula, oscillating at a frequency of 25,000 K hertz. The spatula is bent 45° at its end, and allows 
the spreading of the ultrasonic waves along the tissue surface, exploiting the principle of 
CAVITATION. 
 
This phenomenon occurs when a liquid is subject to a significant depression. When the absolute 
pressure becomes less  than  the  ‘’tension’’  of the  liquid,  a force  field  is created which  
transforms, copiously, the liquid into vapour, in the  form  of micro-bubbles of gases. This 
enables the removal of dead skin cells and residues of make-up and impurities deposited in the  
sebaceous follicles. 
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Furthermore, with the Bright SKIN handset it is possible to combine, in relation to the selected 
programme, the emission of galvanic micro-currents for transdermal delivery or electric peeling, 
exploiting the synergy between the  action of ultrasound (sonic thrust) and  galvanic micro-current 
(ionic thrust). 
 
CAVITATION PHASES 
 
 
 
 
BRIGHT SKIN TREATMENT PROGRAMME 
 
 
PROGRAMME WAVE TREATMENT 
 
 
Dermopurification 
 
Continuous 
 
Exfoliation & cleanse 
 
Deep  dermo-purification 
 
Continuous 
combined with 
galvanic current 
 
Exfoliation & deep cleanse 
 
Deep  purification & Tone-up 
 
Pulsating wave 
with galvanic 
current 
 
Exfoliation, cleanse & tone-
up with mechanical 
massage 
 
Tone-up action 
 
Pulsating wave 
 
Toning with deep 
moisturization 
(active  principles 
penetrate into the  skin) 
 
Skin reactivation 
 
Continuous wave 
with galvanic current 
 
Cellular  stimulation with deep 
moisturization (active  
principles penetrate into the  
skin) 
 
Reactivation & Tone-up 
 
Pulsating wave 
with galvanic 
current 
 
Cellular  stimulation and 
toning with deep 
moisturization 
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THE SINERGIC TECHNIQUE:  ULTRASOUND + ISOPHORESIS 
In conclusion, applications with EPOREX in combination with ultra-sound are particularly 
effective: 
 
ULTRASOUND= Bright Skin is utilised initially for cleansing with sonic waves, removing dirt and oil 
from the skin’s surface as well as a portion of corneal layer in a method similar to that of a slight 
microdermabrasion of the  skin. 
 
WAVE FORM - EPOREX In the second phase of the treatment, the sequenced wave shapes are 
able to penetrate 90% of the substance to a chosen depth. 
 
The wave shapes are used in combination with a conducting current in gel, thus permitting the 
treatment of the active agents to the depth required. In the applied clinical studies it is shown that a 
range of depth from 0.5 cm to 10 cm might be carried in the tissue. 
 
The key for optimum transmission in aesthetic treatments is the EPOREX patented hand piece 
incorporating a dispenser with 60 ml of conductive gel. 
 
The hand piece, made with a “roller” mechanism, distributes the mix of conductive gel and the 
important activated ingredients to be transferred, over the surface of the tissue. 
 
The treatment time is approximately 20 minutes and the operator can select the treatment 
parameters according to the special needs of the patient. Furthermore, no visible sign of the 
treatment remain on the surface of the skin and the patient’s experience is totally painless and not 
unpleasant. 
 
APPLICATION FIELDS AND ACTIVITIES 
MEDICINE 
Analgesic 
Anaesthetic  
Anti-Inflammatory  
Antiphlogistic  
Muscle Relaxant  
Antieoedematous 
 
AESTHETIC MEDICINE 
Cellulite Reduction 
Targeted Fat Reduction  
Body Toning 
Stretch Marks  
Acne 
  Anti-Ageing 
Facial Rejuvenation 
Mesolift  
Tired Eye Treatment  
Hair Restoration  
Breast Firming 
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FINAL CONSIDERATIONS 
 
Eporex is the f i rs t  computer-driven, transdermal delivery system that 
can perform a variety of different types of treatments. 
 
Its microprocessor allows the setting of delivery treatments with 
different frequencies, penetrating the actives to the required depth 
without tissue damage. 
 
Each o p e r a t i o n  is visible o n  the  c o n t e m p o r a r y  designed control 
panel, where the entire electronic functions are set. 
 
Easy to use and handy: thanks to its portability and its streamlined 
software, enables clear and simple employment. 
 
Its  innovative, patented  hand-piece, featured by  a  constant  
capacity of carrying performance, ensures optimal sanitary 
standards, in compliance with  health regulations, since its parts 
are  removable, and  therefore can be cleaned and  sterilized. 
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Kind Client, 
 
We thank you for the preference reserved to our  equipment and we wish 
that it can respond to Your expectations. 
 
What customer of  Medical & Technology you  now have the privilege to 
have in every moment a staff of specialized technicians to Your complete 
disposition. 
 
For every question don't hesitate to contact us with the means that you will 
think  fitter and opportune; to the purpose of our answers to make more 
exhaustive we beg you to always quote the model and the serial  number of  
Your instrument. 
 
We invite you to meticulously follow the indications brought in the 
present user manual , this will be for you a valid help for the optimal use 
and  maintain unchanged in the time the characteristics of Your 
equipment. 
 
        Cordially we wish you a good job.
© Central University of Technology, Free State
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2. DICHIARAZIONE DI CONFORMITA’ 
Declaration of conformity 
 
Medical & Technology 
Via della fiera 87 
47900 Rimini (RN) 
 
Dichiara sotto la propria responsabilità che il prodotto  
EPOREX K 69-E 
Declares on it’s own sole responsibility that the product 
EPOREX K 69-E 
 
dichiara sotto la propria responsabilità che il dispositivo di cui all'oggetto 
soddisfa tutte le disposizioni applicabili nelle direttive 
 
2006/95/CEE  concernente la bassa tensione 
 
89/336/CEE concernente la compatibilità elettromagnetica 
 
Standard CEI 62-24: Norma particolare per la sicurezza degli stimolatori 
neuromuscolari 
 
Standard CEI 62-23 Norme particolari per la sicurezza delle apparecchiature 
per terapie a ultrasuoni 
 
Declares on it’s own responsibility that the mentioned device satisfies all the 
dispositions directives: 
 
2006/95/CEE concerning the low voltage 
 
89/336/CEE concerning the electromagnetic compatibility 
 
Standard CEI 62-24: Particular safety for the nerve and muscle stimulators 
 
Standard CEI 62-23: Particular requirement for the safety of ultrasonic physiotherapy 
equipment 
 
A tale scopo la scrivente garantisce e dichiara sotto la propria responsabilità quanto segue: 
For this purpose the undersigned guarantees and declares on it’s own responsibility the following:  
 
- Tipologia del dispositivo: dispositivo per veicolazione transdermica 
- Type of device: device for transdermical electric veiculation 
- il dispositivo in oggetto soddisfa i requisiti essenziali richiesti dall'allegato I della direttiva 
2006/95/CEE e dell’allegato III della Direttiva 89/336/CEE 
The present device complies with the essential requirements in the attachment 1 of the  2006/95/CEE 
Directive and the attachment III of the 89/336/CEE Directive; 
 
 
                 ROSSI FIORENZO 
      CEO 
Medical & Technology S.r.l.
Rimini il 01/09/2006 
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3. INSTRUCTIONS AND SAFETY PRECAUTIONS 
 
 
BEFORE PROCEEDING TO THE USE OF THE DEVICE READ CAREFULLY THIS 
USER MANUAL AND THE FOLLOW THE INSTRUCTIONS AND PRECAUTIONS 
 
o Avoid the exposure to excessive heat sources. The temperature of use must 
be  between 10 and 40 °C; 
 
o Use only the present device in conformity to its destination of use, Medical 
& Technology does not assume any responsibility for damages to things or 
people caused by a non correct use of the device; 
 
o Use only the device with the original accessories and suitable substances 
listed in the manual present of use; 
 
o Regarding the choice of the substances to use,  follow to the dispositions for 
the intramuscular therapies; 
 
 
o Eporex K69-E can delivery any substance water soluble; 
  
o The device must be used only from qualified and educated personel on the 
techniques of application; 
 
o Verify that the characteristics of the electrical system are suitable to the 
requisites  of the device, written on the label and in the present user 
manual; 
 
o Any manipulation, substitution, intervention on the device not performed 
from authorized personnel by Medical & Technology involves the decadence 
of the warranty and thus the manufacturer will be not responsible for 
damages to people or things that can derive of it; 
 
o Don't use the device in presence of inflammable mixtures; 
 
o Don't use on the patient other devices besides Eporex K69-E; 
 
o Don't use the device in the case in which it presents breaking on the 
enclosure, on the handle dispenser, on the spatula: call immediatly the 
Medical & Technology technical service; 
 
o Don't use the device in environments with elevated electromagnetic fields 
that could cause malfunctions of the Eporex K69-E and of the other 
instruments in the surrounding environment; 
 
o A simultaneous connection of a Patient to an Instrument of high frequency 
electrosurgery device, can result in  burns in correspondence of the 
electrodes of the device and can result on damages of Eporex K69-E; 
 
o Operating in proximity of devices for  short or micro waves therapy (eg. 1 
m) can produce instability in the outputs of the Eporex K69-E; 
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o Absolutely do not to use the device on people carriers of peace-maker or 
other devices on whose use of device can interferes with the 
electromagnetic fields and the electrostatic current. In doubtful case you 
have to consult the physician. 
 
o Treatments to the face could interfere with acoustic instruments that must 
be removed before the application. 
 
Adviced against use: 
 
o Contour of the eyes, heart disease people, pregnancy, areas to be treated 
interesting infections, neoplasticis, ulcers and bedsores, abrasions, wounds, 
obliterating arteriopathie, phlebitis, trombophlebitis, suspicious snows, 
subjects with redoubt cutaneous sensibility, subjects unable to 
communicate. (different medical prescription excepted); 
o Prosthesis or metallic osteosintesys (different medical prescription 
excepted); 
o Spastic paralysis (different medical prescription excepted); 
o Avoid the use on patient connected with equipments of monitoring of the 
vital parameters; 
 
Don't apply the electrodes on: 
o Traumatized parts, cuts, lips and mucous generally, carotid and its 
proximities, area of the breast, central anterior surface of the neck, cardiac 
area; 
 
o Don't use the spatula Brightskin in presence of liquids or in immersion in 
liquid. Brightskin is not protected against the liquid penetration.The degree 
of protection IP is 0. If Brightskin shold be in contact with a liquid, 
immediately suspend the treatment and to contact the technical support of 
Medical & Technology. 
 
o Don't use Brighskin on the wet skin 
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4. INTENDED USE 
 
 
Eporex K69-E is a device for transdermical electroveiculation and ultrasounds treatments. 
The principles on which it founds its employment are those diffused in the scientific 
community of the ionoforesi, elettrorepulsion and elettroporation. 
The shape of wave created by the generator allow to transport any subatances (applied on 
an electrode with equal polarity to that of the ions of the substance) solution from an 
electrode to another of opposite polarity through the technique of the transdermical 
electroveiculation. 
The device can be used by aesthetical qualified personnel, Eporex K69-E allows to use the 
transdermical electroveiculation for the subcutaneous transfer of cosmetic substances, for 
the contrast of the beauty flaw of the cellulitis, to improve the cutaneous and muscular 
tone. 
The application of the ultrasounds spatula allows 
 A deep purification of the skin 
 An invigorating action for the derma 
 A cutaneous reactivation 
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5. USED SYMBOLS 
 
In the present user manual symbols are used for recalling the attention of the user on 
information and observations of particular importance, the symbols are the followings:  
 
 
 Warning – High Voltage 
 
  
 Warning – see the documentation 
 
  
 Follow the instruction for use 
 
  
 CE Marking of European Conformity 
 
  
 Fuse 
 
 
 Equipotential 
 
 
 Aplies part  BF type 
 
 
 
 
Fig. 6 Waste Electric and Electronic Directive Symbol 
Dir. 2002/96/CE 
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6. DESCRIPTION OF THE PRODUCT 
 
 6.1 General Features 
 
 Eporex K69-E is a device that allows to make to penetrate, through the generation of 
pulsated currents, substances to high and low molecular weight through the dermo-epidermal 
barrier without occur any damage to it. 
The penetration of the substances through the derma is obtained by using the transdermical 
electroveiculation, such penetration happens thanks to the increased ability of transcutaneous 
absorption that follows the deliver of periodic current impulses. 
Such impulses allow the opening of opportune "hydroelecttropores", through which penetrate 
the select substances. 
The active substance, dissolved in specific gel are electrically loaded by the application of 
pulsated currents and made ready to the ionic transport. 
Eporex K69-E can deliver any product dissolved in watery base, to subdermals depth and 
therefore to allow the veiculation of a cosmetic substabces without any invasivity for the 
patient. 
The possibility to deliver substances in subdermals depths allows applications in all that fields 
in which it is necessary to transfer a substance through the derma. 
 The use of Eporex K69-E in aesthetical applications, is obtained by the mean of the  
cavitation principles, through the use of an ultrasounds spatula. The cavitation is the 
formation and activity of bubbles (or hollow) inside a liquid submitted to an intense ultrasonic 
field. 
In a liquid, the ultrasonic waves produced by a transducer, create high pressure and low 
depression waves at high speed. These waves of pressure and depression in the liquid 
originate the phenomenon of cavitation. During the phase of depression, are created inside 
the liquid a multitude of little bubbles. During the second phase of ultrasonic compression, 
the enormous pressure stored into the little bubble, compresses the same up to make it 
implode with consequent release of energy directed to the object to clean. 
The output signals, generator of currents are available on two separate channels and 
galvanically isolated to the device, the negative electrode is constituted by a plate of plastic 
material, the positive electrode is constituted by the re-usable handle dispenser. 
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6.2 Content of the package 
 
The package of Eporex K69-E contains the following elements: 
The package of Eporex K69 contains the following elements: 
 n° 1 Base Unit 
 n° 1 Power supply cable 
 n° 1 Transdermic handle dispenser 
 n° 2 Rolls Electrodes for body application of the transdermic handle dispenser 
 n° 2 Bull Electrodes for face application of the transdermic handle dispenser 
 n° 1 Ultrasonic Spatula 
 n° 1 Conductor wrist strap 
 n° 2 Complete Connection cables for transdermic handle dispenser 
n° 2 Ground plates 
 n. 2 Sponges for ground plate 
 n .2 Power key for the base unit 
 n. 1 500 ml Ultrapeel 
n. 1 Ultragel skin for face 
n. 1 Ulragel white 
n. 1 Ultragelo striae 
 n° 25 packages of 60 ml conductive  gel  
 n° 5 packages of face treatments powder 
n° 5 packages of breast treatments powder 
n° 5 packages of stretch marks treatments powder 
n° 5 packages of toning treatments powder 
n° 5 packages of cellulites treatments powder 
 
 
 
 
 
 
Powder packages and gel bottles are intended only for the first use of the system focused 
to: 
 Test the functionality and setting the system components 
 Execute the training of the user from authorized and skilled  M&T technicians 
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Fig 1. Base Unit 
Fig.2 Connection cables for transdermic 
handle dispenser 
Fig.3 Wrist strap with earth cable 
Fig.4 Rolls Electrode for body 
application of transdermic handle 
dispenser 
Fig.5 Bull Electrode for face 
application of transdermic handle 
dispenser 
Fig.6 Mass Plate 
 
 Fig.7 Ultrasonic Spatula 
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7. TECHNICAL SPECIFICATIONS 
 
MODEL        Eporex K69-E 
CENTRAL UNIT 
POWER SUPPLY VOLTAGE     90V,220V c.a. 
WORKING FREQUENCY      50 Hz, 60 Hz 
INTERNAL WORKING VOLTAGE    24 Vcc 
MAX POWER ABSORBED      40 VA 
FUSES         2x R 2A 250V 
ELECTRICAL SECURITY CLASS    I BF 
MAX OUTPUT VOLTAGE      45 V 
MAX OUTPUT CURRENT (R=1K)    45mA 
MAX WORKING FREQUENCY     1760 Hz 
BRIGHTSKIN SPATULA 
POWER SUPPLY VOLTAGE     24 V c.c. 
WORKING VOLTAGE      5 V c.c. 
WORKING FREQUENCY      25KHz 
MAXIMUM POWER  BRIGHTSKIN SPATULA  0,1 mW 
CENTRAL UNIT DIMENSIONS (LxAxP)   550x260x230 mm 
CENTRAL UNIT WEIGHT      6 Kg 
BRIGHTSKIN SPATULA DIMENSIONS(LxAxP)  50x20x150 mm 
BRIGHTSKIN SPATULA WEIGHT    0,2 Kg 
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8. PANEL AND CONTROLS 
 
 8.1 Frontal panel 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Adjustment of intensity of the 
electrode 1 
Adjustment of intensity of the 
electrode 2 
ESC to cancel  
ENT key for the choiche of the 
selection 
Selection key 
 Fig.8 Front panel 
 Fig.9 Keys of the command 
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8.2 Rear panel 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Socket for the 
ultrasonic spatula 
Socket for the electrode n° 1 
Socket for the electrode n° 2 
Socket for the electrostatic 
wrist strap 
Warning label 
Device Identification label
Power on indicator 
Power supply socket 
Turning on key-switch 
 Fig.9 Sockets 
 Fig.10 Rear Panel 
Label for the RAEE Directive 
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9. LABELS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 Fig.11 Device Label 
Fig. 12 Label, Warning high voltage. Waste Electric 
and Electronic Directive Simbol  (Rif. Directive 
2002/96/CE) 
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10. INTRODUCING THE SYSTEM 
 
 10.1 Generalities on the transdermic veiculation 
The technique of the transdermic veicultation  allows to make to penetrate "actively" 
substances to high and low molecular weight through the dermo-epidermal barrier, without 
that such barrier suffers any type of damage. 
The transport of substances happens thanks to the peculiar association of electropulsed 
wave – chamber of ionization, that promote the increase of the ability of transcutaneous 
absorption, following the delivery of electric periodic impulses. Such impulses allow the 
opening of "hydroelecttropores", electric intracellular doors, through which penetrate the 
active principles mixed preventively to a specific loaded gel and made ready to the ionic 
transport. 
The advantages of the transdermic veiculation are : 
 Delivery of the active principle directly in the extracellular compartment. 
The high concentrations obtained with this technique allow to quickly 
activate the metabolism of the cells target which begin to immediately use 
the communicated substances 
 Possibility to deliver any type of molecules avoiding painful somministration 
approach 
  Fast results, in clinical and aesthetical circle 
 Possibility to be able to choose the depth of penetration of the substance 
from 0.1 cm up to 10 cm 
 High concentration of the quantity of substance that reaches the zone to 
treat (90% against 5% of the traditional techniques) 
 
 
 10.2 Generalities on the cavitation  
The phenomenon of the cavitation consists in the formation of bubbles (or hollow) inside a 
liquid submitted to an intense ultrasonic field. This phenomenon manifests when a liquid is 
submitted to a notable depression; in the moment in which the absolute pressure becomes 
inferior to the intramolecular tension of the liquid, an intense energetic field is created 
which creates a pressure and depression waves to high speed. These waves of pressure 
and depression in the liquid originate the phenomenon of cavitation. During the phase of 
depression, are created inside the liquid little bubbles. During the second phase of 
ultrasonic compression, the enormous pressure stored into little bubbles, compresses the 
same one up to make them collapse with consequent release of energy that strikes  the 
object to clean. The created energy is used then for promote the separation of died cells on 
the epidermal surface.  
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11. TURNING ON THE SYSTEM 
 
11.1 Base Unit installation 
 
After having fixed the basic unit to the support, extract from the suitcase all the 
components of the system. 
  
• Connect the power supply cable to the relative socket on the back of the 
basic unit and to the electrical system; 
• Insert the key-switch of the system; 
• Rotate the switch in hourly sense to turn on the system, the light indicator 
will turn on;  
• Press the enter key to enter the main menù 
 
 
 
 
 
 
Fig.14 Initail screen  
Fig.15 Main Menù 
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11.2 Connceting the transdermic handle dispenser 
 
 
For the conncecton of the transdermic veicultation handle dispenser, proceed as  follows: 
  
Connect the connection cable for transdermic handpice to the special connector 
as shown in figure: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
o Connect tje red plug of the cables fo the transdermic handle dispenser 
acting on the knob on such plug 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Knob for the locking of the handle 
dispenser  
Electrode 
Socket of electrode 1 
Socket of electrode 2 
Fig.16 Connection of cables to base unit 
Fig.17 Connection of the cables to the transdermic handle 
dispenser 
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o Choose the type of handle dispenser according to the part of the body to 
treat,  single roll handle dispenser for treatments of the face, double roll 
handle dispenser for treatments to the body 
 
o Connect the black cable in the special lodging of the plate of mass. 
 
o Put the plate of mass in a position diametrically opposite on the body of the 
patient to the area of treatment, having care to have a contact uniform 
between the whole surface of the plate and the body of the patient. 
Interpose between plate and the body a conductive gel. 
 
 
 
 
 
 
 
 
 
 
 
 
o Insert the solution in the transdermic handle dispenser 
 
For the installation of the second electrode perform the same operations described in 
precedence, connecting the electrode to the socket with the Roman number 2  
 
 
11.3 Installation of the ultrasound spatula 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
For the connection of the ultrasounds spatula  connect the connector of the spatula to the 
socket denominated "spatula" 
 
Fig.18 Connection of the cables to the earth plate 
Fig.19 Connection of the ultrasonic spatula to the base unit 
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IN SOME THERAPIES IT IS NECESSARY TO CONNECT THE WRIST STRAP OF MASS TO THE 
DEVICE IT IS TO MAKE IT WEAR TO THE PATIENT. THE NECESSITY OF THE CONNECTION IS 
VISUALIZED BY THE DEVICE THROUGH THE FOLLOWING WARNING ON THE DISPLAY  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
THE WRIST STRAP MUST BE WET WITH WATER BEFORE BEING WORN TO THE 
PATIENT, THIS TO AVOID IRRITATIONS ON THE POINT OF CONTACT WITH THE 
SKIN. FOR A CORRECT HYGIENE PUT  AMONG THE WRIST STRAP AND THE SKIN 
A ROLL OF WET TNT WITH WATER THAT MUST HAVE REPLACED TO EVERY 
TREATMENT 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Connect the wrist strap of mass to the special connection as illustrated in figure 
Connect the 
earth wrist 
strap 
Fig.20 Screen that indicates to connect the earth wrist strap 
Fig.21 Connection between the earth wrist strap and the base unit 
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 12. TREATMENT PROCEDURES 
 
      Before starting: 
 
 
The areas destined to the treatment must carefully be cleaned with suitable solutions to 
remove impurity and possible residues of makeup (in the case of treatment revitalising for 
the face). 
  
To facilitate the cavitation process it is to  recommends to use rinsing detergents, such 
process will precede the treatment of veiculation. 
  
Make to strip the patient of every metal object in contact with the skin 
  
Before beginning the treatment with the ultrasounds, we recommend to prepare the 
choosen gels for the treatment of the veiculation, by the mean of a good mixing, 
vigorously shake them. 
 
12.1 TRANSDERMIC VEICULATION MODE 
 
 
 12.1.1 P.E.F.S. / Cellulite 
 
The methodic is suitable in the treatment of patients with located adiposity and P.E.F.S. 
After having developed the preliminary procedures of preparation, make to stretch prone 
the patient for the treatment of the trocanter zone, or supine for the treatment of the 
intern part  of the thigh and of the knee. Carefully mix the select substances (in powder) 
with the gel, and screw the bottle dispenser to the transdermic veiculation handle 
dispenser. 
Position the plate of mass and select the electroveiculation program. 
 
o From the main menu, select, the desired treatment; 
o Press the key ENT to confirm the choice; 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.22 Choosing of the treatment mode from the  
main menu 
 
Waveforms 
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o Set the duration of the treatment through the keys of selection; 
o Set the intensity of treatment acting on the keys of regulation intensity; 
o Set the correct intensity of treatment to begin from the low level of intensity up to 
make to warn a light feeling of prickle to the patient watching out for not to 
make it become annoying. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
o Press the key ENT to begin the treatment, an intermittent symbol will flash at the 
beginning of the treatment; 
o The time of treatment on the display start to increase; 
 
 
 
 
o To interrupt the treatment press the key ESC. 
o Press the key ESC to return to the principal menu 
 
Begin the treatment putting the steel part of the handle dispenser in contact with the 
zone to treat of the patient and apply a massage contemporarily practicing a light 
pressure on the dispenser to facilitate the spillage of the gel.  
At the end of the time of treatment, massage the zone treated for favoring the absorption 
of the residual product. 
 
Fig.23 Setting of the treatment duration 
Fig.24 Setting the treatment intensity 
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 12.1.2.Muscle Toning 
 
After having developed the preliminary procedures of preparation, make to stretch prone 
the patient for the treatment of the trocanter zone, or supine for the treatment of the part  
intern thigh and of the knee. Carefully mix the select substances (in powder) with the gel, 
and to screw the bottle dispenser to the transdermic veiculation handle dispenser. 
Position the plate of mass and select the electroveiculation program. 
 
o From the main menu, select, the desired treatment; 
o Press the key ENT to confirm the choice; 
 
 
 
 
o Set the duration of the treatment through the keys of selection; 
o Set the intensity of treatment acting on the keys of regulation intensity; 
o Set the correct intensity of treatment to begin from the low level of intensity up to 
make to warn a light feeling of prickle to the patient watching out for not to 
make it become annoying. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
o Press the key ENT to begin the treatment, an intermittent symbol will flash at the 
beginning of the treatment; 
o The time of treatment on the display start to increase; 
 
 
Fig.25 Choosing of the treatment mode from the  
main menu 
Fig.26 Setting of the treatment duration 
 
Waveforms 
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o To interrupt the treatment press the key ESC. 
o Press the key ESC to return to the principal menu 
 
Begin the treatment putting the stell part of the handle dispenser in contact with the zone 
to treat of the patient and make the massage contemporarily practicing a light pressure 
on the dispenser to facilitate the spillage of the gel.  
At the end of the time of treatment, massage the zone treated for favoring the absorption 
of the residual product. 
 
 
 12.1.3 Skin Texture/Stretch-mark 
 
 
After having developed the preliminary procedures of preparation, make to stretch prone 
the patient for the treatment of the trocanter zone, or supine for the treatment of the part  
intern thigh and of the knee. Carefully mix the select substances (in powder) with the gel, 
and to screw the bottle dispenser to the transdermic veiculation handle dispenser. 
Position the plate of mass and select the electroveiculation program. 
 
o From the main menu, select, the desired treatment; 
o Press the key ENT to confirm the choice; 
 
 
 
 
 
o Set the duration of the treatment through the keys of selection; 
o Set the intensity of treatment acting on the keys of regulation intensity; 
o Set the correct intensity of treatment to begin from the low level of intensity up to 
make to warn a light feeling of prickle to the patient watching out for not to make it 
become annoying. 
 
 
 
Fig.23 Setting the treatment intensity 
 
Fig.27 Choosing of the treatment mode from 
the main menu  
 
 
Waveforms 
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o Press the key ENT to begin the treatment, an intermittent symbol will flash at the 
beginning of the treatment; 
o The time of treatment on the display start to increase; 
 
 
 
 
 
o To interrupt the treatment press the key ESC. 
o Press the key ESC to return to the principal menu 
 
Begin the treatment putting the stell part of the handle dispenser in contact with the zone 
to treat of the patient and make the massage contemporarily practicing a light pressure 
on the dispenser to facilitate the spillage of the gel.  
At the end of the time of treatment, massage the zone treated for favoring the absorption 
of the residual product. 
 
 
 12.1.4 Face Toning 
 
For this treatment we recommend the use of the handle dispenser with single (to see 
page 9) roll. Carefully mix the select substances (in powder) with the gel, and screw the 
bottle dispenser to the transdermic handle dispenser. 
Position the electrode of mass and predispose the use of the program for the 
ettroveiculation. 
 
o From the main menu, select, the desired treatment; 
o Press the key ENT to confirm the choice; 
 
 
Fig.28 Setting of the treatment duration 
 
Fig.29 Setting the treatment intensity 
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o Set the duration of the treatment through the keys of selection; 
o Set the intensity of treatment acting on the keys of regulation intensity; 
o Set the correct intensity of treatment to begin from the low level of intensity up to 
make to warn a light feeling of prickle to the patient watching out for not to make it 
become annoying. 
 
 
 
 
 
o Press the key ENT to begin the treatment, an intermittent symbol will flash at the 
beginning of the treatment; 
o The time of treatment on the display start to increase; 
 
 
 
 
 
 
o To interrupt the treatment press the key ESC. 
o Press the key ESC to return to the principal menu 
 
 
Fig.30 Choosing of the treatment mode from the 
main menu 
Fig.31 Setting of the treatment duration 
Fig.32 Setting the treatment intensity 
 
Waveforms 
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Begin the treatment putting the stell part of the handle dispenser in contact with the zone 
to treat of the patient and make the massage contemporarily practicing a light pressure 
on the dispenser to facilitate the spillage of the gel.  
Move the handle dispenser slowly following the tension face lines, treat singles areas by 
dividing the total time previously selected in the treatment mode selected. 
At the end of the time of treatment, massage the zone treated for favoring the absorption 
of the residual product. 
 
 
 12.1.5 Wellness Treatments 
 
 
 
After having developed the preliminary procedures of preparation, make to stretch the 
prone patient for the treatment of the zone trocantera, or supine for the treatment of the 
part intern thigh and of the knee. Carefully mix the select substances (in powder) with the 
gel, and screw the bottle dispenser to the transdermic veicultation handle dispenser. 
Position the electrode of mass and predispose the use of the electroveicultation program. 
Il trattamento è indicato, ad esempio, nel trattamento di stati dolorosi infiammatori.   
 
o From the main menu, select, the desired treatment; 
o Press the key ENT to confirm the choice; 
 
 
 
 
o Once pressed the key ENT  will appear another menu for the choice of the depth of 
penetration of the substance; are available three options 
 
 Low Level (For light pain) 
 Medium Level 
 High Level (For deep pain) 
 
o Choose the preferred formality through the keys of selection 
o Confirm pressing the key ENT. 
 
 
 
Fig.33 Choosing of the treatment mode from the main menu 
Fig.34 Setting of the treatment level 
 
Waveforms 
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o Set the duration of the treatment through the keys of selection; 
o Set the intensity of treatment acting on the keys of regulation intensity; 
o Set the correct intensity of treatment to begin from the low level of intensity up to 
make to warn a light feeling of prickle to the patient watching out for not to make 
her/it become annoying. 
o  Press the key ENT to begin the treatment, an intermittent symbol will start flashing 
during the execution; the time of suitable treatment on the display will start to 
increase; 
 
 
 
 
 
o To interrupt the treatment press the key ESC. 
o Press the key ESC to return to the principal menu 
 
Begin the treatment putting the stell part of the handle dispenser in contact with the zone 
to treat of the patient and make the massage contemporarily practicing a light pressure 
on the dispenser to facilitate the spillage of the gel.  
Move the handle dispenser slowly following the tension face lines, treat singles areas by 
dividing the total time previously selected in the treatment mode selected. 
At the end of the time of treatment, massage the zone treated for favoring the absorption 
of the residual product. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.35 Setting the treatment intensity 
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 12.1.6 Free Treatment 
 
   
After having performed the preliminary procedures of preparation, make to stretch the 
prone patient for the treatment of the zone trocantera, or supine for the treatment of the 
part intern thigh and of the knee. Carefully mix the select substances (in powder) with the 
gel, and screw the bottle dispenser to the transdermic veicultation handle dispenser. 
Position the electrode of mass and predispose the use of the electroveicultation program. 
 
o From the main menu, select, the desired treatment; 
o Press the key ENT to confirm the choice; 
 
 
 
 
 
o Once pressed the ENT key,  will appear another menu for the choice of the depth of 
penetration of the substance; are available three options 
 
 
 
 
o Set the duration of the treatment through the selection keys; 
o Set the intensity of treatment acting on the keys of regulation intensity; 
o Set the correct intensity of treatment to begin from the low level of intensity up to 
o make to warn a light feeling of prickle to the patient watching out for not to make 
 it become annoying. 
 
 
Fig.36 Choosing of the treatment 
 mode from the main menu 
Fig.37 Setting of the treatment deep 
Fig.38 Setting of the treatment duration 
 
Waveforms 
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o Press the key ENT to begin the treatment, an intermittent symbol will start flashing 
during the execution; the time of suitable treatment on the display will start to 
increase; 
 
 
 
 
 
 
 
 
 
 
 
o  
 
 
 
 
 
o To interrupt the treatment press the key ESC. 
o Press the key ESC to return to the principal menu 
 
Begin the treatment putting the stell part of the handle dispenser in contact with the zone 
to treat of the patient and make the massage contemporarily practicing a light pressure 
on the dispenser to facilitate the spillage of the gel.  
Move the handle dispenser slowly following the tension face lines, treat singles areas by 
dividing the total time previously selected in the treatment mode selected. 
At the end of the time of treatment, massage the zone treated for favoring the absorption 
of the residual product. 
 
 
 
 
Fig.39 Setting the treatment intensity 
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12.2 BRIGHTSKIN ULTRASOUND TREATMENT 
 
 
The system Eporex K69-E, thanks to the use of the Ultrasounds handle dispenser and 
principles of the cavitation is able to remove died cells by the horny layer. 
The ultrasonic handle dispenser, equipped with a  piezoelectric oscillating device at 25 
KHz, has in the distal part a metallic spatula, that allows an accurate job of cleaning 
and preparation to the transdermical electroveiculation. 
Don't use the Brightskin spatula in presence of liquids or in immersion in liquid. 
Brightskin is not protected against the liquids, the immersion or penetration of liquids. 
If Brightskin should be put in contact with a liquid, immediately suspend the treatment 
and contact the technical support Medical & Technology. 
  
  
 WARNING:  read carefully the instructions 
 
 Do not use the ultrasounds probe on the skin without water, gel or 
appropriate product; 
 Do not dip the probe in water, the degree of protection is IP 0. Only the tip 
can be brought in contact with liquid;  
 Absolutely keep away from children; 
 Do not use the spatula in perpendicular position referred to the surface to 
treat; 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Do not use the probe on subjects carriers of pacemaker or other devices 
whose operation could be influenced by electrostatic electromagnetic or 
current interferences; 
  
 The treatment to the face could interfere with acoustic instruments, it is 
necessary to remove them before the beginning of the treatment;        
  
 Don not to use the spatula in the immediate contour eyes, on patient with 
heart disease, on pregnancy patients, patient with affections on the 
treatment area like neoplasticis, ulcers and bedsores, abrasions, wounds, 
obliterating arteriopatie, phlebitis, trombophlebitis, varicouse,suspicious 
snows; 
 Do not use the spatula on subjects with reduced cutaneous sensibility, 
unable to communicate or affected by paralysis (different medical 
prescription excepted); 
 
  
NO 
Fig.40 Wrong use of the ultrasonic spatula 
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 Avoid the use on subjects connected to equipments of monitoring of the vital 
parameters; 
 
  Do not  apply the electrodes on traumatized parts, cuts, lips and mucous 
generally, carotid and its proximities, area of the breast, cardiac area; 
 
12.2.1 Bightskin Menu 
 
From the principal menu, acting on the selection buttons , set the "Brightskink ultra-
sound" mode, push the  ENT key to confirm 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Once confirmed the choice, set the type of skin to treat, using the keys of selection and  
confirm by pressing the ENT key; 
 
 
 
 
The following menu shows the available types of treatment in the brightskin ultrasound 
treatment mode. 
Choose the desired treatment by pressing  the  selection keys and confirm the choice 
pressing the key ENT: 
 
 
Fig.41 Choose of the treatment mode from the main menu 
Fig.42 Setting of the type of skin 
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12.2.2 Dermopurification  
 
The Dermopurification mode is suitable for the execution of peeling and cleaning of the 
treated areas. 
o From the menu Brightskin select dermpurification and press ENT 
o Set the time of treatment acting on the keys of selection 
o Begin the treatment pressing the ENT key 
o To end the treatment press the  ESC key 
o Press the ESC key to return to the Brightskin menu 
 
 
 
 
12.2.3 Deep Purification 
 
The Deep Dermopurification treatment  is suitable for the execution of peeling and deep 
cleaning of the treated areas. 
o From the menu Brightskin select deep dermpurification and press ENT 
o Set the time of treatment acting on the keys of selection 
o Begin the treatment pressing the ENT key 
o To end the treatment press the  ESC key 
o Press the ESC key to return to the Brightskin menu 
Fig.43 Treatment modalities of the brightskin menu 
Fig.44 Dermopurification treatment screen 
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The wrist strap must be wet with water before being worn to the client, this to avoid irritations on the 
point of contact with the skin.  In order to keep a correct hygienic behavior  always interpose between the 
wrist strap and the skin a roll of well wet TNT (Fabric not Fabric) with water, this has to be replaced after 
every treatment. 
 
12.2.4 Deep Purification Tone-up 
 
The Deep Ton up Dermopurification is suitable for the execution of peeling and deep 
cleaning of the treated areas and for a firm of the same. 
o From the menu Brightskin select deep tone up dermpurification and press ENT 
o Set the time of treatment acting on the keys of selection 
o Begin the treatment pressing the ENT key 
o To end the treatment press the  ESC key 
o Press the ESC key to return to the Brightskin menu 
 
 
 
 
The wrist strap must be wet with water before being worn to the client, this to avoid 
irritations on the point of contact with the skin.  In order to keep a correct hygienic 
behavior  always interpose between the wrist strap and the skin a roll of well wet 
TNT (Fabric not Fabric) with water, this has to be replaced after every treatment. 
 
 
 
 
 
 
 
Connect the wrist strap with the mass 
cable to the wrist or on the arm of the 
patient when required by the selected 
treatment; the application is 
recommended from the presence on 
the display of the sign + or - 
Fig.45 View of the deep dermopurification treatment 
Fig.46 View of the deep tone up dermopurification treatment 
Connect the wrist strap with the 
mass cable to the wrist or on the arm 
of the patient when required by the 
selected treatment; the application is 
recommended from the presence 
on the display of the sign + or - 
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12.2.5 Tone Up Action 
The tone up action treatment is suitable for the firm of the treated areas. 
o From the menu Brightskin select tone up treatment action and press ENT 
o Set the time of treatment acting on the keys of selection 
o Begin the treatment pressing the ENT key 
o To end the treatment press the  ESC key 
o Press the ESC key to return to the Brightskin menu 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
o  
 
 
12.2.6 Skin Reactivation 
 
o From the menu Brightskin select cutaneous treatment reactivation  and  press ENT 
o Set the time of treatment acting on the keys of selection 
o Begin the treatment pressing the ENT key 
o To end the treatment press the  ESC key 
Press the ESC key to return to the Brightskin menu 
 
 
 
The wrist strap must be wet with water before being worn to the client, this to avoid 
irritations on the point of contact with the skin.  In order to keep a correct hygienic 
behavior  always interpose between the wrist strap and the skin a roll of well wet 
TNT (Fabric not Fabric) with water, this has to be replaced after every treatment. 
 
 
 
 
Fig.47 View of the tone up action treatment 
 
Fig.48 View of the cutaneous treatment reactivation 
Connect the wrist strap with the 
mass cable to the wrist or on the 
arm of the patient when required by 
the selected treatment; the 
application is recommended from 
the presence on the display of the 
sign + or - 
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12.2.7 Reactivation tone-up 
 
o From the menu Brightskin select tone up reactivation treatment and  press ENT 
o Set the time of treatment acting on the keys of selection 
o Begin the treatment pressing the ENT key 
o To end the treatment press the  ESC key 
Press the ESC key to return to the Brightskin menu 
 
 
 
 
 
The wrist strap must be wet with water before being worn to the client, this to avoid 
irritations on the point of contact with the skin.  In order to keep a correct hygienic 
behavior  always interpose between the wrist strap and the skin a roll of well wet 
TNT (Fabric not Fabric) with water, this has to be replaced after every treatment. 
 
Fig.49 View of the tone up reactivation screen  
Connect the wrist strap with the mass 
cable to the wrist or on the arm of the 
patient when required by the selected 
treatment; the application is 
recommended from the presence on 
the display of the sign + or - 
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           For a correct use in the folloqing treatments: 
 
o Dermopurification 
o Deep Dermopurification 
o Toning Action 
 
Use the ultrasonic handle dispenser as shown in the figure: 
 
 
 
 
 
 
 
 
 
 
 
 
 
            For a correct use in the folloqing treatments: 
 
 
o Toning Action 
o Cuteneous Reactivation 
o Toning reactivation 
 
Use the ultrasonic handle dispenser as shown in the figure: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
YES 
45° 
30° 
Change the orientation 
of the tip 
Fig.50 Correct use handling of the ultrasonic handle dispenser 
Fig.51 Correct use handling of the ultrasonic handle dispenser 
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13. MAINTENANCE 
 
13.1  Ordinary Maintenance 
 
The Eporex K69-E system has been developed for working in reliable way with a minimum 
maintenance. We advise to perform periodic interventions of maintenance from 
specialized personnel  authorized by the Medical & Technology. The Medical & Technology 
can instruct personnel for technical interventions and  ordinary maintenance.  
Note: The Eporex K69-E system doesn't contain sharp parts that must have submitted to 
maintenance. Every attempt of reparation, restoration or change of the system, that is  
not contemplated in this user guide, from not authorized Medical & Technology personnel  
will make void the guarantee. 
Don't remove the covering to prevent the risk of electric shocks. Every technical 
intervention must be entirely effected by skilled personnel. For every intervention  contact 
a representative of the company. 
 
13.2 Cleaning and Disinfection of the device 
 
Warning: before effecting the cleaning or the disinfection of the unit, disconnect the 
equipment from the power supply. Keep the equipment away from water. 
The wrap of the console can be clean with a damp cloth. Is possible to use an antiseptic 
detergent or a non aggressive detergent. Avoid use chemical detergents, aggressive 
chemical detergents or rough cloths that could damage the surface of the wrap. 
The device is not protected against the penetration of liquids (IP 20), avoid spray or 
infiltrations of liquids or immersions of any type.  
Cleaning and hygienization  of the handle dispensers  
Make an accurate cleaning of the metallic rolls, inside the chamber of ionization with the 
purpose to avoid possible stagnations of gel e/o substances treating. 
With the purpose to avoid the solidification of gel residues inside the chamber of 
ionization, it is recommended  to dip the handle dispensers (Fig.4. Fig. 5) completely in 
water at the end of the treatment  
Don't effect the disinfection with corrosive products 
Cleaning and hygienization  of the ultrasound probe   
Clean the ultrasounds probe with a soft cloth dampened with water and neutral 
detergent. Clean the metallic spatula with non-corrosive products not nuked, applied with 
cloths and napkins humidified. 
In the case in which infiltration of liquid had to be verified in the probe, leave it 
suspended with the spatula head orientated toward earth to make t the liquid flow out, do 
not it until the probe is completely dry. 
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For the substitution of the ultrasounds probes Brightskin contact the distributor of zone or 
to the laboratories Medical & Technology. 
13.3  Fuses replacement 
 
For the fuses replacement  
 
 
 
 
 
 
13.4  Planned Maintenance  
 
Perform, with illustrated cadency in the following chart the following operations: 
 
  
Maintenance Personal Lilt 
Cleaning and hygienization of the console Operator Daily 
Cleaning and patient hygienization of the 
cables 
Operator Daily 
Cleaning, hygienization or substitution of the 
accessories to direct contact with the patient 
Operator 
At the end of 
every session 
Visual control of the integrity of the power 
supply cables 
Operator Weekly 
Visual control of integrity of the cables in 
contact with the patient 
Operator Weekly 
Inside cleaning of the console, verification of 
the functionality, revision and setting 
Laboratorie
s Medical & 
Technology 
Annual 
Verification of the current of dispersion and 
the electric safety 
Laboratory 
qualitficato 
Annual 
Calibration ultrasound probe, Examination   
of treatments head -examination of the 
cables 
Laboratorie
s Medical & 
Technology 
Annual 
      
 
 
 
 
 
Pull and change the fuses 
Fig.52 Replacement of fused 
Fig.53 Programmed maintenance table 
© Central University of Technology, Free State
Eporex K69-E 
File:man_epo-E_r01_eng.doc      Cod. FT Eporex_E/man      Rev. n° 01    date 01/01/07 Pag. 39 di 41 
13.5 Technical assistance 
 
Medical & Technology on request, will make available schematics diagrams of connection, 
lists of the parts of exchange, descriptions and other information that can allow the 
qualified technical personnel to effect the ordinary maintenance of the device Eporex K69-
E. If the Medical & Technology had to believe that the parts cannot be repaired or if a 
training were necessary or a special equipment to effect the reparation or the regulation, 
the Medical & Technology can refuse the information for safety motives. If is necessary 
the restitution of the device Eporex K69-E to the Medical & Technology, the unity must be 
accompanies from a declaration on the state of contamination.  
 
13.6 Disposal 
 
As required by the Directive 2002/96 pertaining the Waste of Electronic and Electric 
(RAEE) Equipments, are necessary: 
  
not do dispose the RAEEs as common refuse and effect a separate disposal of such 
RAEE; 
  
Contact your own City of Residence for information around the centers of separate 
disposal for the RAEEs; 
 
 
 
 
 
The right differed disposal for the following start of the negleted instrument to the 
recycling, to the treatment and the disposal environmentally compatibilie contribute to 
avoid negative effects on the environment and on the health and it favors the recycle of 
some materials which the product is composed. 
14. RESOLUTION OF THE PROBLEMS 
 
1. The device does not turn on: 
· check to have connected the power supply cable to the socket of the electric power net 
· verify the presence of tension on the electric net 
· verify the integrity of the fuses 
  
2. The substance doesn't flow out  from the handle dispenser 
· Verify the cleaning of the nozzles of the rolls 
· Verify the connections of the cables of connection between the handle dispenser and 
base unit 
  
3. The ultrasounds spatula doesn't work 
· Verify the correct connection of the spatula to the base unit 
· Verify to have connected the wrist strap of mass for the applications that ask for it 
  
4. The handle dispensers (Fig.4. Fig.5) doesn't transmit energy and/or the red cable 
deattach from the electrode  
· Replace the terminal part of the red cable with a new one 
•   
 
 
 
This symbol stand for indicate that the waste ha sto be trated separatly from 
other discards (Ref.Directive 2002/96/CE) 
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15. WARRANTY 
 
Medical & Technology guarantees the system Eporex K69-E against defects of material 
and production for a period of 24 months. During this period you can be agreed with the 
Medical & Technology contract of extension of guarantee and programmed assistance.  
 The guarantee starts from the date of the installation. 
 Note: every attempt of reparation, restoration or change of the system, that is 
not contemplated in this user guide, from not authorized personnel by Medical & 
Technology, will make decay the warranty. 
 To Obtain the  warranty intervention, the buyer, immediately after the accertain of the 
event related to the claim, must contact the Medical & Technology via mail or telephone.  
Under no circumstances Medical & Technology, will be responsible of direct damages, 
indirect, special, accidental, consequential from convention, from civil crime or from other 
legal concept. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Via della Fiera 87- 47900 Rimini(Rn)              
WWW.medical-technology.it                     
info@medical-technology.it  
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APPENDIX B 
Participant information card 
 
 
 
 
 
 
 
 
 
CLIENT CARD CONSULTATION SHEET  
  
Identification number: Date of Birth: 
Race: Date: 
Consultant: 
 CONTRA-INDICATIONS 
 Epilepsy   Jaundice/ hepatitis/TB/HIV   Back/neck pain 
 
Pacemaker   High blood pressure   Menopause 
 
Cancer   Ulcer   Cuts/sores/abrasions 
 
Pregnant/ breastfeeding    Rheumatic   Asthma 
 
Serious medical conditions   Hormonal problems/ imbalance    Drink alcohol 
 
Infectious conditions   Diabetic   Smoker 
 
Menstruation   Thyroid problems   Metal implants 
 
Stroke   Bra size/ptosis   Reduction amount 
 
Height   Weight    BMI 
  
Do you take any medication including vitamins? If yes, please list. 
  
 
Are you currently under a physician’s care? (Y/N) 
  
 
Are you allergic to anything ( e.g. metal, penicillin) (Y/N) 
  
 
Do you have a tendency to develop scars / healing ability? (e.g. Good, poor)  
  
 Notes 
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Participants Identification number: __________________________  
   
Treatment number  Date Intensity 
1.   
2.   
3.   
4.   
5.   
6.   
7.   
8.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Comments / observations prior to treatment: 
1.___________________________________________________________________________________
____________________________________________________________________________________
2.___________________________________________________________________________________
____________________________________________________________________________________ 
3.___________________________________________________________________________________
____________________________________________________________________________________ 
4.___________________________________________________________________________________
____________________________________________________________________________________ 
5.___________________________________________________________________________________
____________________________________________________________________________________ 
6.___________________________________________________________________________________
____________________________________________________________________________________ 
7.___________________________________________________________________________________
____________________________________________________________________________________ 
8.___________________________________________________________________________________
____________________________________________________________________________________  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
______________ 
 
 
 
 
 
 
Comments / observations after completion of treatment: 
1.___________________________________________________________________________________
____________________________________________________________________________________ 
2.___________________________________________________________________________________ 
3.___________________________________________________________________________________ 
4.___________________________________________________________________________________ 
5.___________________________________________________________________________________ 
6.___________________________________________________________________________________ 
7.___________________________________________________________________________________ 
8.___________________________________________________________________________________
____________________________________________________________________________________ 
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APPENDIX C 
Mammary reduction surgical technique  
 
A summary of the Wise pattern with inferior pedicle operative technique 
 
 Once in theatre the pedicle was measured (anatomical position) 2cm above 
the nipple areola complex with 6-8cm measured in width on either side of the 
nipple in order to centre the nipple areola complex on the breast meridian 
(Figure C1). 
 Participants were then placed in the supine position, anaesthetized and 
intubated before surgery commenced. 
 
 
 
 
 
 
 
 
 
 
 
Figure C1 Markings of the inferior skin resection pattern 
 
 The surgeon started with the U-shape procedure (inferior pedicle incision), 
starting at the inframammary fold; from the fold, the incision moved up and 
around the nipple area.  
 
 The areola was stretched, and depending on the participant‟s breast size, a 
circular marking of 3.5-4.5cm in diameter was made around the areola (Figure 
C2).  
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Figure C2 Marking of the areola complex using a cookie cutter 
 
 Following the markings, the skin was incised up to the dermal layer.  
 De-epithelialisation of the inferior pedicle skin followed and incisions were 
made on both the lateral and medial sides of the breast (Figure C3).  
 
 
 
 
 
 
 
 
 
 
 
Figure C3 De-epithelialisation of the inferior pedicle skin 
 The breast tissues of the superior flaps were then thinned out to achieve the 
natural breast shape and size, as determined prior to surgery (Figure C4).  
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Figure C4 Thinning out breast tissue on the superior flaps  
 
 On completion of the breast tissue removal, a latex free surgivac drainage 
system (DJH, Defty Chemist, Bloemfontein, Free State) was inserted below 
the superior flaps of both breasts to ensure proper drainage of the serous fluid 
(Figure C5).  
 
 
 
 
 
 
 
 
 
 
Figure C5 Insertion of the surgivac drainage system 
 
 To ensure an adequate opening for the „new‟ nipple areola complex, the 
thinned out superior flaps were pulled towards each other utilizing a 2/0 
mocryl monofilament absorbable surgical suture (Ethicon, Johnson & 
Johnson, Bloemfontein, Free State). One suture was inserted (Figure C6). 
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Figure C6 Insertion of 2/0 mocryl surgical suture pulling superior flaps towards 
each other 
 
 Once the nipple areola complex was in position, the vertical line down to the 
inframammary fold was sutured. This was followed by suturing the 
inframammary fold creating an inverted T (Figure C7). Continuous intra-
dermal sutures (4/0 mocryl monofilament absorbable surgical sutures; 
Ethicon, Johnson & Johnson, Bloemfontein, Free State) were used. 
 
 
 
 
 
 
 
Figure C7 Positioning of the new nipple areola complex  
 
 The same procedure was followed on the second breast.  
 The amount of breast tissue removed (g) was weighed and recorded. 
 To support healing of the breast tissue a silver acticoat plaster (Figure C8 A) 
was placed on the sutured lines. Further, to encourage natural breast shape 
development, a white micro foam plaster (DJH, Defty Chemist, Bloemfontein, 
Free State) was applied in a figure 8 around the breasts (Figure C8 B).  
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Figure C8 Application of plaster on surgical incisions after mammary reduction 
surgery (A – silver acticoat plaster, B – white micro foam plaster 
    
 
 One week post-operatively, the latex free surgivac drainage system (DJH, 
Defty Chemist, Bloemfontein, Free State) was removed and to maintain 
breast support tan micro pore surgical tape (GMS Medical, Bloemfontein, 
Free State) was placed on the inverted T incision to assist in wound healing 
and limit scarring.  
 A “Yummy mummy” bra (Conquest surgical, Johannesburg, Gauteng) was 
provided to each participant to support the breasts and provide comfort once 
the micro foam plaster was removed.  
  
A B 
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APPENDIX D 
Vancouver Scar Scale 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PARAMETER DESCRIPTOR POINTS 
Vascularity 
Normal 0 
Pink 1 
Red 2 
Purple 3 
Pigmentation  
Normal 0 
Hypo-pigmentation 1 
Hyper-pigmentation 2 
Pliability 
Normal 0 
Supple 1 
Yielding 2 
Firm  3 
Ropes 4 
Contracture 5 
Height 
Flat 0 
<2mm 1 
2-5 mm 2 
>5 mm 3 
Total score /13 
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APPENDIX E 
Pre set VSS Vancouver Scar Scale (VSS) assessment card with colour index 
 
Participant Number: _____________  Observer: _______________  
Treatment number: ______________  Date of assessment: 
______________ 
 
 
 
 
 
 
 
 
 
Scale characteristics Score R L 
Vascularity Normal 0   
 Pink 1   
 Red 2   
 Purple 3   
Pigmentation  Normal 0   
 Hypo pigmentation 1   
 Hyper pigmentation 2   
Pliability Normal 0   
 Supple 1   
 Yielding 2   
 Firm  3   
 Ropes 4   
 Contracture 5   
Height Flat 0   
 <2mm 1   
 2-5 mm 2   
 >5 mm 3   
Total score 13   
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Colour index assessing vascularity using the Vancouver Scar Scale 
Pink Red Purple 
Pink refers to a light shade of 
red 
Red refers to a colour or 
pigment; the chromatic colour 
resembling the hue of blood. 
An intermediate colour between 
red and blue, however more red 
than blue. 
*The amount of redness assessed in scar tissue is dependent on the presence of blood vessels in the area, which is tested by
how quickly the skin turns red after blanching (pressure applied to the scar using the pointer finger and then releasing allowing 
blood flow to return to the area) 
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APPENDIX F 
Breast photographic observations 
 
Breast Photography 
 
Photographic assessments were performed to visually compare the control breasts 
to the experimental breasts prior to the first, and after the last, treatment. Note that 
these photographs are not regarded as a scientific result but only added for 
illustration purposes.  
Photographs of both breasts were taken prior to the 1st Mesotherapy Eporex 
treatment and after the 8th treatment for all 30 participants. This was done to visually 
compare the experimental breast with the control breast to evaluate whether an 
improvement on scar appearance was visible with the naked eye after the 
Mesotherapy Eporex treatments. The visual images of the three participants 
displayed in Figures F1, F2 and F3 were randomly selected and the left breast (B1: 
before treatment and B2: after 8th treatment) served as the experimental breast and 
the right breast (C1: control breast before treatment of experimental breast and C2: 
control breast after 8th treatment of experimental breast) served as the control breast 
(natural healing). Each participant‟s breasts were photographed from a frontal view 
(Figures F1 A, F2 A and F3 A). Close-up photographs were taken of the left 
experimental breasts (Figures F1, F2 and F3 - B1 before and B2 after Mesotherapy 
Eporex treatments).  
 
Visual improvement can be seen when comparing the experimental breasts before 
and after images (red arrows). Improvement is seen in the vascularity, pigmentation 
and height of the scar appearance. Natural healing (black arrows) is visually evident 
on the control breasts. Although the experimental breast healed quicker, the control 
breast continued healing naturally thus supporting the results presented in Figures 
F1, F2 and F3 - C1 before and C2 after Mesotherapy Eporex treatments. 
 
 
 
 
 
 
 
 
 
 
© Central University of Technology, Free State
142 
 
Figure F1 Participant 27- A 36 year old patient with a Grade 3, major (16cm) 
ptosis. Patient underwent mammary reduction (Left breast - 530g, 
Right breast -502g) using the Wise pattern with inferior pedicle 
technique. [A1 - frontal view before treatment; A2 - frontal view after treatment; B1 - left breast before
treatment; B2 - left breast after treatment, C1 and C2- right breasts natural healing] 
12-06-2014 
12-06-2014 
12-06-2014 
10-07-2014 
10-07-2014 
10-07-2014 
A1 A2 
BEFORE TREATMENT AFTER 8
th
 TREATMENT
B1: Left experimental breast before 
treatment 
C1: Right control breast before treatment of 
experimental breast 
C2: Right control breast after 8th treatment 
of experimental breast 
B2: Left experimental breast after 8th
treatment 
© Central University of Technology, Free State
143 
 
Figure F2 Participant 19 - A 35 year old patient with a Grade 3, major (44cm) 
ptosis. Patient underwent mammary reduction (Left breast - 
2398g, Right breast -3446g) using the Wise pattern with inferior 
pedicle technique. [A1 - frontal view before treatment; A2 - frontal view after treatment; B1 - left
breast before treatment; B2 - left breast after treatment, C1 and C2- right breasts natural healing] 
15-07-2013 
15-07-2013 
15-07-2013 
13-08-2013 
13-08-2013 
13-08-2013 
A1 A2 
B1: Left experimental breast before 
treatment 
B2: Left experimental breast after 8th
treatment 
C1: Right control breast before treatment 
of experimental breast 
C2: Right control breast after 8th
treatment of experimental breast 
AFTER 8
th
 TREATMENTBEFORE 1
st
 TREATMENT 
13-08-2013 
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Figure F3 Participant 15- A 37 year old patient with a Grade 3, major (21cm) 
ptosis. Patient underwent mammary reduction (Left breast - 
2173g, Right breast -2207g) using the Wise pattern with inferior 
pedicle technique. [A1 - frontal view before treatment; A2 - frontal view after treatment; B1 - left
breast before treatment; B2 - left breast after treatment, C1 and C2- right breasts natural healing] 
18-11-2013 
18-11-2013 
18-11-2013 
06-12-2013 
06-12-2013 
06-12-2013 
C1: Right control breast before treatment of 
experimental breast 
C2: Right control breast after 8th treatment
of experimental breast 
B1: Left experimental breast before 
treatment 
B2: Left experimental breast after 8th
treatment 
A1 A2 
BEFORE 1
st
 TREATMENT AFTER 8
th
 TREATMENT
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APPENDIX G 
Ethical Clearance 
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